WHO: Final Phase of Gaza Polio Vaccine Campaign Postponed as Conflict Escalates 23/10/2024 Elaine Ruth Fletcher Final phase of oral polio vaccine campaign in northern Gaza has been postponed due to escalating violence. The final phase of a planned polio campaign in northern Gaza has been postponed due to escalating violence in the area, the World Health Organization announced on Wednesday. “Due to the escalating violence, intense bombardment, mass displacement orders, and lack of assured humanitarian pauses across most of northern Gaza, the Polio Technical Committee for Gaza… and partners have been compelled to postpone the third phase of the polio vaccination campaign, which was set to begin today,” WHO said in a press statement. “This final phase of the ongoing campaign aimed to vaccinate 119 279 children across northern Gaza.” Since 14 October, the campaign to administer a second oral polio dose (nOPV2) to Gaza children under the age of 10 was rolled out successfully in central and southern Gazan regions, reaching some 442,885 children, WHO said. It followed a first-dose oral polio vaccine campaign in September that succeeded in reaching 559,161 children, or an estimated 95% of those eligible, during a series of pre-arranged ‘humanitarian pauses’ that both Israel and Hamas observed. The campaign followed on the identification of vaccine derived poliovirus in sewage over the summer, followed by a confirmed case of the paralytic disease in a ten-month old baby. Second round faces more challenging circumstances However, the second and final vaccination round, which began 14 October has taken place under much more challenging circumstances, particularly in northern Gaza where Israel has launched a major new military initiative in and around Jabalia refugee camp, ostensibly to root out Hamas forces that have resumed operations in the area; on 7 October, the anniversary of the first Hamas incursion into southern Israel, a barrage of missiles launched from nothern Gaza triggered sirens in Israel as far as Tel Aviv. Palestinians and UN human rights agencies, however, have charged that the Israeli bombardment of Jabalia is part of a campaign to “ethnically cleanse” the northern part of the 365 square kilometer enclave, to make way for renewed Jewish resettlement of Gaza. WHO has said that the escalation in violence made the final phase of the vaccine campaign impossible to execute right now. “Given that the area currently approved for temporary humanitarian pauses was substantially reduced—now limited only to Gaza City, a significant decrease from the first round—many children in northern Gaza would have missed out on the polio vaccine dose,” WHO said in its statement. Mass evacuation orders issued by Israel for people still living in Jabalia and other areas outside of Gaza City, would have also impeded the campaign’s reach, WHO said. Some 20,000 people have reportedly fled Jabalya in recent days. “To interrupt poliovirus transmission, at least 90% of all children in every community and neighbourhood must be vaccinated – a prerequisite for an effective campaign to interrupt the outbreak and prevent its further spread,” WHO said. “Humanitarian pauses are essential for its success, allowing partners to deliver vaccination supplies to health facilities, families to safely access vaccination sites, and mobile teams of health workers to reach children in their communities,” it added warning that, “a delay in administering a second dose of nOPV2 within six weeks reduces the impact of two closely spaced rounds, concurrently boosting the immunity of all children and interrupting poliovirus transmission.” Barriers to medical evacuations and hospital resupply The increased violence has also impeded medical evacuations as well as the delivery of vital medical supplies to still partially-functioning hospitals, WHO said in a separate statement on Tuesday. On a high-risk mission to northern Gaza on 20-21 October, WHO managed to evacuate 14 patiens and 10 caregivers, but was prevented from delivering “critical medical supplies, blood and fuel” to two Kamal Adwan and Al-Awda Hospitals, two partially functioning facilities still serving the area. “Despite an initial agreement, the delivery of critical medical supplies, blood, and fuel – resources essential for keeping Kamal Adwan and Al-Awda hospitals operational – was denied just a few hours before the mission began on 20 October,” WHO said in a separate statement Tuesday. The stepped-up fighting in Gaza takes place against the background of escalating violence between Israel and Lebanon, following Israel’s assassination of Hezbollah leader and Hamas ally, Hassan Nasrallah, on 27 September. That has included heavy Israeli bombing of alleged Hezbollah targets as far north as Beirut, and hundreds of Hezbollah missiles fired into northern and central Israeli cities daily. Against that landscape, WHO’s Director General Dr Tedros Adhanom Ghebreyesus, last week protested the fact that nearly a dozen hospitals in southern Lebanon have been forced to curtail activities or close, while flight cancellations to Beirut airport have also impeded the delivery of vital aid to the country. Image Credits: WHO. Several Opportunities to Address the Health Impact of Climate at COP29 23/10/2024 Kerry Cullinan The venue of COP29 in Baku, Azerbaijan. The United Nations (UN) climate change meeting, COP29, will feature a Health Day on 18 November as part of the negotiations in Baku, Azerbaijan. The World Health Organization’s (WHO) Maria Neira said that the global body wants to ensure that health is “very prominent” in all the member states’ climate negotiations, which run from 11-22 November. “We have two objectives. One is making sure that everybody understands that the climate crisis is a health crisis, and that climate change is negatively affecting our health, and we need to respond to that,” Neira told a media briefing on Wednesday. “The second objective is to convince all the negotiators, participants, and member states that whatever they do to mitigate the process of climate change will have enormous potential health benefits,” said Neira, who directs the WHO’s Department of Public Health, Environment and Social Determinants of Health. The Health Day will kick off with a high-level meeting on the Baku Initiative on Human Development for Climate Resilience, which aims to strengthen human development to address climate change, particularly in education, health, social protection, and green jobs and skills. COP29 presidency official Elmar Mammador “As part of the Baku initiative’s guiding principles, we emphasize the importance of science, knowledge generation and sharing as a part of the climate action,” COP presidency official Elmar Mammador told the briefing. Other events focused on food, agriculture and water have health implications, while a high-level roundtable on 19 November on One Health “highlights the interconnectedness of human, animal and environmental health”, he added. Mammador said that nine declarations had been finalised so far and some also offered opportunities for health interventions, including green energy, organic waste and pathways to resilient and healthy cities. A high-level meeting on resilient cities will be held on 20 November, which includes the integration of health in city planning. “The President’s Climate and Health Continuity Coalition will have as one of its focus areas a platform where stakeholders can share reports and research findings on climate and health, and on biodiversity and health. Human health is inseparable from the health of our ecosystems, and biodiversity is essential to safeguarding human health,” said Mammador. The WHO, in collaboration with the Wellcome Trust, is also hosting a Health Pavilion at the COP29 which aims to “ensure health and equity are placed at the centre of climate negotiations”, according to WHO. “It will offer a rich two-week programme of events showcasing evidence, initiatives and solutions to maximize the health benefits of tackling climate change across regions, sectors and communities,” said Neira. Local Manufacturers Drive New Initiative to Boost East Africa’s Medical Oxygen Supply 22/10/2024 Kerry Cullinan Kenyan manufacturer Synergy’s new medical oxygen manufacturing unit is unveiled in Mombasa, supported by Unitaid. A sod-turning ceremony in Mombasa, Kenya, on Tuesday marked the launch of the East African Programme on Oxygen Access (EAPOA), which aims to massively boost access to medical oxygen in the region. Unitaid is investing $22 million in support for Kenyan manufacturers Hewatele and Synergy, and Tanzania Oxygen Limited to set up Africa’s first liquid oxygen regional manufacturing initiative. Medical oxygen is an essential lifesaving medicine used to treat a wide range of diseases and chronic heart and lung conditions including pneumonia, COVID-19, advanced HIV infection, severe tuberculosis and malaria. It is also vital for maternal and newborn survival as well as in surgeries, emergency, and critical care. Yet many parts of sub-Saharan Africa remain severely under-resourced with some countries accessing less than 10% of the oxygen they need. The initiative is projected to save 154,000 lives in the two countries alone over the next decade, with the three manufacturers expanding the production capacity threefold by over 60 tons per day, enabling treatment of thousands of additional patients each month. “The key role of medical oxygen at all levels of care cannot be over-emphasised. Kenya’s drive towards universal health coverage requires uninterrupted access to all health products and technologies including medical oxygen,” said Harry Kimtai, Principal Secretary of the Ministry of Health of Kenya. “I congratulate Unitaid and all their partners for making funding available and providing technical support to make this possible. We look forward to working together to continue advancing initiatives that boost availability of other health products and technologies apart from medical oxygen” I attended the groundbreaking ceremony for the oxygen production plant in Kokotoni, Rabai Sub-County, which is a collaborative effort between the Clinton Health Access Initiative (CHAI), UNITAID, and Synergy Gases (K) Limited. This initiative holds great promise not just for the… pic.twitter.com/Yh5zJ5xHGT — Gideon M. Mung’aro, OGW (@GideonMungaroM) October 22, 2024 “This is Africa’s first regional manufacturing approach to increasing access to medical oxygen,” according to Unitaid, which is working with governments in both countries and other partners. “The program aims to expand medical oxygen production by 300% in East Africa and reduce oxygen prices by up to 27%, making it more affordable for health care systems across the region, and enabling treatment of thousands of additional patients each month,” added Unitaid in a media release. The Clinton Health Access Initiative (CHAI) will lead on market strategy, while PATH will focus on community and civil society engagement. Blended financing “Using an innovative blended financing approach that combines grants awarded to Unitaid by Canada and Japan, concessional loans, and support from MedAccess through volume guarantees, this program will strengthen the capacity of Kenyan and Tanzanian oxygen suppliers, fostering competition in the market and ensuring a sustainable, affordable oxygen supply across East and Southern Africa,” according to Unitaid. The EAPOA aims to develop a regional network of liquid oxygen production facilities, known as air separation units, to ensure medical oxygen reaches underserved communities. Air separation units produce bulk liquid oxygen, which is the gold standard for medical applications, with compact storage, economic efficiencies, and high purity level. However, building these units requires significant capital investment. Aside from the Mombasa facility, other facilities are planned in the Kenyan capital of Nairobi, Kenya, and Tanzania’s Dar es Salaam. These will serve as the key hubs for the production and distribution of liquid medical oxygen to their home countries and their neighbours, including Malawi, Mozambique, Uganda and Zambia. Medical oxygen is essential for treatment many illnesses. “The Mombasa facility is just the beginning of a larger effort to transform oxygen access across Africa,” said Unitaid executive director Dr Philippe Duneton. “Medical oxygen is critical for saving lives, yet too many health facilities in this region struggle with access. By working together with Kenyan and Tanzanian manufacturers and other partners, we are ensuring that oxygen is no longer a luxury but a basic right for all patients, especially in times of critical need.” The program is part of a broader Unitaid strategy to increase regional and local production of essential health products in Africa, in line with continental initiatives to enhance health security, such as Africa CDC’s Partnership for the Harmonization of African Health Products Manufacturing. “The Project will focus on three main aspects ensuring its sustainability,” said CHAI country director of East and Southern Africa, Gerald Macharia. “Well-placed infrastructure selected in partnership with Ministries of Health, longer-term budgeting for liquid oxygen supply, and the grant/ loan /volume guarantees available to companies, which aim to facilitate lower pricing, patient access, and regular payment for services in the long-term.” New US Lead Pipe Regulation Could Protect Nearly a Million Infants from Low Birthweight 22/10/2024 Sophia Samantaroy A lead poisoning prevention workshop in Kathmandu, Nepal organized by the Ministry of Health and Population (MoHP) and WHO Country Office for Nepal. The US Environmental Protection Agency (EPA) recently announced a new ruling that requires drinking water systems to replace lead pipes within 10 years. The rule also strengthens requirements to locate lead pipes, improve testing for lead in water, and ensure that exposure is minimized while lead pipe replacement efforts are underway. “Families like yours, exposed to lead in the water–they deserve better… We’re finally addressing an issue that should have been addressed a long time ago: the danger lead pipes pose to our drinking water,” said President Biden earlier this month. The EPA estimates that up to nine million US homes are served through legacy lead pipes across the country, many of which are located in lower-income communities and communities of color, “creating disproportionate lead exposure burden for these families,” the agency said in a press release. To remove the millions of lead pipes still in use, the EPA has tapped $2.6 billion from the Bipartisan Infrastructure Law. The agency estimates that the public health and economic benefits of the final rule are estimated to be up to “13 times greater than the costs,” including protecting 900,000 infants from low birthweight, preventing 2,600 cases of ADHD, and reducing 1,500 cases of premature death from heart disease each year following the ruling. The EPA’s new ruling could over two thousand cases of ADHD and protect nearly a million infants from being born with low birthweight each year. The Biden Administration’s announcement came just two weeks before International Lead Poisoning Prevention Week, which highlighted the persistent threat of lead for the world’s children population. “Lead continues to be one of the greatest public health concerns,” said Dr Maria Neira, World Health Organization (WHO) environment director. “Urgent action is required from member states to prevent exposure to lead.” The United Nations Children’s Fund (UNICEF) estimates that one in three children have blood lead levels at or above 5µg/dl – levels that can cause lifelong neurological, behavioral, and health problems like anemia, hypertension, and toxicity to reproductive organs. “The science is clear,” noted an EPA statement, “lead is a potent neurotoxin and there is no safe level of exposure.” Both the EPA and US Centers for Disease Control and Prevention (CDC) recommend having children tested for lead as the best way to determine exposure, especially if living in a house built before 1978. High risk of elevated lead in South Asia South Asia, Africa, and parts of South America are lead exposure hotspots. UNICEF’s landmark 2020 lead poisoning report exposed the scale at which children are exposed to high levels of lead. Of the 815 million children estimated to have elevated blood lead levels, nearly half live in India, Pakistan, Nepal, and other South Asian countries. The reasons for higher exposure, the UNICEF report notes, comes from a high prevalence of unsafe lead-acid battery recycling, and contaminated spices, ceramics, and toys. Children can also be exposed to lead in soil, dust, air, and water. Fewer regulations and enforcement leaves industries lacking environmentally safe practices, and the absence of blood lead screening make it difficult to protect children from lead hazards. The report also cites poor nutrition as a risk factor for higher lead absorption in lower-and middle-income countries. Educational materials in Rochester, New York, for people at higher risk for lead poisoning. “With few early symptoms, lead silently wreaks havoc on children’s health and development, with possibly fatal consequences,” said Henrietta Fore, UNICEF’s Executive Director at the time, at the report launch. “Knowing how widespread lead pollution is — and understanding the destruction it causes to individual lives and communities — must inspire urgent action to protect children once and for all.” “Since the 1970s, efforts to reduce lead in paint, gasoline, water, yards and even playgrounds have resulted in considerable success in reducing blood lead levels among children in the United States,” wrote the report authors. “The issue of lead poisoning is not new, but our understanding of the scope and scale of its impacts and feasible solutions has never been better. Proven solutions exist for low- and middle-income countries, those most burdened by this challenge. Those solutions can be implemented today.” Image Credits: S. Samantaroy/HPW, WHO, EPA, UNICEF. Rwanda’s High-Level Critical Care Ensures Low Marburg Fatality Rate 21/10/2024 Kerry Cullinan Rwandan Health Minister Dr Sabin Nsanzimana (left) and WHO Director General Dr Tedros Adhanom Ghebreyesus address a media briefing in Kigali on Sunday. After a full week of no new Marburg cases, Rwanda appears to have contained one of the biggest recorded of the deadly virus outbreaks – and with a low case fatality rate of 24%. World Health Organization (WHO) Director-General Dr Tedros Adhanom Ghebreyesus, who visited the country over the weekend, praised the level of Rwanda’s critical care for patients as well as how the country deployed high-level leadership to address the viral haemorrhagic fever, which often kills over 80% of those infected. “Two of the patients we met had experienced all of the symptoms of Marburg, including multiple organ failure, but they were put on life support, they were successfully intubated and extubated, and are now recovering,” Tedros told a media briefing in Rwanda on Sunday. “We believe this is the first time patients with Marburg virus have been extubated in Africa. These patients would have died in previous outbreaks.” Intubation involves inserting a tube through a patient’s nose or mouth into their windpipe (trachea) to help them breathe. This tube can be connected to a ventilator. Extubation is when the tube is removed. Tedros added that Rwanda had worked for many years to “strengthen its health system, to develop capacities for critical care and life support that can be deployed both in regular hospital care and in emergencies”. However, he warned that Marburg is “one of the world’s most dangerous viruses, and continued vigilance is essential”. The outbreak will only be declared over once no new cases have been recorded for 21 days, potentially on 5 November. Sabin’s vaccine candidate used Although there are no approved vaccines or therapeutics for Marburg, Rwanda fast-tracked the trials of a vaccine candidate from the Sabin Vaccine Institute, and an antiviral drug, remdesivir. On 5 October, Sabin delivered 700 doses of its single-dose candidate vaccine, followed by a further 1,000 on 12 October. These have been used to vaccinate health workers “as part of a Phase 2 rapid response open-label trial, sponsored by the Rwanda Biomedical Centre”, according to Sabin. Patients’ close contacts have also been vaccinated. Rwanda developed its own trial protocol after rejecting the WHO’s protocol which would have involved a control group that got vaccinated three weeks after the trial group, according to the journal, Science. Rwanda opted to vaccinate all trial participants at once. However, the remdesivir trial does involve a control group. “The swift initiation of the open-label trial was set in motion on 26 September, when the Rwandan President’s office contacted Sabin CEO Amy Finan to request assistance with the outbreak response,” Sabin said in a statement. Rwanda officially declared the outbreak the next day. “In an outbreak, every moment counts, and our seamless collaboration with the Rwandan government was key to accelerating the process,” said Finan. Sabin’s manufacturing partner, Italy-based ReiThera, produced the drug substance and filled and finished doses for shipment to Rwanda. “On our side, we moved quickly by leveraging our experience with other outbreaks and having vaccine doses and supporting documents ready, thanks to a strong partnership with ReiThera,” Finan added. Sabin’s team only consists of 15 staff members, but Finan said that “their dedication, along with that of our Rwandan colleagues, BARDA [the US Center for the Biomedical Advanced Research and Development Authority] and other partners, enabled us to mobilise so rapidly. “This remarkable effort highlights the power of partnerships and preparedness in addressing urgent public health needs,” said Finan, who also visited Rwanda over the weekend. Meanwhile, Tedros congratulated Rwanda for the speed with which it initiated trials of both vaccines and therapeutics, adding that the WHO hopes that these trials “will help to generate the data to support approval of these products for future outbreaks”. Belen Calvo Uyarra, the European Union’s Ambassador to Rwanda, also praised the country’s rapid response to containing the virus. “Respect to the government of Rwanda and the Rwanda Ministry of Health for proactive leadership, rapid and robust continued response, and professionalism of health workers,” Uyarra posted on X. She and Tedros also visited the site of the BioNTech vaccine manufacturing facility, announced two years ago to facilitate local production of vaccines. Two years ago I visited #Rwanda for the groundbreaking ceremony of the BioNTech facility in Kigali, which raised great hope for local production of vaccines in Africa. Today, I returned to the site and was proud to witness the fast progress of construction of the facility.… pic.twitter.com/8YGwcTVaYe — Tedros Adhanom Ghebreyesus (@DrTedros) October 20, 2024 “I was very pleased to see the significant progress in construction,” said Tedros. “One of the key lessons of the COVID-19 pandemic was the need to expand local production of vaccines to avoid the inequitable access to vaccines that we saw, and we’re pleased to see the way Rwanda and BioNTech are investing in local production. “You know how Africa was treated when the vaccines arrived, with vaccine inequity and vaccine nationalism, and we hope these strategic investments will fix the inequity problems we faced during COVID.” Cities Face ‘Severe Degradation’ Without Meaningful Climate Action, Warn Experts 21/10/2024 Sophia Samantaroy Experts at the yearly Lancet International Health lecture argued that green urban planning can improve health. Cities that fail to take meaningful climate action face a future of severe degradation with infrastructure collapse and environmental deterioration, warned climate and health experts at the yearly Academy of Medical Sciences & The Lancet International Health Lecture in London. “Madrid’s climate in 2050 will resemble Marrakech’s climate today. I don’t think we want that,” said Professor Mark Nieuwenhuijsen, the keynote speaker. To stave off this scenario, cities must adapt with health priorities at the forefront. “For our cities, we’re looking towards solutions that reduce CO2 emissions and also improve environment, equality and, of course, liveability and health.” By 2050, two-thirds of the global population is expected to live in a city. Yet climate change is increasingly threatening human health in urban areas, where swaths of asphalt and concrete exacerbate rising temperatures. Climate change accounts for 37% of heat-related deaths, leaving cities especially vulnerable to heat waves and extreme heat. Dr Mark Nieuwenhuijsen argues that urban planners must consider health is designing the future of cities. Preventing climate-related mortality in cities requires urban planning with an intentional health focus, commented Nieuwenhuijsen. He argued that smart urban planning reduces greenhouse gas emissions and promotes health, but only if we can break away from an “addiction” to fossil fuels. “We know that these fossil fuels are responsible for more than 5 million deaths each year because of air pollution.” Despite the growing knowledge of the health burden of fossil fuels, cities continue to sprawl “with Europe leading the way.” Fossil fuel use has led to “car-centric asphalt-dominated urban planning and extensive urban sprawl, which have detrimental effects on health,” said Nieuwenhuijsen. Sprawling urban areas increases car dependency, even though public transport systems and active transportation – like walking and cycling – are more cost effective. Compact vs green cities – policies that include the best of both models Four different European city configurations vary in their health and environmental effects–with compact cities being the lowest emittors yet having the highest mortality rates compared to less dense cities. In Europe, where many cities are growing faster than their populations, high population density has potential advantages like shortened commute times, decreased care dependency, higher energy efficiency, and decreased building material consumption. The more compact a city, the more efficient. Yet compact cities have potential drawbacks, including higher mortality rates, traffic density, air and noise pollution, and excess heat. Nieuwenhuijsen presented European cities as falling into one of four groups: compact high-density cities, open low-rise medium-density cities, open lowrise low-density cities, and green low-density cities. Analyzing cities across these categories show a split: cities either fall into higher mortality but lower greenhouse emissions, or lower mortality but higher emissions. A city like Barcelona – compact and high-density -–can expect to have a 10-15% higher mortality rate, poorer air quality, and stronger heat island effect, but lower emission, explained Nieuwenhuijsen. Overall, the researchers estimated that poor urban planning results in 20% of premature mortality. “Barcelona is a wonderful city, but it has too much air pollution, too much noise, not enough green space.” “In contrast, greener and less densely populated cities have lower mortality rates, lower air pollution levels, and a lower urban heat island effect, but higher carbon footprints per person.” This dichotomy – where current urban configurations are either high emitters with better health quality, or lower emitters with worse health – means that cities must implement policies that better health and reduce emissions. Nieuwenhuijsen believes that both are possible. Policies that lower air pollution levels and reliance on cars, and increase green space, cycling lanes, and physical activity would “substantially reduce the mortality rate,” he argued. Super blocks, green space, and 15-minute cities Barcelona is one a several major cities implementing innovative urban planning to improve environmental and human health. Several cities have begun implementing innovative urban models that bridge the goals of lower emissions and healthier environments, especially in how they use public land. “A lot of our public space in our cities is, at the moment, actually used by cars. I mean, in Spain, 69% of public space is used by cars because our roads are also public space. Parking is public space. I mean, this is the kind of space that we could use in a much better way,” commented Nieuwenhuijsen. In Paris, a vision to become a “15-minute city” – where all major destinations can be reached within 15 minutes of the home – has increased investments in bike lanes and car-free zones. Barcelona’s “superblocks,” London’s low traffic neighborhoods, and the Vauban Freiburg car-free neighborhood are all promising solutions to reduce premature deaths and increase green spaces. Nieuwenhuijsen and other experts convened at the event pointed to these examples and others as evidence that urban design changes are possible. Several Chinese cities have also embraced the intersection of urban planning and novel technologies to prevent flooding through their Sponge city designs, commented Dr Maria Neira, the World Health Organization’s director of Public Health, Environment and Social Determinants of Health. “More and more we need to be prepared to work with urban planners, the architects working at the city level. And I have the impression that sometimes they are better prepared, more advanced, more engaged and more passionate, than our public health officers working at the city level,” said Neira. “So we need to sort it out and create these very strong arguments for our public health officers as well, to push at the city level, at the Urban level, for engagement with the Urban healthy urban planning.” Image Credits: Michele Castrezzati, Fons Heijnsbroek, The Lancet, The Lancet. Rwanda’s Marburg Outbreak Wanes But Mpox Continues to Spread 17/10/2024 Kerry Cullinan Dr Jean Kaseya and Dr Sabin Nsanzimana. While Rwanda appears to have its Marburg virus outbreak under control with no new cases reported in the past three days in Rwanda, mpox continues to spread – now affecting 18 countries with 3051 new cases in the past week. Since declaring the Marburg outbreak three weeks ago, Rwanda has confirmed 62 cases, of which 15 have died, 38 have recovered and nine cases are still receiving treatment with the majority improving, said Health Minister Dr Sabin Nsanzimana on Thursday. “The case fatality rate overall is 24% and we’ve vaccinated 856 people,” Nsanzimana told an Africa Centres for Disease Control and Prevention (CDC) briefing, describing the trend as “very encouraging”. As the vaccine is “investigational”, its rollout required more rigorous consent, sampling and documentation, but demand for it has been “very high”, he added. the vaccines you are providing highly accepted, especially among healthcare providers. Around 90% of those infected are health workers and their close contacts from the intensive care units of two hospitals that treated the very first patients. The index patients was co-infected with malaria which slowed the diagnosis of Marburg, which has similar symptoms. Rwanda’s health ministry has also tested over 4,000 people “to make sure we don’t miss any cases”, added Nsanzimana. He attributed “intense activity on the ground”, ring vaccination [vaccinating the close contacts of people with Marburg] and new antivirals for the turnaround in what is the biggest Marburg outbreak ever recorded. The virus, which is from the same family as Ebola and, in some outbreaks, has killed over 80% of those infected. While the zoonotic origin of the outbreak is still unknown, Nsanzimana said Rwanda will be reporting its findings on the the serology and gene sequencing of the virus within a few days. At the same time, it has a team on the ground hunting for the source of the virus. Mpox ‘not under control’ Mpox cases have now been identified in 18 African countries, with new additions being Zambia and Zimbabwe. In the past week, 3051 new cases have been reported – including two male prisoners in Uganda. “Mpox is not under control,” warned Africa CDC Director-General Dr Jean Kaseya. Despite calling a continental meeting in April to warn countries of the risk, cases have risen exponentially: from slightly under 6,000 then to 42,438 suspected mpox cases at present – although only 8,113 have been clinically confirmed. A rapid test to diagnose mpox is in the pipeline and will transform the testing landscape, said Kaseya. Kaseya flagged the threat to internally displaced people (IDP), particularly in the Democratic Republic of Congo (DRC), and prisoners – both groups characterised by close contact. In the eastern DRC, conflict has displaced some 2.5 million people who are now living in camps in close quarters with limited access to water, sanitation and hygiene. The two Ugandan prisoners were initially diagnosed with chicken pox – which has small lesions that are itchy not painful like mpox. DRC vaccination plan includes MSM, transgender people The DRC’s vaccination campaign started two weeks ago in three provinces – North Kivu, South Kivu and Tshopo – and is “moving well”, said Kaseya, who hails from DRC. The country’s plan includes men who have sex with men (MSM) and sex workers, as mpox can be sexually transmitted. In DRC, same-sex sexual contact is not outlawed as it is in many of the other countries currently affected by mpox – Uganda, Burundi, Kenya, Tanzania, Zambia and Zimbabwe. “When are talking about MSM, we are clear as Africa CDC. We are saying all human beings have the same rights, and we are supporting countries to plan vaccination for all of them, including men having sex with other men,” said Kaseya empathically. “We are proud and we are glad to see in DRC that we have MSM included,” he added. Kaseya said that early messaging about mpox Clade 1B only being associated with sexual transmission was wrong – as was the failure to talk about MSM as the main mode of transmission iun the 2022 outbreak. “There was the stigma talking about men having sex with other men as the main transmission mode of mpox. But if we put it in the context in Africa, that one in some countries is still a taboo. “We believe with our effort, what we are doing is sensitizing countries, and we are proud to see that DRC are mentioning that.” He added that risk communication and community engagement involving “people who are openly saying we are these key populations” was also important. Uganda tightened its anti-LGBTQ laws recently and, while it plans to test all 1,087 prisoners who possibly had contact with the two prisoners recently diagnosed with mpox, it is unclear how it will approach MSM as a mode of transmission other than to crack down further on smae-sex activity. Europe’s New Air Quality Law is a Breakthrough for Clean Air Globally 16/10/2024 Jane Burston Dirty smoke billows from chimneys in Poland. Europe is now poised to deliver cleaner, healthier air – thanks to adoption this week of the revised Ambient Air Quality Directive (AAQD) by the European Union. This marks a crucial victory for the health and wellbeing of millions across the EU and serves as a beacon for the clean air movement worldwide. The AAQD underpins Europe’s air quality standards, and its revision is a significant breakthrough in addressing the public health crisis of air pollution. Each year, air pollution cuts short the lives of nearly 300,000 Europeans, contributing to respiratory illnesses, cardiovascular disease, and other serious health conditions, according to the EU’s impact assessment report. Improving air quality is a public health imperative. It’s also crucial for the environment and the economy, making the case for stronger EU-wide legislation even clearer. A healthier future The revised AAQD brings Europe’s air quality standards closer to the World Health Organization’s (WHO) air quality guidelines. It sets tougher, legally binding limits on harmful pollutants like nitrogen dioxide (NO₂) and fine particulate matter (PM2.5), representing a doubling of ambition for these two major pollutants, in line with WHO’s interim targets. These pollutants have long been linked to severe health impacts that are particularly harmful for vulnerable groups, such as babies and young children and people with certain conditions such as Chronic Obstructive Pulmonary Disease. By delivering cleaner air, the AAQD could mean the difference between a lifetime of illness and a healthy future for future generations. The AAQD also strengthens the monitoring and measuring provisions for air quality, introducing air quality roadmaps to support progress ahead of its 2030 deadline. The new rules bring about a fairer regime for people affected by air pollution as the rules for access to justice and compensation for those whose health have been impacted by dirty air have been improved. Some of the most polluted regions within member states can delay meeting the new targets for up to 10 years (until 2040) under certain conditions. Although these derogations (or exceptions) provide more leeway than originally envisaged, the compromise, alongside strict conditions for delays, ensure that none of the 27 Member States are left behind. Significant impact if properly implemented Overall, the Directive remains a significant win with ambitious targets and tightly regulated conditions for any delays. Importantly, the initially proposed ambition on limit values remained intact following the two-year legislative process, despite widespread pushback against legislation falling under the EU Green Deal, indicating the scale of this victory for clean air campaigners. One of the key reasons for the AAQD’s success is that it is both an environmental law and a critical public health intervention. By recognising that air quality is a matter of life and death, policymakers have acknowledged the need to protect the most vulnerable in our society. The impact of the new legislation in Europe will be significant if the AAQD is properly implemented. The new rules can prevent more than 55% of premature deaths linked to air pollution in the EU. That’s not just a number – that’s hundreds of thousands of people, each with families, who will live longer, healthier lives. In addition to delivering significant health and environmental benefits, improving the air we breathe makes economic sense. Investing €6 billion annually in cleaner air will deliver up to €121 billion in benefits (according to the EU’s analysis). That’s equivalent to building hundreds of new hospitals or creating hundreds of thousands of new jobs in green industries. Echoing this analysis, the Brussels-based think tank, Bruegel, estimated that implementing clean air measures could boost economic growth by €50 to €60 billion every year[3] and save approximately €600 billion each year in the European Union, the equivalent to 4% of GDP. Ripple effect The importance of the AAQD extends beyond the EU’s borders. By taking decisive action, the EU has positioned itself among the global leaders in air quality management, setting an example for other regions grappling with similar challenges. Air pollution is a global problem, responsible for eight million premature deaths annually worldwide, as reported in the British Medical Journal, and the EU’s solutions will, I hope, inspire other countries to pursue stronger actions. Ongoing engagement and sustained political will are key to ensuring the success of these measures. The real test will come as member states move to transpose the Directive into law and work to implement these new standards. National and local governments will need to invest in cleaner technologies, green transport and clean heating while improving air quality monitoring and ensuring that enforcement is taken seriously. Let’s celebrate this moment, but also remain focused on the work that still needs to be done. Air pollution is an invisible killer, shortening lives and ravaging our communities. With this new Directive, we are fighting back. Jane Burston founded and leads the Clean Air Fund (CAF), a global philanthropic organisation working with governments, funders, businesses and campaigners to create a future where everyone breathes clean air. Before setting up CAF, Jane worked as head of Climate and Energy Science in the UK government. Prior to that, as head of Energy and Environment at the UK National Physical Laboratory, she managed a team of 150 scientists working in air quality, GHG measurement and renewable energy. Image Credits: Janusz Walczak/ Unsplash. World Can Halve Premature Deaths by 2050, Lancet Commission Reports 15/10/2024 Stefan Anderson BERLIN – Countries worldwide, regardless of income level, can halve premature death rates by 2050, a new Lancet report presented at the closing of the World Health Summit in Berlin suggests. Fifteen key health threats are driving premature deaths worldwide, with tobacco use leading the pack “by far”, the Lancet Commission for Investing in Health found. Targeting interventions in these areas – with over half involving maternal, newborn, child, and infectious diseases – could dramatically reduce global deaths before age 70, the Commission said. “Sharp reductions in mortality and morbidity can be achieved by focusing on 15 priority conditions,” Dr Angela Chang from the University of Southern Denmark and lead author of the report, told a panel at the World Health Summit in Berlin on Tuesday. “Doubling down on past health investments, focusing resources on a narrow set of conditions, scaling up financing and developing new technologies can continue to have an enormous impact despite the headwinds.” The 15 priority conditions, selected from over 17,000 internationally recognized health diagnoses, account for approximately 80% of the life expectancy gap between most regions and the North Atlantic, defined in the report as North America and Europe. These conditions account for 86% of the gap between China and the North Atlantic, and 74% between sub-Saharan Africa and the North Atlantic. “There’s a 22-year gap in life expectancy between Sub-Saharan Africa and the North Atlantic, Chang explained. “Close to 80% of this gap can be explained by these 15 priority conditions, and over half of the difference can be attributed to eight infectious and maternal health conditions.” If the global goal is met, the average premature mortality rate worldwide would fall to about 15%, matching levels currently seen in Europe and North America—today’s global benchmark. Achieving this would mean dramatic improvements for billions, especially in low- and middle-income countries. In Sub-Saharan Africa, the worst-performing region, premature mortality sits at 52%. Setting priorities straight The report’s optimism is rooted in historical data. Globally, the probability of dying before 70 has halved since the 1960s, falling from 62% to 31% for individuals born in 2019. Thirty-seven countries, including populous nations like Bangladesh, China, Japan, and Vietnam, have already halved their premature death rates in similar or shorter periods than the 26 years remaining until the 2050 target date. The Commission recommends public financing for essential medicines targeting the 15 key conditions driving premature mortality. It suggests mobilizing international funding and joint procurement efforts, similar to strategies used by GAVI, PEPFAR, and the Global Fund, to reduce costs for patients and governments alike. “Inadequate access to medicines and high out-of-pocket costs are major threats to cutting premature mortality,” Chang noted. “We learned from the Global Fund’s experience how national government subsidies can steer resources towards priority interventions and reduce out-of-pocket payments.” While the Commission believes halving premature mortality by 2050 is globally achievable, it acknowledges this target may be “perhaps only aspirational for some countries, realistically speaking.” “We have a tendency to focus on the new, shiny things,” Chang added. “Our message is for countries to stay focused on these priority conditions.” ‘Tobacco is the new tobacco’ Six out of ten smokers, or 750 million people globally want to quit tobacco use. High tobacco taxes are “by far” the most crucial policy tool for reducing premature deaths, according to the report. “You often hear about other risk factors, but we argue tobacco is the new tobacco,” Chang explained. Recent research suggests raising excise taxes on tobacco, alcohol, and sugary drinks by 50% could yield $2.1 trillion for low- and middle-income countries over five years. This could boost healthcare spending in these nations by 40% if directed towards health initiatives. The Commission highlights the Middle East and North Africa as an example of untapped potential in tobacco control. With 160 million smokers and rising prevalence among youth and women, the region faces a growing health crisis. Egypt’s smoking rates doubled between 2000 and 2018, while tobacco became more affordable in conflict-affected countries like Iraq and Syria. The region’s tobacco taxes, second-lowest globally, fall far short of the World Health Organization’s recommended 70% excise tax. “Despite wide experience with its successful use, tobacco taxation remains a policy tool that is still greatly underused,” the Commission found. “Raising taxes on tobacco can do more to reduce premature mortality than any other single health policy.” High risk of ‘COVID magnitude’ pandemic in next decade The Lancet Comission estimates there is a 23% change of a COVID-scale pandemic in the next decade. New modeling for the Commission’s report indicates a 23% chance of a pandemic as severe as COVID-19 occurring within a decade. Unprepared health systems could see progress on reducing premature deaths plummet if caught off guard again. “There is a high risk of another pandemic of Covid-like magnitude,” Chang warned. “To put it another way, in most years there will be zero pandemic deaths, and in some years there will be millions of pandemic deaths.” The Commission’s analysis estimates an average of 2.5 million deaths per year due to pandemics when viewed over a long time horizon. This figure is comparable to the current annual death toll from AIDS, malaria, and tuberculosis combined, and significantly exceeds even pessimistic projections for annual climate change-related deaths in coming decades. “People should wake up at that figure,” Helen Clark, former Prime Minister of New Zealand, warned the summit. The warning from the Commission comes as global headwinds from conflict, climate change and debt hammer health budgets. Neglecting pandemic preparedness could have severe consequences, particularly for poorer countries less equipped to handle sudden outbreaks. “We need to learn the lessons not just from COVID, but from Mpox, Ebola … and avoid this panic-neglect cycle,” said Dr Seth Berkley, former CEO of Gavi, the Vaccine Alliance. “Unfortunately, I don’t think we’re doing a very good job.” From 1993 to Berlin A figure from the World Bank’s 1993 report making the case for health as an economic investment. The Lancet Comission report is the latest in a line of studies that traces its lineage back to a pivotal World Bank report that changed the landscape of global health finance. The World Bank’s 1993 report, Investing in Health, the only report on health ever published by the Bank, was the first to make an argument still used by health advocates and ministers across the globe: health is an investment. “The World Bank saying investing in health is no just a cost to society, but an investment that was justified on pure economic grounds … was revolutionary,” Berkley recalled. “Prior to this, people saw it as a cost – if you get richer, you can afford health, but this really changed the thinking.” The Commission’s work has expanded on the World Bank’s initial calculations, incorporating factors such as the impact of out-of-pocket health costs on economies and personal livelihoods. This broader perspective has significantly increased the estimated economic benefits of maintaining healthy societies, from the World Bank’s initial 11% to 24%. “The important thing is that each one of these reports, including this one, says the case is better than ever for investing in health, and we need to keep talking about that, particularly at a time when the headwinds are so strong,” Berkley emphasizes. The latest report continues this tradition, reaffirming that health investment remains one of the most effective strategies for improving both individual and societal outcomes. “Today, the case is better than ever for going for mortality reduction,” said Dr Gavin Yamey, director of Duke University’s Center for Policy Impact in Global Health and lead author of the commission report “It’s a prize within reach. It will have extraordinary health, welfare and economic benefits.” Image Credits: Sarah Johnson. Transformative Potential of Long-Acting Preventive Drugs Takes Centre Stage at HIV Conference 14/10/2024 Edith Magak At a HIVR4P’s press conference: Jeremy Nuttall, Elizabeth Irungu, Mark Marzinke, Alessandro Grattoni, William Hahn and Colleen Kelley. LIMA, Peru – The infection-prevention potential of Lenacapavir, the long-acting anti-HIV injectable administered just twice a year, took centre stage at the fifth HIV Research for Prevention Conference (HIVR4P) held last week. However, several other important studies were also unveiled, including an injectable that combines contraception and HIV protection, results from a three-month vaginal ring, and real-world findings from Zambia’s rollout of long-acting injectable cabotegravir. Lenacapavir in diverse populations Lenacapavir reduced HIV infections by 96% in a gender-diverse population, according to results from the PURPOSE 2 trial, which enrolled over 3,200 participants from Argentina, Brazil, Mexico, Peru, South Africa, Thailand, and the US between June 2021 and December 2023. Participants were randomly assigned to one of two groups: one receiving lenacapavir injections every six months and the other taking daily oral pills for pre-exposure prophylaxis (PrEP) with matched placebos. The average age of participants was 28, with over one-third under the age of 25. Around 70% identified as non-white, and the gender breakdown featured cisgender men, transgender men, transgender women, and non-binary individuals who have sex with partners assigned male at birth. At 39 weeks, only two HIV cases occurred in the lenacapavir group of 2,179 individuals, translating to a 96% reduction in HIV incidence, according to Dr Colleen Kelley from Emory University. In contrast, there were nine new HIV cases among the 1,087 participants taking daily oral TDF pills (comprising tenofovir disoproxil fumarate and emtricitabine and marketed as Truvada). This makes lenacapavir 89% more effective than oral PrEP. The findings echoed earlier results from the PURPOSE 1 trial, which showed 100% efficacy in preventing HIV among cisgender women in Africa. With regulatory filings expected to begin globally by the end of 2024, lenacapavir has the potential to be a transformative HIV prevention tool. Future phases of the study will focus on other groups, including women in the US (PURPOSE 3) and people who inject drugs (PURPOSE 4). The twice-yearly injectable, lenacapavir (marketed as Sunlenca in the US) could make a huge difference to HIV prevention is widely accessible. Injectable contraceptive and HIV prevention in one For millions of young women worldwide, two major health concerns often intersect: HIV acquisition and unintended pregnancy. Many have expressed a preference for a method that protects against both. At the conference, Melissa Peet from CONRAD presented results from a promising solution—a silica-based hydrogel injectable that combines HIV antiretroviral drugs with contraception in a single shot. In designing this dual-purpose method, researchers selected long-acting cabotegravir (CAB-LA) as the HIV prevention drug and levonorgestrel (LNG) as the contraceptive. The hydrogel injectable they developed is a silica-biodegradable material comprising two compartments, one for each medication. The injectable is capable of delivering both drugs with a single injection offering dual protection for three months. Preclinical tests in rats showed sustained drug levels in the bloodstream without significant interactions or safety concerns, and the researchers are now conducting additional studies in non-human primates to fine-tune dosing and asses the duration of protective drug concentration. No interactions between Cabotegravir and contraceptives One concern with combining HIV prevention and contraception has been the potential for drug interactions, particularly between long-acting HIV medications like cabotegravir (CAB-LA) and commonly used contraceptives. To address this, Dr. Mark Marzinke from Johns Hopkins University presented results from a sub-study within the HPTN 084 trial to explore any potential interactions. The study included 170 participants from South Africa with a median age of 23. A total of 80 women were randomised to the CAB-LA arm and 90 in the oral PrEP arm. Participants used three types of hormonal contraceptives: etonogestrel implants, injectable norethindrone, or medroxyprogesterone acetate (MPA), alongside either CAB-LA or oral PrEP. Researchers measured drug concentrations at enrolment and again at weeks 25, 49, and 73 to determine if there were any drug interactions. The results were reassuring: plasma concentrations of the contraceptives remained high enough to prevent pregnancy in both the CAB-LA and oral PrEP groups. CAB-LA concentrations were also consistent across contraceptive types, indicating that CAB-LA does not interfere with contraceptive effectiveness. However, tenofovir concentrations were unquantifiable for most participants, regardless of contraceptive type, due to low adherence to oral PrEP. New data on the three-month vaginal ring For women seeking long-term HIV prevention, the dapivirine vaginal ring, sometimes called the PrEP ring, has been a promising option. This is a flexible silicone ring that is placed in the vagina that releases the anti-HIV drug, dapivirine, over a month. Delegates at the conference heard results from a South African study comparing the bioavailability of the standard one-month dapivirine ring with a new three-month version. The study enrolled 124 women, but only 104 completed the trial. This was a crossover trial with two treatment phases: half the group started with the one-month ring (containing 25 mg of dapivirine) and then switched to the three-month ring, containing 100 mg of dapivirine. The other group followed the reverse order; they began with the three-month ring and later switched to the one-month ring. The three-month ring was identical to the one-month version in silicone, dimensions, and appearance. Plasma and vaginal fluid samples were collected throughout the study to measure drug levels. Based on dapivirine concentrations in plasma, results showed that the three-month ring provided greater overall drug exposure than the one-month version, indicating equal or possibly higher efficacy in preventing HIV. Jeremy Nuttall from the Population Council’s Center for Biomedical Research, who presented the findings, noted that the reduced frequency of ring changes might increase acceptability and adherence, potentially improving overall effectiveness. He also highlighted that the estimated cost of the three-month ring is $16, making it a potentially more affordable option, projecting that the three-month ring could become available on the market by 2026. Roxana Bretoneche protesting about the lack of community participation at HIVR4P. Real-world results from Zambia’s CAB-LA rollout Zambia became the first country in sub-Saharan Africa to roll out long-acting injectable PrEP (CAB-LA) beyond clinical trials, sharing results from their first three months (February to April 2024) in real-world settings. A total of 609 individuals with a median age of 24 were enrolled across six health facilities in two districts. Among the clients, 55% were female, 20% were adolescent boys and young men, 7% identified as key populations, and 40% as other high-risk populations. Adamson Ndhlovu from Zambia’s JSI USAID DISCOVER-Health Project shared that over 90% of participants due for their second injection received it on time. A total of 24 participants (about 4%) discontinued CAB-LA. Most discontinuations were due to hepatitis B (20 cases), with two participants stopping due to pregnancy, one due to a severe rash, and one because of severe pain at the injection site. Those who discontinued were switched to oral PrEP. During a press briefing at the conference, Professor Lloyd Mulenga from Zambia’s Ministry of Health stated that four of those enrolled had acquired HIV, explaining that they likely had undetected HIV at the time they started PrEP. The real-world implementation of CAB-LA is anticipated to expand, as ViiV Healthcare, the manufacturer, announced at the conference its plans to triple the supply of cabotegravir that will be available for low- and middle-income countries in 2025-2026 to at least two million doses. Image Credits: Nicole Bergman / IAS, Gilead, Nicole Bergman / IAS. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Several Opportunities to Address the Health Impact of Climate at COP29 23/10/2024 Kerry Cullinan The venue of COP29 in Baku, Azerbaijan. The United Nations (UN) climate change meeting, COP29, will feature a Health Day on 18 November as part of the negotiations in Baku, Azerbaijan. The World Health Organization’s (WHO) Maria Neira said that the global body wants to ensure that health is “very prominent” in all the member states’ climate negotiations, which run from 11-22 November. “We have two objectives. One is making sure that everybody understands that the climate crisis is a health crisis, and that climate change is negatively affecting our health, and we need to respond to that,” Neira told a media briefing on Wednesday. “The second objective is to convince all the negotiators, participants, and member states that whatever they do to mitigate the process of climate change will have enormous potential health benefits,” said Neira, who directs the WHO’s Department of Public Health, Environment and Social Determinants of Health. The Health Day will kick off with a high-level meeting on the Baku Initiative on Human Development for Climate Resilience, which aims to strengthen human development to address climate change, particularly in education, health, social protection, and green jobs and skills. COP29 presidency official Elmar Mammador “As part of the Baku initiative’s guiding principles, we emphasize the importance of science, knowledge generation and sharing as a part of the climate action,” COP presidency official Elmar Mammador told the briefing. Other events focused on food, agriculture and water have health implications, while a high-level roundtable on 19 November on One Health “highlights the interconnectedness of human, animal and environmental health”, he added. Mammador said that nine declarations had been finalised so far and some also offered opportunities for health interventions, including green energy, organic waste and pathways to resilient and healthy cities. A high-level meeting on resilient cities will be held on 20 November, which includes the integration of health in city planning. “The President’s Climate and Health Continuity Coalition will have as one of its focus areas a platform where stakeholders can share reports and research findings on climate and health, and on biodiversity and health. Human health is inseparable from the health of our ecosystems, and biodiversity is essential to safeguarding human health,” said Mammador. The WHO, in collaboration with the Wellcome Trust, is also hosting a Health Pavilion at the COP29 which aims to “ensure health and equity are placed at the centre of climate negotiations”, according to WHO. “It will offer a rich two-week programme of events showcasing evidence, initiatives and solutions to maximize the health benefits of tackling climate change across regions, sectors and communities,” said Neira. Local Manufacturers Drive New Initiative to Boost East Africa’s Medical Oxygen Supply 22/10/2024 Kerry Cullinan Kenyan manufacturer Synergy’s new medical oxygen manufacturing unit is unveiled in Mombasa, supported by Unitaid. A sod-turning ceremony in Mombasa, Kenya, on Tuesday marked the launch of the East African Programme on Oxygen Access (EAPOA), which aims to massively boost access to medical oxygen in the region. Unitaid is investing $22 million in support for Kenyan manufacturers Hewatele and Synergy, and Tanzania Oxygen Limited to set up Africa’s first liquid oxygen regional manufacturing initiative. Medical oxygen is an essential lifesaving medicine used to treat a wide range of diseases and chronic heart and lung conditions including pneumonia, COVID-19, advanced HIV infection, severe tuberculosis and malaria. It is also vital for maternal and newborn survival as well as in surgeries, emergency, and critical care. Yet many parts of sub-Saharan Africa remain severely under-resourced with some countries accessing less than 10% of the oxygen they need. The initiative is projected to save 154,000 lives in the two countries alone over the next decade, with the three manufacturers expanding the production capacity threefold by over 60 tons per day, enabling treatment of thousands of additional patients each month. “The key role of medical oxygen at all levels of care cannot be over-emphasised. Kenya’s drive towards universal health coverage requires uninterrupted access to all health products and technologies including medical oxygen,” said Harry Kimtai, Principal Secretary of the Ministry of Health of Kenya. “I congratulate Unitaid and all their partners for making funding available and providing technical support to make this possible. We look forward to working together to continue advancing initiatives that boost availability of other health products and technologies apart from medical oxygen” I attended the groundbreaking ceremony for the oxygen production plant in Kokotoni, Rabai Sub-County, which is a collaborative effort between the Clinton Health Access Initiative (CHAI), UNITAID, and Synergy Gases (K) Limited. This initiative holds great promise not just for the… pic.twitter.com/Yh5zJ5xHGT — Gideon M. Mung’aro, OGW (@GideonMungaroM) October 22, 2024 “This is Africa’s first regional manufacturing approach to increasing access to medical oxygen,” according to Unitaid, which is working with governments in both countries and other partners. “The program aims to expand medical oxygen production by 300% in East Africa and reduce oxygen prices by up to 27%, making it more affordable for health care systems across the region, and enabling treatment of thousands of additional patients each month,” added Unitaid in a media release. The Clinton Health Access Initiative (CHAI) will lead on market strategy, while PATH will focus on community and civil society engagement. Blended financing “Using an innovative blended financing approach that combines grants awarded to Unitaid by Canada and Japan, concessional loans, and support from MedAccess through volume guarantees, this program will strengthen the capacity of Kenyan and Tanzanian oxygen suppliers, fostering competition in the market and ensuring a sustainable, affordable oxygen supply across East and Southern Africa,” according to Unitaid. The EAPOA aims to develop a regional network of liquid oxygen production facilities, known as air separation units, to ensure medical oxygen reaches underserved communities. Air separation units produce bulk liquid oxygen, which is the gold standard for medical applications, with compact storage, economic efficiencies, and high purity level. However, building these units requires significant capital investment. Aside from the Mombasa facility, other facilities are planned in the Kenyan capital of Nairobi, Kenya, and Tanzania’s Dar es Salaam. These will serve as the key hubs for the production and distribution of liquid medical oxygen to their home countries and their neighbours, including Malawi, Mozambique, Uganda and Zambia. Medical oxygen is essential for treatment many illnesses. “The Mombasa facility is just the beginning of a larger effort to transform oxygen access across Africa,” said Unitaid executive director Dr Philippe Duneton. “Medical oxygen is critical for saving lives, yet too many health facilities in this region struggle with access. By working together with Kenyan and Tanzanian manufacturers and other partners, we are ensuring that oxygen is no longer a luxury but a basic right for all patients, especially in times of critical need.” The program is part of a broader Unitaid strategy to increase regional and local production of essential health products in Africa, in line with continental initiatives to enhance health security, such as Africa CDC’s Partnership for the Harmonization of African Health Products Manufacturing. “The Project will focus on three main aspects ensuring its sustainability,” said CHAI country director of East and Southern Africa, Gerald Macharia. “Well-placed infrastructure selected in partnership with Ministries of Health, longer-term budgeting for liquid oxygen supply, and the grant/ loan /volume guarantees available to companies, which aim to facilitate lower pricing, patient access, and regular payment for services in the long-term.” New US Lead Pipe Regulation Could Protect Nearly a Million Infants from Low Birthweight 22/10/2024 Sophia Samantaroy A lead poisoning prevention workshop in Kathmandu, Nepal organized by the Ministry of Health and Population (MoHP) and WHO Country Office for Nepal. The US Environmental Protection Agency (EPA) recently announced a new ruling that requires drinking water systems to replace lead pipes within 10 years. The rule also strengthens requirements to locate lead pipes, improve testing for lead in water, and ensure that exposure is minimized while lead pipe replacement efforts are underway. “Families like yours, exposed to lead in the water–they deserve better… We’re finally addressing an issue that should have been addressed a long time ago: the danger lead pipes pose to our drinking water,” said President Biden earlier this month. The EPA estimates that up to nine million US homes are served through legacy lead pipes across the country, many of which are located in lower-income communities and communities of color, “creating disproportionate lead exposure burden for these families,” the agency said in a press release. To remove the millions of lead pipes still in use, the EPA has tapped $2.6 billion from the Bipartisan Infrastructure Law. The agency estimates that the public health and economic benefits of the final rule are estimated to be up to “13 times greater than the costs,” including protecting 900,000 infants from low birthweight, preventing 2,600 cases of ADHD, and reducing 1,500 cases of premature death from heart disease each year following the ruling. The EPA’s new ruling could over two thousand cases of ADHD and protect nearly a million infants from being born with low birthweight each year. The Biden Administration’s announcement came just two weeks before International Lead Poisoning Prevention Week, which highlighted the persistent threat of lead for the world’s children population. “Lead continues to be one of the greatest public health concerns,” said Dr Maria Neira, World Health Organization (WHO) environment director. “Urgent action is required from member states to prevent exposure to lead.” The United Nations Children’s Fund (UNICEF) estimates that one in three children have blood lead levels at or above 5µg/dl – levels that can cause lifelong neurological, behavioral, and health problems like anemia, hypertension, and toxicity to reproductive organs. “The science is clear,” noted an EPA statement, “lead is a potent neurotoxin and there is no safe level of exposure.” Both the EPA and US Centers for Disease Control and Prevention (CDC) recommend having children tested for lead as the best way to determine exposure, especially if living in a house built before 1978. High risk of elevated lead in South Asia South Asia, Africa, and parts of South America are lead exposure hotspots. UNICEF’s landmark 2020 lead poisoning report exposed the scale at which children are exposed to high levels of lead. Of the 815 million children estimated to have elevated blood lead levels, nearly half live in India, Pakistan, Nepal, and other South Asian countries. The reasons for higher exposure, the UNICEF report notes, comes from a high prevalence of unsafe lead-acid battery recycling, and contaminated spices, ceramics, and toys. Children can also be exposed to lead in soil, dust, air, and water. Fewer regulations and enforcement leaves industries lacking environmentally safe practices, and the absence of blood lead screening make it difficult to protect children from lead hazards. The report also cites poor nutrition as a risk factor for higher lead absorption in lower-and middle-income countries. Educational materials in Rochester, New York, for people at higher risk for lead poisoning. “With few early symptoms, lead silently wreaks havoc on children’s health and development, with possibly fatal consequences,” said Henrietta Fore, UNICEF’s Executive Director at the time, at the report launch. “Knowing how widespread lead pollution is — and understanding the destruction it causes to individual lives and communities — must inspire urgent action to protect children once and for all.” “Since the 1970s, efforts to reduce lead in paint, gasoline, water, yards and even playgrounds have resulted in considerable success in reducing blood lead levels among children in the United States,” wrote the report authors. “The issue of lead poisoning is not new, but our understanding of the scope and scale of its impacts and feasible solutions has never been better. Proven solutions exist for low- and middle-income countries, those most burdened by this challenge. Those solutions can be implemented today.” Image Credits: S. Samantaroy/HPW, WHO, EPA, UNICEF. Rwanda’s High-Level Critical Care Ensures Low Marburg Fatality Rate 21/10/2024 Kerry Cullinan Rwandan Health Minister Dr Sabin Nsanzimana (left) and WHO Director General Dr Tedros Adhanom Ghebreyesus address a media briefing in Kigali on Sunday. After a full week of no new Marburg cases, Rwanda appears to have contained one of the biggest recorded of the deadly virus outbreaks – and with a low case fatality rate of 24%. World Health Organization (WHO) Director-General Dr Tedros Adhanom Ghebreyesus, who visited the country over the weekend, praised the level of Rwanda’s critical care for patients as well as how the country deployed high-level leadership to address the viral haemorrhagic fever, which often kills over 80% of those infected. “Two of the patients we met had experienced all of the symptoms of Marburg, including multiple organ failure, but they were put on life support, they were successfully intubated and extubated, and are now recovering,” Tedros told a media briefing in Rwanda on Sunday. “We believe this is the first time patients with Marburg virus have been extubated in Africa. These patients would have died in previous outbreaks.” Intubation involves inserting a tube through a patient’s nose or mouth into their windpipe (trachea) to help them breathe. This tube can be connected to a ventilator. Extubation is when the tube is removed. Tedros added that Rwanda had worked for many years to “strengthen its health system, to develop capacities for critical care and life support that can be deployed both in regular hospital care and in emergencies”. However, he warned that Marburg is “one of the world’s most dangerous viruses, and continued vigilance is essential”. The outbreak will only be declared over once no new cases have been recorded for 21 days, potentially on 5 November. Sabin’s vaccine candidate used Although there are no approved vaccines or therapeutics for Marburg, Rwanda fast-tracked the trials of a vaccine candidate from the Sabin Vaccine Institute, and an antiviral drug, remdesivir. On 5 October, Sabin delivered 700 doses of its single-dose candidate vaccine, followed by a further 1,000 on 12 October. These have been used to vaccinate health workers “as part of a Phase 2 rapid response open-label trial, sponsored by the Rwanda Biomedical Centre”, according to Sabin. Patients’ close contacts have also been vaccinated. Rwanda developed its own trial protocol after rejecting the WHO’s protocol which would have involved a control group that got vaccinated three weeks after the trial group, according to the journal, Science. Rwanda opted to vaccinate all trial participants at once. However, the remdesivir trial does involve a control group. “The swift initiation of the open-label trial was set in motion on 26 September, when the Rwandan President’s office contacted Sabin CEO Amy Finan to request assistance with the outbreak response,” Sabin said in a statement. Rwanda officially declared the outbreak the next day. “In an outbreak, every moment counts, and our seamless collaboration with the Rwandan government was key to accelerating the process,” said Finan. Sabin’s manufacturing partner, Italy-based ReiThera, produced the drug substance and filled and finished doses for shipment to Rwanda. “On our side, we moved quickly by leveraging our experience with other outbreaks and having vaccine doses and supporting documents ready, thanks to a strong partnership with ReiThera,” Finan added. Sabin’s team only consists of 15 staff members, but Finan said that “their dedication, along with that of our Rwandan colleagues, BARDA [the US Center for the Biomedical Advanced Research and Development Authority] and other partners, enabled us to mobilise so rapidly. “This remarkable effort highlights the power of partnerships and preparedness in addressing urgent public health needs,” said Finan, who also visited Rwanda over the weekend. Meanwhile, Tedros congratulated Rwanda for the speed with which it initiated trials of both vaccines and therapeutics, adding that the WHO hopes that these trials “will help to generate the data to support approval of these products for future outbreaks”. Belen Calvo Uyarra, the European Union’s Ambassador to Rwanda, also praised the country’s rapid response to containing the virus. “Respect to the government of Rwanda and the Rwanda Ministry of Health for proactive leadership, rapid and robust continued response, and professionalism of health workers,” Uyarra posted on X. She and Tedros also visited the site of the BioNTech vaccine manufacturing facility, announced two years ago to facilitate local production of vaccines. Two years ago I visited #Rwanda for the groundbreaking ceremony of the BioNTech facility in Kigali, which raised great hope for local production of vaccines in Africa. Today, I returned to the site and was proud to witness the fast progress of construction of the facility.… pic.twitter.com/8YGwcTVaYe — Tedros Adhanom Ghebreyesus (@DrTedros) October 20, 2024 “I was very pleased to see the significant progress in construction,” said Tedros. “One of the key lessons of the COVID-19 pandemic was the need to expand local production of vaccines to avoid the inequitable access to vaccines that we saw, and we’re pleased to see the way Rwanda and BioNTech are investing in local production. “You know how Africa was treated when the vaccines arrived, with vaccine inequity and vaccine nationalism, and we hope these strategic investments will fix the inequity problems we faced during COVID.” Cities Face ‘Severe Degradation’ Without Meaningful Climate Action, Warn Experts 21/10/2024 Sophia Samantaroy Experts at the yearly Lancet International Health lecture argued that green urban planning can improve health. Cities that fail to take meaningful climate action face a future of severe degradation with infrastructure collapse and environmental deterioration, warned climate and health experts at the yearly Academy of Medical Sciences & The Lancet International Health Lecture in London. “Madrid’s climate in 2050 will resemble Marrakech’s climate today. I don’t think we want that,” said Professor Mark Nieuwenhuijsen, the keynote speaker. To stave off this scenario, cities must adapt with health priorities at the forefront. “For our cities, we’re looking towards solutions that reduce CO2 emissions and also improve environment, equality and, of course, liveability and health.” By 2050, two-thirds of the global population is expected to live in a city. Yet climate change is increasingly threatening human health in urban areas, where swaths of asphalt and concrete exacerbate rising temperatures. Climate change accounts for 37% of heat-related deaths, leaving cities especially vulnerable to heat waves and extreme heat. Dr Mark Nieuwenhuijsen argues that urban planners must consider health is designing the future of cities. Preventing climate-related mortality in cities requires urban planning with an intentional health focus, commented Nieuwenhuijsen. He argued that smart urban planning reduces greenhouse gas emissions and promotes health, but only if we can break away from an “addiction” to fossil fuels. “We know that these fossil fuels are responsible for more than 5 million deaths each year because of air pollution.” Despite the growing knowledge of the health burden of fossil fuels, cities continue to sprawl “with Europe leading the way.” Fossil fuel use has led to “car-centric asphalt-dominated urban planning and extensive urban sprawl, which have detrimental effects on health,” said Nieuwenhuijsen. Sprawling urban areas increases car dependency, even though public transport systems and active transportation – like walking and cycling – are more cost effective. Compact vs green cities – policies that include the best of both models Four different European city configurations vary in their health and environmental effects–with compact cities being the lowest emittors yet having the highest mortality rates compared to less dense cities. In Europe, where many cities are growing faster than their populations, high population density has potential advantages like shortened commute times, decreased care dependency, higher energy efficiency, and decreased building material consumption. The more compact a city, the more efficient. Yet compact cities have potential drawbacks, including higher mortality rates, traffic density, air and noise pollution, and excess heat. Nieuwenhuijsen presented European cities as falling into one of four groups: compact high-density cities, open low-rise medium-density cities, open lowrise low-density cities, and green low-density cities. Analyzing cities across these categories show a split: cities either fall into higher mortality but lower greenhouse emissions, or lower mortality but higher emissions. A city like Barcelona – compact and high-density -–can expect to have a 10-15% higher mortality rate, poorer air quality, and stronger heat island effect, but lower emission, explained Nieuwenhuijsen. Overall, the researchers estimated that poor urban planning results in 20% of premature mortality. “Barcelona is a wonderful city, but it has too much air pollution, too much noise, not enough green space.” “In contrast, greener and less densely populated cities have lower mortality rates, lower air pollution levels, and a lower urban heat island effect, but higher carbon footprints per person.” This dichotomy – where current urban configurations are either high emitters with better health quality, or lower emitters with worse health – means that cities must implement policies that better health and reduce emissions. Nieuwenhuijsen believes that both are possible. Policies that lower air pollution levels and reliance on cars, and increase green space, cycling lanes, and physical activity would “substantially reduce the mortality rate,” he argued. Super blocks, green space, and 15-minute cities Barcelona is one a several major cities implementing innovative urban planning to improve environmental and human health. Several cities have begun implementing innovative urban models that bridge the goals of lower emissions and healthier environments, especially in how they use public land. “A lot of our public space in our cities is, at the moment, actually used by cars. I mean, in Spain, 69% of public space is used by cars because our roads are also public space. Parking is public space. I mean, this is the kind of space that we could use in a much better way,” commented Nieuwenhuijsen. In Paris, a vision to become a “15-minute city” – where all major destinations can be reached within 15 minutes of the home – has increased investments in bike lanes and car-free zones. Barcelona’s “superblocks,” London’s low traffic neighborhoods, and the Vauban Freiburg car-free neighborhood are all promising solutions to reduce premature deaths and increase green spaces. Nieuwenhuijsen and other experts convened at the event pointed to these examples and others as evidence that urban design changes are possible. Several Chinese cities have also embraced the intersection of urban planning and novel technologies to prevent flooding through their Sponge city designs, commented Dr Maria Neira, the World Health Organization’s director of Public Health, Environment and Social Determinants of Health. “More and more we need to be prepared to work with urban planners, the architects working at the city level. And I have the impression that sometimes they are better prepared, more advanced, more engaged and more passionate, than our public health officers working at the city level,” said Neira. “So we need to sort it out and create these very strong arguments for our public health officers as well, to push at the city level, at the Urban level, for engagement with the Urban healthy urban planning.” Image Credits: Michele Castrezzati, Fons Heijnsbroek, The Lancet, The Lancet. Rwanda’s Marburg Outbreak Wanes But Mpox Continues to Spread 17/10/2024 Kerry Cullinan Dr Jean Kaseya and Dr Sabin Nsanzimana. While Rwanda appears to have its Marburg virus outbreak under control with no new cases reported in the past three days in Rwanda, mpox continues to spread – now affecting 18 countries with 3051 new cases in the past week. Since declaring the Marburg outbreak three weeks ago, Rwanda has confirmed 62 cases, of which 15 have died, 38 have recovered and nine cases are still receiving treatment with the majority improving, said Health Minister Dr Sabin Nsanzimana on Thursday. “The case fatality rate overall is 24% and we’ve vaccinated 856 people,” Nsanzimana told an Africa Centres for Disease Control and Prevention (CDC) briefing, describing the trend as “very encouraging”. As the vaccine is “investigational”, its rollout required more rigorous consent, sampling and documentation, but demand for it has been “very high”, he added. the vaccines you are providing highly accepted, especially among healthcare providers. Around 90% of those infected are health workers and their close contacts from the intensive care units of two hospitals that treated the very first patients. The index patients was co-infected with malaria which slowed the diagnosis of Marburg, which has similar symptoms. Rwanda’s health ministry has also tested over 4,000 people “to make sure we don’t miss any cases”, added Nsanzimana. He attributed “intense activity on the ground”, ring vaccination [vaccinating the close contacts of people with Marburg] and new antivirals for the turnaround in what is the biggest Marburg outbreak ever recorded. The virus, which is from the same family as Ebola and, in some outbreaks, has killed over 80% of those infected. While the zoonotic origin of the outbreak is still unknown, Nsanzimana said Rwanda will be reporting its findings on the the serology and gene sequencing of the virus within a few days. At the same time, it has a team on the ground hunting for the source of the virus. Mpox ‘not under control’ Mpox cases have now been identified in 18 African countries, with new additions being Zambia and Zimbabwe. In the past week, 3051 new cases have been reported – including two male prisoners in Uganda. “Mpox is not under control,” warned Africa CDC Director-General Dr Jean Kaseya. Despite calling a continental meeting in April to warn countries of the risk, cases have risen exponentially: from slightly under 6,000 then to 42,438 suspected mpox cases at present – although only 8,113 have been clinically confirmed. A rapid test to diagnose mpox is in the pipeline and will transform the testing landscape, said Kaseya. Kaseya flagged the threat to internally displaced people (IDP), particularly in the Democratic Republic of Congo (DRC), and prisoners – both groups characterised by close contact. In the eastern DRC, conflict has displaced some 2.5 million people who are now living in camps in close quarters with limited access to water, sanitation and hygiene. The two Ugandan prisoners were initially diagnosed with chicken pox – which has small lesions that are itchy not painful like mpox. DRC vaccination plan includes MSM, transgender people The DRC’s vaccination campaign started two weeks ago in three provinces – North Kivu, South Kivu and Tshopo – and is “moving well”, said Kaseya, who hails from DRC. The country’s plan includes men who have sex with men (MSM) and sex workers, as mpox can be sexually transmitted. In DRC, same-sex sexual contact is not outlawed as it is in many of the other countries currently affected by mpox – Uganda, Burundi, Kenya, Tanzania, Zambia and Zimbabwe. “When are talking about MSM, we are clear as Africa CDC. We are saying all human beings have the same rights, and we are supporting countries to plan vaccination for all of them, including men having sex with other men,” said Kaseya empathically. “We are proud and we are glad to see in DRC that we have MSM included,” he added. Kaseya said that early messaging about mpox Clade 1B only being associated with sexual transmission was wrong – as was the failure to talk about MSM as the main mode of transmission iun the 2022 outbreak. “There was the stigma talking about men having sex with other men as the main transmission mode of mpox. But if we put it in the context in Africa, that one in some countries is still a taboo. “We believe with our effort, what we are doing is sensitizing countries, and we are proud to see that DRC are mentioning that.” He added that risk communication and community engagement involving “people who are openly saying we are these key populations” was also important. Uganda tightened its anti-LGBTQ laws recently and, while it plans to test all 1,087 prisoners who possibly had contact with the two prisoners recently diagnosed with mpox, it is unclear how it will approach MSM as a mode of transmission other than to crack down further on smae-sex activity. Europe’s New Air Quality Law is a Breakthrough for Clean Air Globally 16/10/2024 Jane Burston Dirty smoke billows from chimneys in Poland. Europe is now poised to deliver cleaner, healthier air – thanks to adoption this week of the revised Ambient Air Quality Directive (AAQD) by the European Union. This marks a crucial victory for the health and wellbeing of millions across the EU and serves as a beacon for the clean air movement worldwide. The AAQD underpins Europe’s air quality standards, and its revision is a significant breakthrough in addressing the public health crisis of air pollution. Each year, air pollution cuts short the lives of nearly 300,000 Europeans, contributing to respiratory illnesses, cardiovascular disease, and other serious health conditions, according to the EU’s impact assessment report. Improving air quality is a public health imperative. It’s also crucial for the environment and the economy, making the case for stronger EU-wide legislation even clearer. A healthier future The revised AAQD brings Europe’s air quality standards closer to the World Health Organization’s (WHO) air quality guidelines. It sets tougher, legally binding limits on harmful pollutants like nitrogen dioxide (NO₂) and fine particulate matter (PM2.5), representing a doubling of ambition for these two major pollutants, in line with WHO’s interim targets. These pollutants have long been linked to severe health impacts that are particularly harmful for vulnerable groups, such as babies and young children and people with certain conditions such as Chronic Obstructive Pulmonary Disease. By delivering cleaner air, the AAQD could mean the difference between a lifetime of illness and a healthy future for future generations. The AAQD also strengthens the monitoring and measuring provisions for air quality, introducing air quality roadmaps to support progress ahead of its 2030 deadline. The new rules bring about a fairer regime for people affected by air pollution as the rules for access to justice and compensation for those whose health have been impacted by dirty air have been improved. Some of the most polluted regions within member states can delay meeting the new targets for up to 10 years (until 2040) under certain conditions. Although these derogations (or exceptions) provide more leeway than originally envisaged, the compromise, alongside strict conditions for delays, ensure that none of the 27 Member States are left behind. Significant impact if properly implemented Overall, the Directive remains a significant win with ambitious targets and tightly regulated conditions for any delays. Importantly, the initially proposed ambition on limit values remained intact following the two-year legislative process, despite widespread pushback against legislation falling under the EU Green Deal, indicating the scale of this victory for clean air campaigners. One of the key reasons for the AAQD’s success is that it is both an environmental law and a critical public health intervention. By recognising that air quality is a matter of life and death, policymakers have acknowledged the need to protect the most vulnerable in our society. The impact of the new legislation in Europe will be significant if the AAQD is properly implemented. The new rules can prevent more than 55% of premature deaths linked to air pollution in the EU. That’s not just a number – that’s hundreds of thousands of people, each with families, who will live longer, healthier lives. In addition to delivering significant health and environmental benefits, improving the air we breathe makes economic sense. Investing €6 billion annually in cleaner air will deliver up to €121 billion in benefits (according to the EU’s analysis). That’s equivalent to building hundreds of new hospitals or creating hundreds of thousands of new jobs in green industries. Echoing this analysis, the Brussels-based think tank, Bruegel, estimated that implementing clean air measures could boost economic growth by €50 to €60 billion every year[3] and save approximately €600 billion each year in the European Union, the equivalent to 4% of GDP. Ripple effect The importance of the AAQD extends beyond the EU’s borders. By taking decisive action, the EU has positioned itself among the global leaders in air quality management, setting an example for other regions grappling with similar challenges. Air pollution is a global problem, responsible for eight million premature deaths annually worldwide, as reported in the British Medical Journal, and the EU’s solutions will, I hope, inspire other countries to pursue stronger actions. Ongoing engagement and sustained political will are key to ensuring the success of these measures. The real test will come as member states move to transpose the Directive into law and work to implement these new standards. National and local governments will need to invest in cleaner technologies, green transport and clean heating while improving air quality monitoring and ensuring that enforcement is taken seriously. Let’s celebrate this moment, but also remain focused on the work that still needs to be done. Air pollution is an invisible killer, shortening lives and ravaging our communities. With this new Directive, we are fighting back. Jane Burston founded and leads the Clean Air Fund (CAF), a global philanthropic organisation working with governments, funders, businesses and campaigners to create a future where everyone breathes clean air. Before setting up CAF, Jane worked as head of Climate and Energy Science in the UK government. Prior to that, as head of Energy and Environment at the UK National Physical Laboratory, she managed a team of 150 scientists working in air quality, GHG measurement and renewable energy. Image Credits: Janusz Walczak/ Unsplash. World Can Halve Premature Deaths by 2050, Lancet Commission Reports 15/10/2024 Stefan Anderson BERLIN – Countries worldwide, regardless of income level, can halve premature death rates by 2050, a new Lancet report presented at the closing of the World Health Summit in Berlin suggests. Fifteen key health threats are driving premature deaths worldwide, with tobacco use leading the pack “by far”, the Lancet Commission for Investing in Health found. Targeting interventions in these areas – with over half involving maternal, newborn, child, and infectious diseases – could dramatically reduce global deaths before age 70, the Commission said. “Sharp reductions in mortality and morbidity can be achieved by focusing on 15 priority conditions,” Dr Angela Chang from the University of Southern Denmark and lead author of the report, told a panel at the World Health Summit in Berlin on Tuesday. “Doubling down on past health investments, focusing resources on a narrow set of conditions, scaling up financing and developing new technologies can continue to have an enormous impact despite the headwinds.” The 15 priority conditions, selected from over 17,000 internationally recognized health diagnoses, account for approximately 80% of the life expectancy gap between most regions and the North Atlantic, defined in the report as North America and Europe. These conditions account for 86% of the gap between China and the North Atlantic, and 74% between sub-Saharan Africa and the North Atlantic. “There’s a 22-year gap in life expectancy between Sub-Saharan Africa and the North Atlantic, Chang explained. “Close to 80% of this gap can be explained by these 15 priority conditions, and over half of the difference can be attributed to eight infectious and maternal health conditions.” If the global goal is met, the average premature mortality rate worldwide would fall to about 15%, matching levels currently seen in Europe and North America—today’s global benchmark. Achieving this would mean dramatic improvements for billions, especially in low- and middle-income countries. In Sub-Saharan Africa, the worst-performing region, premature mortality sits at 52%. Setting priorities straight The report’s optimism is rooted in historical data. Globally, the probability of dying before 70 has halved since the 1960s, falling from 62% to 31% for individuals born in 2019. Thirty-seven countries, including populous nations like Bangladesh, China, Japan, and Vietnam, have already halved their premature death rates in similar or shorter periods than the 26 years remaining until the 2050 target date. The Commission recommends public financing for essential medicines targeting the 15 key conditions driving premature mortality. It suggests mobilizing international funding and joint procurement efforts, similar to strategies used by GAVI, PEPFAR, and the Global Fund, to reduce costs for patients and governments alike. “Inadequate access to medicines and high out-of-pocket costs are major threats to cutting premature mortality,” Chang noted. “We learned from the Global Fund’s experience how national government subsidies can steer resources towards priority interventions and reduce out-of-pocket payments.” While the Commission believes halving premature mortality by 2050 is globally achievable, it acknowledges this target may be “perhaps only aspirational for some countries, realistically speaking.” “We have a tendency to focus on the new, shiny things,” Chang added. “Our message is for countries to stay focused on these priority conditions.” ‘Tobacco is the new tobacco’ Six out of ten smokers, or 750 million people globally want to quit tobacco use. High tobacco taxes are “by far” the most crucial policy tool for reducing premature deaths, according to the report. “You often hear about other risk factors, but we argue tobacco is the new tobacco,” Chang explained. Recent research suggests raising excise taxes on tobacco, alcohol, and sugary drinks by 50% could yield $2.1 trillion for low- and middle-income countries over five years. This could boost healthcare spending in these nations by 40% if directed towards health initiatives. The Commission highlights the Middle East and North Africa as an example of untapped potential in tobacco control. With 160 million smokers and rising prevalence among youth and women, the region faces a growing health crisis. Egypt’s smoking rates doubled between 2000 and 2018, while tobacco became more affordable in conflict-affected countries like Iraq and Syria. The region’s tobacco taxes, second-lowest globally, fall far short of the World Health Organization’s recommended 70% excise tax. “Despite wide experience with its successful use, tobacco taxation remains a policy tool that is still greatly underused,” the Commission found. “Raising taxes on tobacco can do more to reduce premature mortality than any other single health policy.” High risk of ‘COVID magnitude’ pandemic in next decade The Lancet Comission estimates there is a 23% change of a COVID-scale pandemic in the next decade. New modeling for the Commission’s report indicates a 23% chance of a pandemic as severe as COVID-19 occurring within a decade. Unprepared health systems could see progress on reducing premature deaths plummet if caught off guard again. “There is a high risk of another pandemic of Covid-like magnitude,” Chang warned. “To put it another way, in most years there will be zero pandemic deaths, and in some years there will be millions of pandemic deaths.” The Commission’s analysis estimates an average of 2.5 million deaths per year due to pandemics when viewed over a long time horizon. This figure is comparable to the current annual death toll from AIDS, malaria, and tuberculosis combined, and significantly exceeds even pessimistic projections for annual climate change-related deaths in coming decades. “People should wake up at that figure,” Helen Clark, former Prime Minister of New Zealand, warned the summit. The warning from the Commission comes as global headwinds from conflict, climate change and debt hammer health budgets. Neglecting pandemic preparedness could have severe consequences, particularly for poorer countries less equipped to handle sudden outbreaks. “We need to learn the lessons not just from COVID, but from Mpox, Ebola … and avoid this panic-neglect cycle,” said Dr Seth Berkley, former CEO of Gavi, the Vaccine Alliance. “Unfortunately, I don’t think we’re doing a very good job.” From 1993 to Berlin A figure from the World Bank’s 1993 report making the case for health as an economic investment. The Lancet Comission report is the latest in a line of studies that traces its lineage back to a pivotal World Bank report that changed the landscape of global health finance. The World Bank’s 1993 report, Investing in Health, the only report on health ever published by the Bank, was the first to make an argument still used by health advocates and ministers across the globe: health is an investment. “The World Bank saying investing in health is no just a cost to society, but an investment that was justified on pure economic grounds … was revolutionary,” Berkley recalled. “Prior to this, people saw it as a cost – if you get richer, you can afford health, but this really changed the thinking.” The Commission’s work has expanded on the World Bank’s initial calculations, incorporating factors such as the impact of out-of-pocket health costs on economies and personal livelihoods. This broader perspective has significantly increased the estimated economic benefits of maintaining healthy societies, from the World Bank’s initial 11% to 24%. “The important thing is that each one of these reports, including this one, says the case is better than ever for investing in health, and we need to keep talking about that, particularly at a time when the headwinds are so strong,” Berkley emphasizes. The latest report continues this tradition, reaffirming that health investment remains one of the most effective strategies for improving both individual and societal outcomes. “Today, the case is better than ever for going for mortality reduction,” said Dr Gavin Yamey, director of Duke University’s Center for Policy Impact in Global Health and lead author of the commission report “It’s a prize within reach. It will have extraordinary health, welfare and economic benefits.” Image Credits: Sarah Johnson. Transformative Potential of Long-Acting Preventive Drugs Takes Centre Stage at HIV Conference 14/10/2024 Edith Magak At a HIVR4P’s press conference: Jeremy Nuttall, Elizabeth Irungu, Mark Marzinke, Alessandro Grattoni, William Hahn and Colleen Kelley. LIMA, Peru – The infection-prevention potential of Lenacapavir, the long-acting anti-HIV injectable administered just twice a year, took centre stage at the fifth HIV Research for Prevention Conference (HIVR4P) held last week. However, several other important studies were also unveiled, including an injectable that combines contraception and HIV protection, results from a three-month vaginal ring, and real-world findings from Zambia’s rollout of long-acting injectable cabotegravir. Lenacapavir in diverse populations Lenacapavir reduced HIV infections by 96% in a gender-diverse population, according to results from the PURPOSE 2 trial, which enrolled over 3,200 participants from Argentina, Brazil, Mexico, Peru, South Africa, Thailand, and the US between June 2021 and December 2023. Participants were randomly assigned to one of two groups: one receiving lenacapavir injections every six months and the other taking daily oral pills for pre-exposure prophylaxis (PrEP) with matched placebos. The average age of participants was 28, with over one-third under the age of 25. Around 70% identified as non-white, and the gender breakdown featured cisgender men, transgender men, transgender women, and non-binary individuals who have sex with partners assigned male at birth. At 39 weeks, only two HIV cases occurred in the lenacapavir group of 2,179 individuals, translating to a 96% reduction in HIV incidence, according to Dr Colleen Kelley from Emory University. In contrast, there were nine new HIV cases among the 1,087 participants taking daily oral TDF pills (comprising tenofovir disoproxil fumarate and emtricitabine and marketed as Truvada). This makes lenacapavir 89% more effective than oral PrEP. The findings echoed earlier results from the PURPOSE 1 trial, which showed 100% efficacy in preventing HIV among cisgender women in Africa. With regulatory filings expected to begin globally by the end of 2024, lenacapavir has the potential to be a transformative HIV prevention tool. Future phases of the study will focus on other groups, including women in the US (PURPOSE 3) and people who inject drugs (PURPOSE 4). The twice-yearly injectable, lenacapavir (marketed as Sunlenca in the US) could make a huge difference to HIV prevention is widely accessible. Injectable contraceptive and HIV prevention in one For millions of young women worldwide, two major health concerns often intersect: HIV acquisition and unintended pregnancy. Many have expressed a preference for a method that protects against both. At the conference, Melissa Peet from CONRAD presented results from a promising solution—a silica-based hydrogel injectable that combines HIV antiretroviral drugs with contraception in a single shot. In designing this dual-purpose method, researchers selected long-acting cabotegravir (CAB-LA) as the HIV prevention drug and levonorgestrel (LNG) as the contraceptive. The hydrogel injectable they developed is a silica-biodegradable material comprising two compartments, one for each medication. The injectable is capable of delivering both drugs with a single injection offering dual protection for three months. Preclinical tests in rats showed sustained drug levels in the bloodstream without significant interactions or safety concerns, and the researchers are now conducting additional studies in non-human primates to fine-tune dosing and asses the duration of protective drug concentration. No interactions between Cabotegravir and contraceptives One concern with combining HIV prevention and contraception has been the potential for drug interactions, particularly between long-acting HIV medications like cabotegravir (CAB-LA) and commonly used contraceptives. To address this, Dr. Mark Marzinke from Johns Hopkins University presented results from a sub-study within the HPTN 084 trial to explore any potential interactions. The study included 170 participants from South Africa with a median age of 23. A total of 80 women were randomised to the CAB-LA arm and 90 in the oral PrEP arm. Participants used three types of hormonal contraceptives: etonogestrel implants, injectable norethindrone, or medroxyprogesterone acetate (MPA), alongside either CAB-LA or oral PrEP. Researchers measured drug concentrations at enrolment and again at weeks 25, 49, and 73 to determine if there were any drug interactions. The results were reassuring: plasma concentrations of the contraceptives remained high enough to prevent pregnancy in both the CAB-LA and oral PrEP groups. CAB-LA concentrations were also consistent across contraceptive types, indicating that CAB-LA does not interfere with contraceptive effectiveness. However, tenofovir concentrations were unquantifiable for most participants, regardless of contraceptive type, due to low adherence to oral PrEP. New data on the three-month vaginal ring For women seeking long-term HIV prevention, the dapivirine vaginal ring, sometimes called the PrEP ring, has been a promising option. This is a flexible silicone ring that is placed in the vagina that releases the anti-HIV drug, dapivirine, over a month. Delegates at the conference heard results from a South African study comparing the bioavailability of the standard one-month dapivirine ring with a new three-month version. The study enrolled 124 women, but only 104 completed the trial. This was a crossover trial with two treatment phases: half the group started with the one-month ring (containing 25 mg of dapivirine) and then switched to the three-month ring, containing 100 mg of dapivirine. The other group followed the reverse order; they began with the three-month ring and later switched to the one-month ring. The three-month ring was identical to the one-month version in silicone, dimensions, and appearance. Plasma and vaginal fluid samples were collected throughout the study to measure drug levels. Based on dapivirine concentrations in plasma, results showed that the three-month ring provided greater overall drug exposure than the one-month version, indicating equal or possibly higher efficacy in preventing HIV. Jeremy Nuttall from the Population Council’s Center for Biomedical Research, who presented the findings, noted that the reduced frequency of ring changes might increase acceptability and adherence, potentially improving overall effectiveness. He also highlighted that the estimated cost of the three-month ring is $16, making it a potentially more affordable option, projecting that the three-month ring could become available on the market by 2026. Roxana Bretoneche protesting about the lack of community participation at HIVR4P. Real-world results from Zambia’s CAB-LA rollout Zambia became the first country in sub-Saharan Africa to roll out long-acting injectable PrEP (CAB-LA) beyond clinical trials, sharing results from their first three months (February to April 2024) in real-world settings. A total of 609 individuals with a median age of 24 were enrolled across six health facilities in two districts. Among the clients, 55% were female, 20% were adolescent boys and young men, 7% identified as key populations, and 40% as other high-risk populations. Adamson Ndhlovu from Zambia’s JSI USAID DISCOVER-Health Project shared that over 90% of participants due for their second injection received it on time. A total of 24 participants (about 4%) discontinued CAB-LA. Most discontinuations were due to hepatitis B (20 cases), with two participants stopping due to pregnancy, one due to a severe rash, and one because of severe pain at the injection site. Those who discontinued were switched to oral PrEP. During a press briefing at the conference, Professor Lloyd Mulenga from Zambia’s Ministry of Health stated that four of those enrolled had acquired HIV, explaining that they likely had undetected HIV at the time they started PrEP. The real-world implementation of CAB-LA is anticipated to expand, as ViiV Healthcare, the manufacturer, announced at the conference its plans to triple the supply of cabotegravir that will be available for low- and middle-income countries in 2025-2026 to at least two million doses. Image Credits: Nicole Bergman / IAS, Gilead, Nicole Bergman / IAS. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Local Manufacturers Drive New Initiative to Boost East Africa’s Medical Oxygen Supply 22/10/2024 Kerry Cullinan Kenyan manufacturer Synergy’s new medical oxygen manufacturing unit is unveiled in Mombasa, supported by Unitaid. A sod-turning ceremony in Mombasa, Kenya, on Tuesday marked the launch of the East African Programme on Oxygen Access (EAPOA), which aims to massively boost access to medical oxygen in the region. Unitaid is investing $22 million in support for Kenyan manufacturers Hewatele and Synergy, and Tanzania Oxygen Limited to set up Africa’s first liquid oxygen regional manufacturing initiative. Medical oxygen is an essential lifesaving medicine used to treat a wide range of diseases and chronic heart and lung conditions including pneumonia, COVID-19, advanced HIV infection, severe tuberculosis and malaria. It is also vital for maternal and newborn survival as well as in surgeries, emergency, and critical care. Yet many parts of sub-Saharan Africa remain severely under-resourced with some countries accessing less than 10% of the oxygen they need. The initiative is projected to save 154,000 lives in the two countries alone over the next decade, with the three manufacturers expanding the production capacity threefold by over 60 tons per day, enabling treatment of thousands of additional patients each month. “The key role of medical oxygen at all levels of care cannot be over-emphasised. Kenya’s drive towards universal health coverage requires uninterrupted access to all health products and technologies including medical oxygen,” said Harry Kimtai, Principal Secretary of the Ministry of Health of Kenya. “I congratulate Unitaid and all their partners for making funding available and providing technical support to make this possible. We look forward to working together to continue advancing initiatives that boost availability of other health products and technologies apart from medical oxygen” I attended the groundbreaking ceremony for the oxygen production plant in Kokotoni, Rabai Sub-County, which is a collaborative effort between the Clinton Health Access Initiative (CHAI), UNITAID, and Synergy Gases (K) Limited. This initiative holds great promise not just for the… pic.twitter.com/Yh5zJ5xHGT — Gideon M. Mung’aro, OGW (@GideonMungaroM) October 22, 2024 “This is Africa’s first regional manufacturing approach to increasing access to medical oxygen,” according to Unitaid, which is working with governments in both countries and other partners. “The program aims to expand medical oxygen production by 300% in East Africa and reduce oxygen prices by up to 27%, making it more affordable for health care systems across the region, and enabling treatment of thousands of additional patients each month,” added Unitaid in a media release. The Clinton Health Access Initiative (CHAI) will lead on market strategy, while PATH will focus on community and civil society engagement. Blended financing “Using an innovative blended financing approach that combines grants awarded to Unitaid by Canada and Japan, concessional loans, and support from MedAccess through volume guarantees, this program will strengthen the capacity of Kenyan and Tanzanian oxygen suppliers, fostering competition in the market and ensuring a sustainable, affordable oxygen supply across East and Southern Africa,” according to Unitaid. The EAPOA aims to develop a regional network of liquid oxygen production facilities, known as air separation units, to ensure medical oxygen reaches underserved communities. Air separation units produce bulk liquid oxygen, which is the gold standard for medical applications, with compact storage, economic efficiencies, and high purity level. However, building these units requires significant capital investment. Aside from the Mombasa facility, other facilities are planned in the Kenyan capital of Nairobi, Kenya, and Tanzania’s Dar es Salaam. These will serve as the key hubs for the production and distribution of liquid medical oxygen to their home countries and their neighbours, including Malawi, Mozambique, Uganda and Zambia. Medical oxygen is essential for treatment many illnesses. “The Mombasa facility is just the beginning of a larger effort to transform oxygen access across Africa,” said Unitaid executive director Dr Philippe Duneton. “Medical oxygen is critical for saving lives, yet too many health facilities in this region struggle with access. By working together with Kenyan and Tanzanian manufacturers and other partners, we are ensuring that oxygen is no longer a luxury but a basic right for all patients, especially in times of critical need.” The program is part of a broader Unitaid strategy to increase regional and local production of essential health products in Africa, in line with continental initiatives to enhance health security, such as Africa CDC’s Partnership for the Harmonization of African Health Products Manufacturing. “The Project will focus on three main aspects ensuring its sustainability,” said CHAI country director of East and Southern Africa, Gerald Macharia. “Well-placed infrastructure selected in partnership with Ministries of Health, longer-term budgeting for liquid oxygen supply, and the grant/ loan /volume guarantees available to companies, which aim to facilitate lower pricing, patient access, and regular payment for services in the long-term.” New US Lead Pipe Regulation Could Protect Nearly a Million Infants from Low Birthweight 22/10/2024 Sophia Samantaroy A lead poisoning prevention workshop in Kathmandu, Nepal organized by the Ministry of Health and Population (MoHP) and WHO Country Office for Nepal. The US Environmental Protection Agency (EPA) recently announced a new ruling that requires drinking water systems to replace lead pipes within 10 years. The rule also strengthens requirements to locate lead pipes, improve testing for lead in water, and ensure that exposure is minimized while lead pipe replacement efforts are underway. “Families like yours, exposed to lead in the water–they deserve better… We’re finally addressing an issue that should have been addressed a long time ago: the danger lead pipes pose to our drinking water,” said President Biden earlier this month. The EPA estimates that up to nine million US homes are served through legacy lead pipes across the country, many of which are located in lower-income communities and communities of color, “creating disproportionate lead exposure burden for these families,” the agency said in a press release. To remove the millions of lead pipes still in use, the EPA has tapped $2.6 billion from the Bipartisan Infrastructure Law. The agency estimates that the public health and economic benefits of the final rule are estimated to be up to “13 times greater than the costs,” including protecting 900,000 infants from low birthweight, preventing 2,600 cases of ADHD, and reducing 1,500 cases of premature death from heart disease each year following the ruling. The EPA’s new ruling could over two thousand cases of ADHD and protect nearly a million infants from being born with low birthweight each year. The Biden Administration’s announcement came just two weeks before International Lead Poisoning Prevention Week, which highlighted the persistent threat of lead for the world’s children population. “Lead continues to be one of the greatest public health concerns,” said Dr Maria Neira, World Health Organization (WHO) environment director. “Urgent action is required from member states to prevent exposure to lead.” The United Nations Children’s Fund (UNICEF) estimates that one in three children have blood lead levels at or above 5µg/dl – levels that can cause lifelong neurological, behavioral, and health problems like anemia, hypertension, and toxicity to reproductive organs. “The science is clear,” noted an EPA statement, “lead is a potent neurotoxin and there is no safe level of exposure.” Both the EPA and US Centers for Disease Control and Prevention (CDC) recommend having children tested for lead as the best way to determine exposure, especially if living in a house built before 1978. High risk of elevated lead in South Asia South Asia, Africa, and parts of South America are lead exposure hotspots. UNICEF’s landmark 2020 lead poisoning report exposed the scale at which children are exposed to high levels of lead. Of the 815 million children estimated to have elevated blood lead levels, nearly half live in India, Pakistan, Nepal, and other South Asian countries. The reasons for higher exposure, the UNICEF report notes, comes from a high prevalence of unsafe lead-acid battery recycling, and contaminated spices, ceramics, and toys. Children can also be exposed to lead in soil, dust, air, and water. Fewer regulations and enforcement leaves industries lacking environmentally safe practices, and the absence of blood lead screening make it difficult to protect children from lead hazards. The report also cites poor nutrition as a risk factor for higher lead absorption in lower-and middle-income countries. Educational materials in Rochester, New York, for people at higher risk for lead poisoning. “With few early symptoms, lead silently wreaks havoc on children’s health and development, with possibly fatal consequences,” said Henrietta Fore, UNICEF’s Executive Director at the time, at the report launch. “Knowing how widespread lead pollution is — and understanding the destruction it causes to individual lives and communities — must inspire urgent action to protect children once and for all.” “Since the 1970s, efforts to reduce lead in paint, gasoline, water, yards and even playgrounds have resulted in considerable success in reducing blood lead levels among children in the United States,” wrote the report authors. “The issue of lead poisoning is not new, but our understanding of the scope and scale of its impacts and feasible solutions has never been better. Proven solutions exist for low- and middle-income countries, those most burdened by this challenge. Those solutions can be implemented today.” Image Credits: S. Samantaroy/HPW, WHO, EPA, UNICEF. Rwanda’s High-Level Critical Care Ensures Low Marburg Fatality Rate 21/10/2024 Kerry Cullinan Rwandan Health Minister Dr Sabin Nsanzimana (left) and WHO Director General Dr Tedros Adhanom Ghebreyesus address a media briefing in Kigali on Sunday. After a full week of no new Marburg cases, Rwanda appears to have contained one of the biggest recorded of the deadly virus outbreaks – and with a low case fatality rate of 24%. World Health Organization (WHO) Director-General Dr Tedros Adhanom Ghebreyesus, who visited the country over the weekend, praised the level of Rwanda’s critical care for patients as well as how the country deployed high-level leadership to address the viral haemorrhagic fever, which often kills over 80% of those infected. “Two of the patients we met had experienced all of the symptoms of Marburg, including multiple organ failure, but they were put on life support, they were successfully intubated and extubated, and are now recovering,” Tedros told a media briefing in Rwanda on Sunday. “We believe this is the first time patients with Marburg virus have been extubated in Africa. These patients would have died in previous outbreaks.” Intubation involves inserting a tube through a patient’s nose or mouth into their windpipe (trachea) to help them breathe. This tube can be connected to a ventilator. Extubation is when the tube is removed. Tedros added that Rwanda had worked for many years to “strengthen its health system, to develop capacities for critical care and life support that can be deployed both in regular hospital care and in emergencies”. However, he warned that Marburg is “one of the world’s most dangerous viruses, and continued vigilance is essential”. The outbreak will only be declared over once no new cases have been recorded for 21 days, potentially on 5 November. Sabin’s vaccine candidate used Although there are no approved vaccines or therapeutics for Marburg, Rwanda fast-tracked the trials of a vaccine candidate from the Sabin Vaccine Institute, and an antiviral drug, remdesivir. On 5 October, Sabin delivered 700 doses of its single-dose candidate vaccine, followed by a further 1,000 on 12 October. These have been used to vaccinate health workers “as part of a Phase 2 rapid response open-label trial, sponsored by the Rwanda Biomedical Centre”, according to Sabin. Patients’ close contacts have also been vaccinated. Rwanda developed its own trial protocol after rejecting the WHO’s protocol which would have involved a control group that got vaccinated three weeks after the trial group, according to the journal, Science. Rwanda opted to vaccinate all trial participants at once. However, the remdesivir trial does involve a control group. “The swift initiation of the open-label trial was set in motion on 26 September, when the Rwandan President’s office contacted Sabin CEO Amy Finan to request assistance with the outbreak response,” Sabin said in a statement. Rwanda officially declared the outbreak the next day. “In an outbreak, every moment counts, and our seamless collaboration with the Rwandan government was key to accelerating the process,” said Finan. Sabin’s manufacturing partner, Italy-based ReiThera, produced the drug substance and filled and finished doses for shipment to Rwanda. “On our side, we moved quickly by leveraging our experience with other outbreaks and having vaccine doses and supporting documents ready, thanks to a strong partnership with ReiThera,” Finan added. Sabin’s team only consists of 15 staff members, but Finan said that “their dedication, along with that of our Rwandan colleagues, BARDA [the US Center for the Biomedical Advanced Research and Development Authority] and other partners, enabled us to mobilise so rapidly. “This remarkable effort highlights the power of partnerships and preparedness in addressing urgent public health needs,” said Finan, who also visited Rwanda over the weekend. Meanwhile, Tedros congratulated Rwanda for the speed with which it initiated trials of both vaccines and therapeutics, adding that the WHO hopes that these trials “will help to generate the data to support approval of these products for future outbreaks”. Belen Calvo Uyarra, the European Union’s Ambassador to Rwanda, also praised the country’s rapid response to containing the virus. “Respect to the government of Rwanda and the Rwanda Ministry of Health for proactive leadership, rapid and robust continued response, and professionalism of health workers,” Uyarra posted on X. She and Tedros also visited the site of the BioNTech vaccine manufacturing facility, announced two years ago to facilitate local production of vaccines. Two years ago I visited #Rwanda for the groundbreaking ceremony of the BioNTech facility in Kigali, which raised great hope for local production of vaccines in Africa. Today, I returned to the site and was proud to witness the fast progress of construction of the facility.… pic.twitter.com/8YGwcTVaYe — Tedros Adhanom Ghebreyesus (@DrTedros) October 20, 2024 “I was very pleased to see the significant progress in construction,” said Tedros. “One of the key lessons of the COVID-19 pandemic was the need to expand local production of vaccines to avoid the inequitable access to vaccines that we saw, and we’re pleased to see the way Rwanda and BioNTech are investing in local production. “You know how Africa was treated when the vaccines arrived, with vaccine inequity and vaccine nationalism, and we hope these strategic investments will fix the inequity problems we faced during COVID.” Cities Face ‘Severe Degradation’ Without Meaningful Climate Action, Warn Experts 21/10/2024 Sophia Samantaroy Experts at the yearly Lancet International Health lecture argued that green urban planning can improve health. Cities that fail to take meaningful climate action face a future of severe degradation with infrastructure collapse and environmental deterioration, warned climate and health experts at the yearly Academy of Medical Sciences & The Lancet International Health Lecture in London. “Madrid’s climate in 2050 will resemble Marrakech’s climate today. I don’t think we want that,” said Professor Mark Nieuwenhuijsen, the keynote speaker. To stave off this scenario, cities must adapt with health priorities at the forefront. “For our cities, we’re looking towards solutions that reduce CO2 emissions and also improve environment, equality and, of course, liveability and health.” By 2050, two-thirds of the global population is expected to live in a city. Yet climate change is increasingly threatening human health in urban areas, where swaths of asphalt and concrete exacerbate rising temperatures. Climate change accounts for 37% of heat-related deaths, leaving cities especially vulnerable to heat waves and extreme heat. Dr Mark Nieuwenhuijsen argues that urban planners must consider health is designing the future of cities. Preventing climate-related mortality in cities requires urban planning with an intentional health focus, commented Nieuwenhuijsen. He argued that smart urban planning reduces greenhouse gas emissions and promotes health, but only if we can break away from an “addiction” to fossil fuels. “We know that these fossil fuels are responsible for more than 5 million deaths each year because of air pollution.” Despite the growing knowledge of the health burden of fossil fuels, cities continue to sprawl “with Europe leading the way.” Fossil fuel use has led to “car-centric asphalt-dominated urban planning and extensive urban sprawl, which have detrimental effects on health,” said Nieuwenhuijsen. Sprawling urban areas increases car dependency, even though public transport systems and active transportation – like walking and cycling – are more cost effective. Compact vs green cities – policies that include the best of both models Four different European city configurations vary in their health and environmental effects–with compact cities being the lowest emittors yet having the highest mortality rates compared to less dense cities. In Europe, where many cities are growing faster than their populations, high population density has potential advantages like shortened commute times, decreased care dependency, higher energy efficiency, and decreased building material consumption. The more compact a city, the more efficient. Yet compact cities have potential drawbacks, including higher mortality rates, traffic density, air and noise pollution, and excess heat. Nieuwenhuijsen presented European cities as falling into one of four groups: compact high-density cities, open low-rise medium-density cities, open lowrise low-density cities, and green low-density cities. Analyzing cities across these categories show a split: cities either fall into higher mortality but lower greenhouse emissions, or lower mortality but higher emissions. A city like Barcelona – compact and high-density -–can expect to have a 10-15% higher mortality rate, poorer air quality, and stronger heat island effect, but lower emission, explained Nieuwenhuijsen. Overall, the researchers estimated that poor urban planning results in 20% of premature mortality. “Barcelona is a wonderful city, but it has too much air pollution, too much noise, not enough green space.” “In contrast, greener and less densely populated cities have lower mortality rates, lower air pollution levels, and a lower urban heat island effect, but higher carbon footprints per person.” This dichotomy – where current urban configurations are either high emitters with better health quality, or lower emitters with worse health – means that cities must implement policies that better health and reduce emissions. Nieuwenhuijsen believes that both are possible. Policies that lower air pollution levels and reliance on cars, and increase green space, cycling lanes, and physical activity would “substantially reduce the mortality rate,” he argued. Super blocks, green space, and 15-minute cities Barcelona is one a several major cities implementing innovative urban planning to improve environmental and human health. Several cities have begun implementing innovative urban models that bridge the goals of lower emissions and healthier environments, especially in how they use public land. “A lot of our public space in our cities is, at the moment, actually used by cars. I mean, in Spain, 69% of public space is used by cars because our roads are also public space. Parking is public space. I mean, this is the kind of space that we could use in a much better way,” commented Nieuwenhuijsen. In Paris, a vision to become a “15-minute city” – where all major destinations can be reached within 15 minutes of the home – has increased investments in bike lanes and car-free zones. Barcelona’s “superblocks,” London’s low traffic neighborhoods, and the Vauban Freiburg car-free neighborhood are all promising solutions to reduce premature deaths and increase green spaces. Nieuwenhuijsen and other experts convened at the event pointed to these examples and others as evidence that urban design changes are possible. Several Chinese cities have also embraced the intersection of urban planning and novel technologies to prevent flooding through their Sponge city designs, commented Dr Maria Neira, the World Health Organization’s director of Public Health, Environment and Social Determinants of Health. “More and more we need to be prepared to work with urban planners, the architects working at the city level. And I have the impression that sometimes they are better prepared, more advanced, more engaged and more passionate, than our public health officers working at the city level,” said Neira. “So we need to sort it out and create these very strong arguments for our public health officers as well, to push at the city level, at the Urban level, for engagement with the Urban healthy urban planning.” Image Credits: Michele Castrezzati, Fons Heijnsbroek, The Lancet, The Lancet. Rwanda’s Marburg Outbreak Wanes But Mpox Continues to Spread 17/10/2024 Kerry Cullinan Dr Jean Kaseya and Dr Sabin Nsanzimana. While Rwanda appears to have its Marburg virus outbreak under control with no new cases reported in the past three days in Rwanda, mpox continues to spread – now affecting 18 countries with 3051 new cases in the past week. Since declaring the Marburg outbreak three weeks ago, Rwanda has confirmed 62 cases, of which 15 have died, 38 have recovered and nine cases are still receiving treatment with the majority improving, said Health Minister Dr Sabin Nsanzimana on Thursday. “The case fatality rate overall is 24% and we’ve vaccinated 856 people,” Nsanzimana told an Africa Centres for Disease Control and Prevention (CDC) briefing, describing the trend as “very encouraging”. As the vaccine is “investigational”, its rollout required more rigorous consent, sampling and documentation, but demand for it has been “very high”, he added. the vaccines you are providing highly accepted, especially among healthcare providers. Around 90% of those infected are health workers and their close contacts from the intensive care units of two hospitals that treated the very first patients. The index patients was co-infected with malaria which slowed the diagnosis of Marburg, which has similar symptoms. Rwanda’s health ministry has also tested over 4,000 people “to make sure we don’t miss any cases”, added Nsanzimana. He attributed “intense activity on the ground”, ring vaccination [vaccinating the close contacts of people with Marburg] and new antivirals for the turnaround in what is the biggest Marburg outbreak ever recorded. The virus, which is from the same family as Ebola and, in some outbreaks, has killed over 80% of those infected. While the zoonotic origin of the outbreak is still unknown, Nsanzimana said Rwanda will be reporting its findings on the the serology and gene sequencing of the virus within a few days. At the same time, it has a team on the ground hunting for the source of the virus. Mpox ‘not under control’ Mpox cases have now been identified in 18 African countries, with new additions being Zambia and Zimbabwe. In the past week, 3051 new cases have been reported – including two male prisoners in Uganda. “Mpox is not under control,” warned Africa CDC Director-General Dr Jean Kaseya. Despite calling a continental meeting in April to warn countries of the risk, cases have risen exponentially: from slightly under 6,000 then to 42,438 suspected mpox cases at present – although only 8,113 have been clinically confirmed. A rapid test to diagnose mpox is in the pipeline and will transform the testing landscape, said Kaseya. Kaseya flagged the threat to internally displaced people (IDP), particularly in the Democratic Republic of Congo (DRC), and prisoners – both groups characterised by close contact. In the eastern DRC, conflict has displaced some 2.5 million people who are now living in camps in close quarters with limited access to water, sanitation and hygiene. The two Ugandan prisoners were initially diagnosed with chicken pox – which has small lesions that are itchy not painful like mpox. DRC vaccination plan includes MSM, transgender people The DRC’s vaccination campaign started two weeks ago in three provinces – North Kivu, South Kivu and Tshopo – and is “moving well”, said Kaseya, who hails from DRC. The country’s plan includes men who have sex with men (MSM) and sex workers, as mpox can be sexually transmitted. In DRC, same-sex sexual contact is not outlawed as it is in many of the other countries currently affected by mpox – Uganda, Burundi, Kenya, Tanzania, Zambia and Zimbabwe. “When are talking about MSM, we are clear as Africa CDC. We are saying all human beings have the same rights, and we are supporting countries to plan vaccination for all of them, including men having sex with other men,” said Kaseya empathically. “We are proud and we are glad to see in DRC that we have MSM included,” he added. Kaseya said that early messaging about mpox Clade 1B only being associated with sexual transmission was wrong – as was the failure to talk about MSM as the main mode of transmission iun the 2022 outbreak. “There was the stigma talking about men having sex with other men as the main transmission mode of mpox. But if we put it in the context in Africa, that one in some countries is still a taboo. “We believe with our effort, what we are doing is sensitizing countries, and we are proud to see that DRC are mentioning that.” He added that risk communication and community engagement involving “people who are openly saying we are these key populations” was also important. Uganda tightened its anti-LGBTQ laws recently and, while it plans to test all 1,087 prisoners who possibly had contact with the two prisoners recently diagnosed with mpox, it is unclear how it will approach MSM as a mode of transmission other than to crack down further on smae-sex activity. Europe’s New Air Quality Law is a Breakthrough for Clean Air Globally 16/10/2024 Jane Burston Dirty smoke billows from chimneys in Poland. Europe is now poised to deliver cleaner, healthier air – thanks to adoption this week of the revised Ambient Air Quality Directive (AAQD) by the European Union. This marks a crucial victory for the health and wellbeing of millions across the EU and serves as a beacon for the clean air movement worldwide. The AAQD underpins Europe’s air quality standards, and its revision is a significant breakthrough in addressing the public health crisis of air pollution. Each year, air pollution cuts short the lives of nearly 300,000 Europeans, contributing to respiratory illnesses, cardiovascular disease, and other serious health conditions, according to the EU’s impact assessment report. Improving air quality is a public health imperative. It’s also crucial for the environment and the economy, making the case for stronger EU-wide legislation even clearer. A healthier future The revised AAQD brings Europe’s air quality standards closer to the World Health Organization’s (WHO) air quality guidelines. It sets tougher, legally binding limits on harmful pollutants like nitrogen dioxide (NO₂) and fine particulate matter (PM2.5), representing a doubling of ambition for these two major pollutants, in line with WHO’s interim targets. These pollutants have long been linked to severe health impacts that are particularly harmful for vulnerable groups, such as babies and young children and people with certain conditions such as Chronic Obstructive Pulmonary Disease. By delivering cleaner air, the AAQD could mean the difference between a lifetime of illness and a healthy future for future generations. The AAQD also strengthens the monitoring and measuring provisions for air quality, introducing air quality roadmaps to support progress ahead of its 2030 deadline. The new rules bring about a fairer regime for people affected by air pollution as the rules for access to justice and compensation for those whose health have been impacted by dirty air have been improved. Some of the most polluted regions within member states can delay meeting the new targets for up to 10 years (until 2040) under certain conditions. Although these derogations (or exceptions) provide more leeway than originally envisaged, the compromise, alongside strict conditions for delays, ensure that none of the 27 Member States are left behind. Significant impact if properly implemented Overall, the Directive remains a significant win with ambitious targets and tightly regulated conditions for any delays. Importantly, the initially proposed ambition on limit values remained intact following the two-year legislative process, despite widespread pushback against legislation falling under the EU Green Deal, indicating the scale of this victory for clean air campaigners. One of the key reasons for the AAQD’s success is that it is both an environmental law and a critical public health intervention. By recognising that air quality is a matter of life and death, policymakers have acknowledged the need to protect the most vulnerable in our society. The impact of the new legislation in Europe will be significant if the AAQD is properly implemented. The new rules can prevent more than 55% of premature deaths linked to air pollution in the EU. That’s not just a number – that’s hundreds of thousands of people, each with families, who will live longer, healthier lives. In addition to delivering significant health and environmental benefits, improving the air we breathe makes economic sense. Investing €6 billion annually in cleaner air will deliver up to €121 billion in benefits (according to the EU’s analysis). That’s equivalent to building hundreds of new hospitals or creating hundreds of thousands of new jobs in green industries. Echoing this analysis, the Brussels-based think tank, Bruegel, estimated that implementing clean air measures could boost economic growth by €50 to €60 billion every year[3] and save approximately €600 billion each year in the European Union, the equivalent to 4% of GDP. Ripple effect The importance of the AAQD extends beyond the EU’s borders. By taking decisive action, the EU has positioned itself among the global leaders in air quality management, setting an example for other regions grappling with similar challenges. Air pollution is a global problem, responsible for eight million premature deaths annually worldwide, as reported in the British Medical Journal, and the EU’s solutions will, I hope, inspire other countries to pursue stronger actions. Ongoing engagement and sustained political will are key to ensuring the success of these measures. The real test will come as member states move to transpose the Directive into law and work to implement these new standards. National and local governments will need to invest in cleaner technologies, green transport and clean heating while improving air quality monitoring and ensuring that enforcement is taken seriously. Let’s celebrate this moment, but also remain focused on the work that still needs to be done. Air pollution is an invisible killer, shortening lives and ravaging our communities. With this new Directive, we are fighting back. Jane Burston founded and leads the Clean Air Fund (CAF), a global philanthropic organisation working with governments, funders, businesses and campaigners to create a future where everyone breathes clean air. Before setting up CAF, Jane worked as head of Climate and Energy Science in the UK government. Prior to that, as head of Energy and Environment at the UK National Physical Laboratory, she managed a team of 150 scientists working in air quality, GHG measurement and renewable energy. Image Credits: Janusz Walczak/ Unsplash. World Can Halve Premature Deaths by 2050, Lancet Commission Reports 15/10/2024 Stefan Anderson BERLIN – Countries worldwide, regardless of income level, can halve premature death rates by 2050, a new Lancet report presented at the closing of the World Health Summit in Berlin suggests. Fifteen key health threats are driving premature deaths worldwide, with tobacco use leading the pack “by far”, the Lancet Commission for Investing in Health found. Targeting interventions in these areas – with over half involving maternal, newborn, child, and infectious diseases – could dramatically reduce global deaths before age 70, the Commission said. “Sharp reductions in mortality and morbidity can be achieved by focusing on 15 priority conditions,” Dr Angela Chang from the University of Southern Denmark and lead author of the report, told a panel at the World Health Summit in Berlin on Tuesday. “Doubling down on past health investments, focusing resources on a narrow set of conditions, scaling up financing and developing new technologies can continue to have an enormous impact despite the headwinds.” The 15 priority conditions, selected from over 17,000 internationally recognized health diagnoses, account for approximately 80% of the life expectancy gap between most regions and the North Atlantic, defined in the report as North America and Europe. These conditions account for 86% of the gap between China and the North Atlantic, and 74% between sub-Saharan Africa and the North Atlantic. “There’s a 22-year gap in life expectancy between Sub-Saharan Africa and the North Atlantic, Chang explained. “Close to 80% of this gap can be explained by these 15 priority conditions, and over half of the difference can be attributed to eight infectious and maternal health conditions.” If the global goal is met, the average premature mortality rate worldwide would fall to about 15%, matching levels currently seen in Europe and North America—today’s global benchmark. Achieving this would mean dramatic improvements for billions, especially in low- and middle-income countries. In Sub-Saharan Africa, the worst-performing region, premature mortality sits at 52%. Setting priorities straight The report’s optimism is rooted in historical data. Globally, the probability of dying before 70 has halved since the 1960s, falling from 62% to 31% for individuals born in 2019. Thirty-seven countries, including populous nations like Bangladesh, China, Japan, and Vietnam, have already halved their premature death rates in similar or shorter periods than the 26 years remaining until the 2050 target date. The Commission recommends public financing for essential medicines targeting the 15 key conditions driving premature mortality. It suggests mobilizing international funding and joint procurement efforts, similar to strategies used by GAVI, PEPFAR, and the Global Fund, to reduce costs for patients and governments alike. “Inadequate access to medicines and high out-of-pocket costs are major threats to cutting premature mortality,” Chang noted. “We learned from the Global Fund’s experience how national government subsidies can steer resources towards priority interventions and reduce out-of-pocket payments.” While the Commission believes halving premature mortality by 2050 is globally achievable, it acknowledges this target may be “perhaps only aspirational for some countries, realistically speaking.” “We have a tendency to focus on the new, shiny things,” Chang added. “Our message is for countries to stay focused on these priority conditions.” ‘Tobacco is the new tobacco’ Six out of ten smokers, or 750 million people globally want to quit tobacco use. High tobacco taxes are “by far” the most crucial policy tool for reducing premature deaths, according to the report. “You often hear about other risk factors, but we argue tobacco is the new tobacco,” Chang explained. Recent research suggests raising excise taxes on tobacco, alcohol, and sugary drinks by 50% could yield $2.1 trillion for low- and middle-income countries over five years. This could boost healthcare spending in these nations by 40% if directed towards health initiatives. The Commission highlights the Middle East and North Africa as an example of untapped potential in tobacco control. With 160 million smokers and rising prevalence among youth and women, the region faces a growing health crisis. Egypt’s smoking rates doubled between 2000 and 2018, while tobacco became more affordable in conflict-affected countries like Iraq and Syria. The region’s tobacco taxes, second-lowest globally, fall far short of the World Health Organization’s recommended 70% excise tax. “Despite wide experience with its successful use, tobacco taxation remains a policy tool that is still greatly underused,” the Commission found. “Raising taxes on tobacco can do more to reduce premature mortality than any other single health policy.” High risk of ‘COVID magnitude’ pandemic in next decade The Lancet Comission estimates there is a 23% change of a COVID-scale pandemic in the next decade. New modeling for the Commission’s report indicates a 23% chance of a pandemic as severe as COVID-19 occurring within a decade. Unprepared health systems could see progress on reducing premature deaths plummet if caught off guard again. “There is a high risk of another pandemic of Covid-like magnitude,” Chang warned. “To put it another way, in most years there will be zero pandemic deaths, and in some years there will be millions of pandemic deaths.” The Commission’s analysis estimates an average of 2.5 million deaths per year due to pandemics when viewed over a long time horizon. This figure is comparable to the current annual death toll from AIDS, malaria, and tuberculosis combined, and significantly exceeds even pessimistic projections for annual climate change-related deaths in coming decades. “People should wake up at that figure,” Helen Clark, former Prime Minister of New Zealand, warned the summit. The warning from the Commission comes as global headwinds from conflict, climate change and debt hammer health budgets. Neglecting pandemic preparedness could have severe consequences, particularly for poorer countries less equipped to handle sudden outbreaks. “We need to learn the lessons not just from COVID, but from Mpox, Ebola … and avoid this panic-neglect cycle,” said Dr Seth Berkley, former CEO of Gavi, the Vaccine Alliance. “Unfortunately, I don’t think we’re doing a very good job.” From 1993 to Berlin A figure from the World Bank’s 1993 report making the case for health as an economic investment. The Lancet Comission report is the latest in a line of studies that traces its lineage back to a pivotal World Bank report that changed the landscape of global health finance. The World Bank’s 1993 report, Investing in Health, the only report on health ever published by the Bank, was the first to make an argument still used by health advocates and ministers across the globe: health is an investment. “The World Bank saying investing in health is no just a cost to society, but an investment that was justified on pure economic grounds … was revolutionary,” Berkley recalled. “Prior to this, people saw it as a cost – if you get richer, you can afford health, but this really changed the thinking.” The Commission’s work has expanded on the World Bank’s initial calculations, incorporating factors such as the impact of out-of-pocket health costs on economies and personal livelihoods. This broader perspective has significantly increased the estimated economic benefits of maintaining healthy societies, from the World Bank’s initial 11% to 24%. “The important thing is that each one of these reports, including this one, says the case is better than ever for investing in health, and we need to keep talking about that, particularly at a time when the headwinds are so strong,” Berkley emphasizes. The latest report continues this tradition, reaffirming that health investment remains one of the most effective strategies for improving both individual and societal outcomes. “Today, the case is better than ever for going for mortality reduction,” said Dr Gavin Yamey, director of Duke University’s Center for Policy Impact in Global Health and lead author of the commission report “It’s a prize within reach. It will have extraordinary health, welfare and economic benefits.” Image Credits: Sarah Johnson. Transformative Potential of Long-Acting Preventive Drugs Takes Centre Stage at HIV Conference 14/10/2024 Edith Magak At a HIVR4P’s press conference: Jeremy Nuttall, Elizabeth Irungu, Mark Marzinke, Alessandro Grattoni, William Hahn and Colleen Kelley. LIMA, Peru – The infection-prevention potential of Lenacapavir, the long-acting anti-HIV injectable administered just twice a year, took centre stage at the fifth HIV Research for Prevention Conference (HIVR4P) held last week. However, several other important studies were also unveiled, including an injectable that combines contraception and HIV protection, results from a three-month vaginal ring, and real-world findings from Zambia’s rollout of long-acting injectable cabotegravir. Lenacapavir in diverse populations Lenacapavir reduced HIV infections by 96% in a gender-diverse population, according to results from the PURPOSE 2 trial, which enrolled over 3,200 participants from Argentina, Brazil, Mexico, Peru, South Africa, Thailand, and the US between June 2021 and December 2023. Participants were randomly assigned to one of two groups: one receiving lenacapavir injections every six months and the other taking daily oral pills for pre-exposure prophylaxis (PrEP) with matched placebos. The average age of participants was 28, with over one-third under the age of 25. Around 70% identified as non-white, and the gender breakdown featured cisgender men, transgender men, transgender women, and non-binary individuals who have sex with partners assigned male at birth. At 39 weeks, only two HIV cases occurred in the lenacapavir group of 2,179 individuals, translating to a 96% reduction in HIV incidence, according to Dr Colleen Kelley from Emory University. In contrast, there were nine new HIV cases among the 1,087 participants taking daily oral TDF pills (comprising tenofovir disoproxil fumarate and emtricitabine and marketed as Truvada). This makes lenacapavir 89% more effective than oral PrEP. The findings echoed earlier results from the PURPOSE 1 trial, which showed 100% efficacy in preventing HIV among cisgender women in Africa. With regulatory filings expected to begin globally by the end of 2024, lenacapavir has the potential to be a transformative HIV prevention tool. Future phases of the study will focus on other groups, including women in the US (PURPOSE 3) and people who inject drugs (PURPOSE 4). The twice-yearly injectable, lenacapavir (marketed as Sunlenca in the US) could make a huge difference to HIV prevention is widely accessible. Injectable contraceptive and HIV prevention in one For millions of young women worldwide, two major health concerns often intersect: HIV acquisition and unintended pregnancy. Many have expressed a preference for a method that protects against both. At the conference, Melissa Peet from CONRAD presented results from a promising solution—a silica-based hydrogel injectable that combines HIV antiretroviral drugs with contraception in a single shot. In designing this dual-purpose method, researchers selected long-acting cabotegravir (CAB-LA) as the HIV prevention drug and levonorgestrel (LNG) as the contraceptive. The hydrogel injectable they developed is a silica-biodegradable material comprising two compartments, one for each medication. The injectable is capable of delivering both drugs with a single injection offering dual protection for three months. Preclinical tests in rats showed sustained drug levels in the bloodstream without significant interactions or safety concerns, and the researchers are now conducting additional studies in non-human primates to fine-tune dosing and asses the duration of protective drug concentration. No interactions between Cabotegravir and contraceptives One concern with combining HIV prevention and contraception has been the potential for drug interactions, particularly between long-acting HIV medications like cabotegravir (CAB-LA) and commonly used contraceptives. To address this, Dr. Mark Marzinke from Johns Hopkins University presented results from a sub-study within the HPTN 084 trial to explore any potential interactions. The study included 170 participants from South Africa with a median age of 23. A total of 80 women were randomised to the CAB-LA arm and 90 in the oral PrEP arm. Participants used three types of hormonal contraceptives: etonogestrel implants, injectable norethindrone, or medroxyprogesterone acetate (MPA), alongside either CAB-LA or oral PrEP. Researchers measured drug concentrations at enrolment and again at weeks 25, 49, and 73 to determine if there were any drug interactions. The results were reassuring: plasma concentrations of the contraceptives remained high enough to prevent pregnancy in both the CAB-LA and oral PrEP groups. CAB-LA concentrations were also consistent across contraceptive types, indicating that CAB-LA does not interfere with contraceptive effectiveness. However, tenofovir concentrations were unquantifiable for most participants, regardless of contraceptive type, due to low adherence to oral PrEP. New data on the three-month vaginal ring For women seeking long-term HIV prevention, the dapivirine vaginal ring, sometimes called the PrEP ring, has been a promising option. This is a flexible silicone ring that is placed in the vagina that releases the anti-HIV drug, dapivirine, over a month. Delegates at the conference heard results from a South African study comparing the bioavailability of the standard one-month dapivirine ring with a new three-month version. The study enrolled 124 women, but only 104 completed the trial. This was a crossover trial with two treatment phases: half the group started with the one-month ring (containing 25 mg of dapivirine) and then switched to the three-month ring, containing 100 mg of dapivirine. The other group followed the reverse order; they began with the three-month ring and later switched to the one-month ring. The three-month ring was identical to the one-month version in silicone, dimensions, and appearance. Plasma and vaginal fluid samples were collected throughout the study to measure drug levels. Based on dapivirine concentrations in plasma, results showed that the three-month ring provided greater overall drug exposure than the one-month version, indicating equal or possibly higher efficacy in preventing HIV. Jeremy Nuttall from the Population Council’s Center for Biomedical Research, who presented the findings, noted that the reduced frequency of ring changes might increase acceptability and adherence, potentially improving overall effectiveness. He also highlighted that the estimated cost of the three-month ring is $16, making it a potentially more affordable option, projecting that the three-month ring could become available on the market by 2026. Roxana Bretoneche protesting about the lack of community participation at HIVR4P. Real-world results from Zambia’s CAB-LA rollout Zambia became the first country in sub-Saharan Africa to roll out long-acting injectable PrEP (CAB-LA) beyond clinical trials, sharing results from their first three months (February to April 2024) in real-world settings. A total of 609 individuals with a median age of 24 were enrolled across six health facilities in two districts. Among the clients, 55% were female, 20% were adolescent boys and young men, 7% identified as key populations, and 40% as other high-risk populations. Adamson Ndhlovu from Zambia’s JSI USAID DISCOVER-Health Project shared that over 90% of participants due for their second injection received it on time. A total of 24 participants (about 4%) discontinued CAB-LA. Most discontinuations were due to hepatitis B (20 cases), with two participants stopping due to pregnancy, one due to a severe rash, and one because of severe pain at the injection site. Those who discontinued were switched to oral PrEP. During a press briefing at the conference, Professor Lloyd Mulenga from Zambia’s Ministry of Health stated that four of those enrolled had acquired HIV, explaining that they likely had undetected HIV at the time they started PrEP. The real-world implementation of CAB-LA is anticipated to expand, as ViiV Healthcare, the manufacturer, announced at the conference its plans to triple the supply of cabotegravir that will be available for low- and middle-income countries in 2025-2026 to at least two million doses. Image Credits: Nicole Bergman / IAS, Gilead, Nicole Bergman / IAS. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
New US Lead Pipe Regulation Could Protect Nearly a Million Infants from Low Birthweight 22/10/2024 Sophia Samantaroy A lead poisoning prevention workshop in Kathmandu, Nepal organized by the Ministry of Health and Population (MoHP) and WHO Country Office for Nepal. The US Environmental Protection Agency (EPA) recently announced a new ruling that requires drinking water systems to replace lead pipes within 10 years. The rule also strengthens requirements to locate lead pipes, improve testing for lead in water, and ensure that exposure is minimized while lead pipe replacement efforts are underway. “Families like yours, exposed to lead in the water–they deserve better… We’re finally addressing an issue that should have been addressed a long time ago: the danger lead pipes pose to our drinking water,” said President Biden earlier this month. The EPA estimates that up to nine million US homes are served through legacy lead pipes across the country, many of which are located in lower-income communities and communities of color, “creating disproportionate lead exposure burden for these families,” the agency said in a press release. To remove the millions of lead pipes still in use, the EPA has tapped $2.6 billion from the Bipartisan Infrastructure Law. The agency estimates that the public health and economic benefits of the final rule are estimated to be up to “13 times greater than the costs,” including protecting 900,000 infants from low birthweight, preventing 2,600 cases of ADHD, and reducing 1,500 cases of premature death from heart disease each year following the ruling. The EPA’s new ruling could over two thousand cases of ADHD and protect nearly a million infants from being born with low birthweight each year. The Biden Administration’s announcement came just two weeks before International Lead Poisoning Prevention Week, which highlighted the persistent threat of lead for the world’s children population. “Lead continues to be one of the greatest public health concerns,” said Dr Maria Neira, World Health Organization (WHO) environment director. “Urgent action is required from member states to prevent exposure to lead.” The United Nations Children’s Fund (UNICEF) estimates that one in three children have blood lead levels at or above 5µg/dl – levels that can cause lifelong neurological, behavioral, and health problems like anemia, hypertension, and toxicity to reproductive organs. “The science is clear,” noted an EPA statement, “lead is a potent neurotoxin and there is no safe level of exposure.” Both the EPA and US Centers for Disease Control and Prevention (CDC) recommend having children tested for lead as the best way to determine exposure, especially if living in a house built before 1978. High risk of elevated lead in South Asia South Asia, Africa, and parts of South America are lead exposure hotspots. UNICEF’s landmark 2020 lead poisoning report exposed the scale at which children are exposed to high levels of lead. Of the 815 million children estimated to have elevated blood lead levels, nearly half live in India, Pakistan, Nepal, and other South Asian countries. The reasons for higher exposure, the UNICEF report notes, comes from a high prevalence of unsafe lead-acid battery recycling, and contaminated spices, ceramics, and toys. Children can also be exposed to lead in soil, dust, air, and water. Fewer regulations and enforcement leaves industries lacking environmentally safe practices, and the absence of blood lead screening make it difficult to protect children from lead hazards. The report also cites poor nutrition as a risk factor for higher lead absorption in lower-and middle-income countries. Educational materials in Rochester, New York, for people at higher risk for lead poisoning. “With few early symptoms, lead silently wreaks havoc on children’s health and development, with possibly fatal consequences,” said Henrietta Fore, UNICEF’s Executive Director at the time, at the report launch. “Knowing how widespread lead pollution is — and understanding the destruction it causes to individual lives and communities — must inspire urgent action to protect children once and for all.” “Since the 1970s, efforts to reduce lead in paint, gasoline, water, yards and even playgrounds have resulted in considerable success in reducing blood lead levels among children in the United States,” wrote the report authors. “The issue of lead poisoning is not new, but our understanding of the scope and scale of its impacts and feasible solutions has never been better. Proven solutions exist for low- and middle-income countries, those most burdened by this challenge. Those solutions can be implemented today.” Image Credits: S. Samantaroy/HPW, WHO, EPA, UNICEF. Rwanda’s High-Level Critical Care Ensures Low Marburg Fatality Rate 21/10/2024 Kerry Cullinan Rwandan Health Minister Dr Sabin Nsanzimana (left) and WHO Director General Dr Tedros Adhanom Ghebreyesus address a media briefing in Kigali on Sunday. After a full week of no new Marburg cases, Rwanda appears to have contained one of the biggest recorded of the deadly virus outbreaks – and with a low case fatality rate of 24%. World Health Organization (WHO) Director-General Dr Tedros Adhanom Ghebreyesus, who visited the country over the weekend, praised the level of Rwanda’s critical care for patients as well as how the country deployed high-level leadership to address the viral haemorrhagic fever, which often kills over 80% of those infected. “Two of the patients we met had experienced all of the symptoms of Marburg, including multiple organ failure, but they were put on life support, they were successfully intubated and extubated, and are now recovering,” Tedros told a media briefing in Rwanda on Sunday. “We believe this is the first time patients with Marburg virus have been extubated in Africa. These patients would have died in previous outbreaks.” Intubation involves inserting a tube through a patient’s nose or mouth into their windpipe (trachea) to help them breathe. This tube can be connected to a ventilator. Extubation is when the tube is removed. Tedros added that Rwanda had worked for many years to “strengthen its health system, to develop capacities for critical care and life support that can be deployed both in regular hospital care and in emergencies”. However, he warned that Marburg is “one of the world’s most dangerous viruses, and continued vigilance is essential”. The outbreak will only be declared over once no new cases have been recorded for 21 days, potentially on 5 November. Sabin’s vaccine candidate used Although there are no approved vaccines or therapeutics for Marburg, Rwanda fast-tracked the trials of a vaccine candidate from the Sabin Vaccine Institute, and an antiviral drug, remdesivir. On 5 October, Sabin delivered 700 doses of its single-dose candidate vaccine, followed by a further 1,000 on 12 October. These have been used to vaccinate health workers “as part of a Phase 2 rapid response open-label trial, sponsored by the Rwanda Biomedical Centre”, according to Sabin. Patients’ close contacts have also been vaccinated. Rwanda developed its own trial protocol after rejecting the WHO’s protocol which would have involved a control group that got vaccinated three weeks after the trial group, according to the journal, Science. Rwanda opted to vaccinate all trial participants at once. However, the remdesivir trial does involve a control group. “The swift initiation of the open-label trial was set in motion on 26 September, when the Rwandan President’s office contacted Sabin CEO Amy Finan to request assistance with the outbreak response,” Sabin said in a statement. Rwanda officially declared the outbreak the next day. “In an outbreak, every moment counts, and our seamless collaboration with the Rwandan government was key to accelerating the process,” said Finan. Sabin’s manufacturing partner, Italy-based ReiThera, produced the drug substance and filled and finished doses for shipment to Rwanda. “On our side, we moved quickly by leveraging our experience with other outbreaks and having vaccine doses and supporting documents ready, thanks to a strong partnership with ReiThera,” Finan added. Sabin’s team only consists of 15 staff members, but Finan said that “their dedication, along with that of our Rwandan colleagues, BARDA [the US Center for the Biomedical Advanced Research and Development Authority] and other partners, enabled us to mobilise so rapidly. “This remarkable effort highlights the power of partnerships and preparedness in addressing urgent public health needs,” said Finan, who also visited Rwanda over the weekend. Meanwhile, Tedros congratulated Rwanda for the speed with which it initiated trials of both vaccines and therapeutics, adding that the WHO hopes that these trials “will help to generate the data to support approval of these products for future outbreaks”. Belen Calvo Uyarra, the European Union’s Ambassador to Rwanda, also praised the country’s rapid response to containing the virus. “Respect to the government of Rwanda and the Rwanda Ministry of Health for proactive leadership, rapid and robust continued response, and professionalism of health workers,” Uyarra posted on X. She and Tedros also visited the site of the BioNTech vaccine manufacturing facility, announced two years ago to facilitate local production of vaccines. Two years ago I visited #Rwanda for the groundbreaking ceremony of the BioNTech facility in Kigali, which raised great hope for local production of vaccines in Africa. Today, I returned to the site and was proud to witness the fast progress of construction of the facility.… pic.twitter.com/8YGwcTVaYe — Tedros Adhanom Ghebreyesus (@DrTedros) October 20, 2024 “I was very pleased to see the significant progress in construction,” said Tedros. “One of the key lessons of the COVID-19 pandemic was the need to expand local production of vaccines to avoid the inequitable access to vaccines that we saw, and we’re pleased to see the way Rwanda and BioNTech are investing in local production. “You know how Africa was treated when the vaccines arrived, with vaccine inequity and vaccine nationalism, and we hope these strategic investments will fix the inequity problems we faced during COVID.” Cities Face ‘Severe Degradation’ Without Meaningful Climate Action, Warn Experts 21/10/2024 Sophia Samantaroy Experts at the yearly Lancet International Health lecture argued that green urban planning can improve health. Cities that fail to take meaningful climate action face a future of severe degradation with infrastructure collapse and environmental deterioration, warned climate and health experts at the yearly Academy of Medical Sciences & The Lancet International Health Lecture in London. “Madrid’s climate in 2050 will resemble Marrakech’s climate today. I don’t think we want that,” said Professor Mark Nieuwenhuijsen, the keynote speaker. To stave off this scenario, cities must adapt with health priorities at the forefront. “For our cities, we’re looking towards solutions that reduce CO2 emissions and also improve environment, equality and, of course, liveability and health.” By 2050, two-thirds of the global population is expected to live in a city. Yet climate change is increasingly threatening human health in urban areas, where swaths of asphalt and concrete exacerbate rising temperatures. Climate change accounts for 37% of heat-related deaths, leaving cities especially vulnerable to heat waves and extreme heat. Dr Mark Nieuwenhuijsen argues that urban planners must consider health is designing the future of cities. Preventing climate-related mortality in cities requires urban planning with an intentional health focus, commented Nieuwenhuijsen. He argued that smart urban planning reduces greenhouse gas emissions and promotes health, but only if we can break away from an “addiction” to fossil fuels. “We know that these fossil fuels are responsible for more than 5 million deaths each year because of air pollution.” Despite the growing knowledge of the health burden of fossil fuels, cities continue to sprawl “with Europe leading the way.” Fossil fuel use has led to “car-centric asphalt-dominated urban planning and extensive urban sprawl, which have detrimental effects on health,” said Nieuwenhuijsen. Sprawling urban areas increases car dependency, even though public transport systems and active transportation – like walking and cycling – are more cost effective. Compact vs green cities – policies that include the best of both models Four different European city configurations vary in their health and environmental effects–with compact cities being the lowest emittors yet having the highest mortality rates compared to less dense cities. In Europe, where many cities are growing faster than their populations, high population density has potential advantages like shortened commute times, decreased care dependency, higher energy efficiency, and decreased building material consumption. The more compact a city, the more efficient. Yet compact cities have potential drawbacks, including higher mortality rates, traffic density, air and noise pollution, and excess heat. Nieuwenhuijsen presented European cities as falling into one of four groups: compact high-density cities, open low-rise medium-density cities, open lowrise low-density cities, and green low-density cities. Analyzing cities across these categories show a split: cities either fall into higher mortality but lower greenhouse emissions, or lower mortality but higher emissions. A city like Barcelona – compact and high-density -–can expect to have a 10-15% higher mortality rate, poorer air quality, and stronger heat island effect, but lower emission, explained Nieuwenhuijsen. Overall, the researchers estimated that poor urban planning results in 20% of premature mortality. “Barcelona is a wonderful city, but it has too much air pollution, too much noise, not enough green space.” “In contrast, greener and less densely populated cities have lower mortality rates, lower air pollution levels, and a lower urban heat island effect, but higher carbon footprints per person.” This dichotomy – where current urban configurations are either high emitters with better health quality, or lower emitters with worse health – means that cities must implement policies that better health and reduce emissions. Nieuwenhuijsen believes that both are possible. Policies that lower air pollution levels and reliance on cars, and increase green space, cycling lanes, and physical activity would “substantially reduce the mortality rate,” he argued. Super blocks, green space, and 15-minute cities Barcelona is one a several major cities implementing innovative urban planning to improve environmental and human health. Several cities have begun implementing innovative urban models that bridge the goals of lower emissions and healthier environments, especially in how they use public land. “A lot of our public space in our cities is, at the moment, actually used by cars. I mean, in Spain, 69% of public space is used by cars because our roads are also public space. Parking is public space. I mean, this is the kind of space that we could use in a much better way,” commented Nieuwenhuijsen. In Paris, a vision to become a “15-minute city” – where all major destinations can be reached within 15 minutes of the home – has increased investments in bike lanes and car-free zones. Barcelona’s “superblocks,” London’s low traffic neighborhoods, and the Vauban Freiburg car-free neighborhood are all promising solutions to reduce premature deaths and increase green spaces. Nieuwenhuijsen and other experts convened at the event pointed to these examples and others as evidence that urban design changes are possible. Several Chinese cities have also embraced the intersection of urban planning and novel technologies to prevent flooding through their Sponge city designs, commented Dr Maria Neira, the World Health Organization’s director of Public Health, Environment and Social Determinants of Health. “More and more we need to be prepared to work with urban planners, the architects working at the city level. And I have the impression that sometimes they are better prepared, more advanced, more engaged and more passionate, than our public health officers working at the city level,” said Neira. “So we need to sort it out and create these very strong arguments for our public health officers as well, to push at the city level, at the Urban level, for engagement with the Urban healthy urban planning.” Image Credits: Michele Castrezzati, Fons Heijnsbroek, The Lancet, The Lancet. Rwanda’s Marburg Outbreak Wanes But Mpox Continues to Spread 17/10/2024 Kerry Cullinan Dr Jean Kaseya and Dr Sabin Nsanzimana. While Rwanda appears to have its Marburg virus outbreak under control with no new cases reported in the past three days in Rwanda, mpox continues to spread – now affecting 18 countries with 3051 new cases in the past week. Since declaring the Marburg outbreak three weeks ago, Rwanda has confirmed 62 cases, of which 15 have died, 38 have recovered and nine cases are still receiving treatment with the majority improving, said Health Minister Dr Sabin Nsanzimana on Thursday. “The case fatality rate overall is 24% and we’ve vaccinated 856 people,” Nsanzimana told an Africa Centres for Disease Control and Prevention (CDC) briefing, describing the trend as “very encouraging”. As the vaccine is “investigational”, its rollout required more rigorous consent, sampling and documentation, but demand for it has been “very high”, he added. the vaccines you are providing highly accepted, especially among healthcare providers. Around 90% of those infected are health workers and their close contacts from the intensive care units of two hospitals that treated the very first patients. The index patients was co-infected with malaria which slowed the diagnosis of Marburg, which has similar symptoms. Rwanda’s health ministry has also tested over 4,000 people “to make sure we don’t miss any cases”, added Nsanzimana. He attributed “intense activity on the ground”, ring vaccination [vaccinating the close contacts of people with Marburg] and new antivirals for the turnaround in what is the biggest Marburg outbreak ever recorded. The virus, which is from the same family as Ebola and, in some outbreaks, has killed over 80% of those infected. While the zoonotic origin of the outbreak is still unknown, Nsanzimana said Rwanda will be reporting its findings on the the serology and gene sequencing of the virus within a few days. At the same time, it has a team on the ground hunting for the source of the virus. Mpox ‘not under control’ Mpox cases have now been identified in 18 African countries, with new additions being Zambia and Zimbabwe. In the past week, 3051 new cases have been reported – including two male prisoners in Uganda. “Mpox is not under control,” warned Africa CDC Director-General Dr Jean Kaseya. Despite calling a continental meeting in April to warn countries of the risk, cases have risen exponentially: from slightly under 6,000 then to 42,438 suspected mpox cases at present – although only 8,113 have been clinically confirmed. A rapid test to diagnose mpox is in the pipeline and will transform the testing landscape, said Kaseya. Kaseya flagged the threat to internally displaced people (IDP), particularly in the Democratic Republic of Congo (DRC), and prisoners – both groups characterised by close contact. In the eastern DRC, conflict has displaced some 2.5 million people who are now living in camps in close quarters with limited access to water, sanitation and hygiene. The two Ugandan prisoners were initially diagnosed with chicken pox – which has small lesions that are itchy not painful like mpox. DRC vaccination plan includes MSM, transgender people The DRC’s vaccination campaign started two weeks ago in three provinces – North Kivu, South Kivu and Tshopo – and is “moving well”, said Kaseya, who hails from DRC. The country’s plan includes men who have sex with men (MSM) and sex workers, as mpox can be sexually transmitted. In DRC, same-sex sexual contact is not outlawed as it is in many of the other countries currently affected by mpox – Uganda, Burundi, Kenya, Tanzania, Zambia and Zimbabwe. “When are talking about MSM, we are clear as Africa CDC. We are saying all human beings have the same rights, and we are supporting countries to plan vaccination for all of them, including men having sex with other men,” said Kaseya empathically. “We are proud and we are glad to see in DRC that we have MSM included,” he added. Kaseya said that early messaging about mpox Clade 1B only being associated with sexual transmission was wrong – as was the failure to talk about MSM as the main mode of transmission iun the 2022 outbreak. “There was the stigma talking about men having sex with other men as the main transmission mode of mpox. But if we put it in the context in Africa, that one in some countries is still a taboo. “We believe with our effort, what we are doing is sensitizing countries, and we are proud to see that DRC are mentioning that.” He added that risk communication and community engagement involving “people who are openly saying we are these key populations” was also important. Uganda tightened its anti-LGBTQ laws recently and, while it plans to test all 1,087 prisoners who possibly had contact with the two prisoners recently diagnosed with mpox, it is unclear how it will approach MSM as a mode of transmission other than to crack down further on smae-sex activity. Europe’s New Air Quality Law is a Breakthrough for Clean Air Globally 16/10/2024 Jane Burston Dirty smoke billows from chimneys in Poland. Europe is now poised to deliver cleaner, healthier air – thanks to adoption this week of the revised Ambient Air Quality Directive (AAQD) by the European Union. This marks a crucial victory for the health and wellbeing of millions across the EU and serves as a beacon for the clean air movement worldwide. The AAQD underpins Europe’s air quality standards, and its revision is a significant breakthrough in addressing the public health crisis of air pollution. Each year, air pollution cuts short the lives of nearly 300,000 Europeans, contributing to respiratory illnesses, cardiovascular disease, and other serious health conditions, according to the EU’s impact assessment report. Improving air quality is a public health imperative. It’s also crucial for the environment and the economy, making the case for stronger EU-wide legislation even clearer. A healthier future The revised AAQD brings Europe’s air quality standards closer to the World Health Organization’s (WHO) air quality guidelines. It sets tougher, legally binding limits on harmful pollutants like nitrogen dioxide (NO₂) and fine particulate matter (PM2.5), representing a doubling of ambition for these two major pollutants, in line with WHO’s interim targets. These pollutants have long been linked to severe health impacts that are particularly harmful for vulnerable groups, such as babies and young children and people with certain conditions such as Chronic Obstructive Pulmonary Disease. By delivering cleaner air, the AAQD could mean the difference between a lifetime of illness and a healthy future for future generations. The AAQD also strengthens the monitoring and measuring provisions for air quality, introducing air quality roadmaps to support progress ahead of its 2030 deadline. The new rules bring about a fairer regime for people affected by air pollution as the rules for access to justice and compensation for those whose health have been impacted by dirty air have been improved. Some of the most polluted regions within member states can delay meeting the new targets for up to 10 years (until 2040) under certain conditions. Although these derogations (or exceptions) provide more leeway than originally envisaged, the compromise, alongside strict conditions for delays, ensure that none of the 27 Member States are left behind. Significant impact if properly implemented Overall, the Directive remains a significant win with ambitious targets and tightly regulated conditions for any delays. Importantly, the initially proposed ambition on limit values remained intact following the two-year legislative process, despite widespread pushback against legislation falling under the EU Green Deal, indicating the scale of this victory for clean air campaigners. One of the key reasons for the AAQD’s success is that it is both an environmental law and a critical public health intervention. By recognising that air quality is a matter of life and death, policymakers have acknowledged the need to protect the most vulnerable in our society. The impact of the new legislation in Europe will be significant if the AAQD is properly implemented. The new rules can prevent more than 55% of premature deaths linked to air pollution in the EU. That’s not just a number – that’s hundreds of thousands of people, each with families, who will live longer, healthier lives. In addition to delivering significant health and environmental benefits, improving the air we breathe makes economic sense. Investing €6 billion annually in cleaner air will deliver up to €121 billion in benefits (according to the EU’s analysis). That’s equivalent to building hundreds of new hospitals or creating hundreds of thousands of new jobs in green industries. Echoing this analysis, the Brussels-based think tank, Bruegel, estimated that implementing clean air measures could boost economic growth by €50 to €60 billion every year[3] and save approximately €600 billion each year in the European Union, the equivalent to 4% of GDP. Ripple effect The importance of the AAQD extends beyond the EU’s borders. By taking decisive action, the EU has positioned itself among the global leaders in air quality management, setting an example for other regions grappling with similar challenges. Air pollution is a global problem, responsible for eight million premature deaths annually worldwide, as reported in the British Medical Journal, and the EU’s solutions will, I hope, inspire other countries to pursue stronger actions. Ongoing engagement and sustained political will are key to ensuring the success of these measures. The real test will come as member states move to transpose the Directive into law and work to implement these new standards. National and local governments will need to invest in cleaner technologies, green transport and clean heating while improving air quality monitoring and ensuring that enforcement is taken seriously. Let’s celebrate this moment, but also remain focused on the work that still needs to be done. Air pollution is an invisible killer, shortening lives and ravaging our communities. With this new Directive, we are fighting back. Jane Burston founded and leads the Clean Air Fund (CAF), a global philanthropic organisation working with governments, funders, businesses and campaigners to create a future where everyone breathes clean air. Before setting up CAF, Jane worked as head of Climate and Energy Science in the UK government. Prior to that, as head of Energy and Environment at the UK National Physical Laboratory, she managed a team of 150 scientists working in air quality, GHG measurement and renewable energy. Image Credits: Janusz Walczak/ Unsplash. World Can Halve Premature Deaths by 2050, Lancet Commission Reports 15/10/2024 Stefan Anderson BERLIN – Countries worldwide, regardless of income level, can halve premature death rates by 2050, a new Lancet report presented at the closing of the World Health Summit in Berlin suggests. Fifteen key health threats are driving premature deaths worldwide, with tobacco use leading the pack “by far”, the Lancet Commission for Investing in Health found. Targeting interventions in these areas – with over half involving maternal, newborn, child, and infectious diseases – could dramatically reduce global deaths before age 70, the Commission said. “Sharp reductions in mortality and morbidity can be achieved by focusing on 15 priority conditions,” Dr Angela Chang from the University of Southern Denmark and lead author of the report, told a panel at the World Health Summit in Berlin on Tuesday. “Doubling down on past health investments, focusing resources on a narrow set of conditions, scaling up financing and developing new technologies can continue to have an enormous impact despite the headwinds.” The 15 priority conditions, selected from over 17,000 internationally recognized health diagnoses, account for approximately 80% of the life expectancy gap between most regions and the North Atlantic, defined in the report as North America and Europe. These conditions account for 86% of the gap between China and the North Atlantic, and 74% between sub-Saharan Africa and the North Atlantic. “There’s a 22-year gap in life expectancy between Sub-Saharan Africa and the North Atlantic, Chang explained. “Close to 80% of this gap can be explained by these 15 priority conditions, and over half of the difference can be attributed to eight infectious and maternal health conditions.” If the global goal is met, the average premature mortality rate worldwide would fall to about 15%, matching levels currently seen in Europe and North America—today’s global benchmark. Achieving this would mean dramatic improvements for billions, especially in low- and middle-income countries. In Sub-Saharan Africa, the worst-performing region, premature mortality sits at 52%. Setting priorities straight The report’s optimism is rooted in historical data. Globally, the probability of dying before 70 has halved since the 1960s, falling from 62% to 31% for individuals born in 2019. Thirty-seven countries, including populous nations like Bangladesh, China, Japan, and Vietnam, have already halved their premature death rates in similar or shorter periods than the 26 years remaining until the 2050 target date. The Commission recommends public financing for essential medicines targeting the 15 key conditions driving premature mortality. It suggests mobilizing international funding and joint procurement efforts, similar to strategies used by GAVI, PEPFAR, and the Global Fund, to reduce costs for patients and governments alike. “Inadequate access to medicines and high out-of-pocket costs are major threats to cutting premature mortality,” Chang noted. “We learned from the Global Fund’s experience how national government subsidies can steer resources towards priority interventions and reduce out-of-pocket payments.” While the Commission believes halving premature mortality by 2050 is globally achievable, it acknowledges this target may be “perhaps only aspirational for some countries, realistically speaking.” “We have a tendency to focus on the new, shiny things,” Chang added. “Our message is for countries to stay focused on these priority conditions.” ‘Tobacco is the new tobacco’ Six out of ten smokers, or 750 million people globally want to quit tobacco use. High tobacco taxes are “by far” the most crucial policy tool for reducing premature deaths, according to the report. “You often hear about other risk factors, but we argue tobacco is the new tobacco,” Chang explained. Recent research suggests raising excise taxes on tobacco, alcohol, and sugary drinks by 50% could yield $2.1 trillion for low- and middle-income countries over five years. This could boost healthcare spending in these nations by 40% if directed towards health initiatives. The Commission highlights the Middle East and North Africa as an example of untapped potential in tobacco control. With 160 million smokers and rising prevalence among youth and women, the region faces a growing health crisis. Egypt’s smoking rates doubled between 2000 and 2018, while tobacco became more affordable in conflict-affected countries like Iraq and Syria. The region’s tobacco taxes, second-lowest globally, fall far short of the World Health Organization’s recommended 70% excise tax. “Despite wide experience with its successful use, tobacco taxation remains a policy tool that is still greatly underused,” the Commission found. “Raising taxes on tobacco can do more to reduce premature mortality than any other single health policy.” High risk of ‘COVID magnitude’ pandemic in next decade The Lancet Comission estimates there is a 23% change of a COVID-scale pandemic in the next decade. New modeling for the Commission’s report indicates a 23% chance of a pandemic as severe as COVID-19 occurring within a decade. Unprepared health systems could see progress on reducing premature deaths plummet if caught off guard again. “There is a high risk of another pandemic of Covid-like magnitude,” Chang warned. “To put it another way, in most years there will be zero pandemic deaths, and in some years there will be millions of pandemic deaths.” The Commission’s analysis estimates an average of 2.5 million deaths per year due to pandemics when viewed over a long time horizon. This figure is comparable to the current annual death toll from AIDS, malaria, and tuberculosis combined, and significantly exceeds even pessimistic projections for annual climate change-related deaths in coming decades. “People should wake up at that figure,” Helen Clark, former Prime Minister of New Zealand, warned the summit. The warning from the Commission comes as global headwinds from conflict, climate change and debt hammer health budgets. Neglecting pandemic preparedness could have severe consequences, particularly for poorer countries less equipped to handle sudden outbreaks. “We need to learn the lessons not just from COVID, but from Mpox, Ebola … and avoid this panic-neglect cycle,” said Dr Seth Berkley, former CEO of Gavi, the Vaccine Alliance. “Unfortunately, I don’t think we’re doing a very good job.” From 1993 to Berlin A figure from the World Bank’s 1993 report making the case for health as an economic investment. The Lancet Comission report is the latest in a line of studies that traces its lineage back to a pivotal World Bank report that changed the landscape of global health finance. The World Bank’s 1993 report, Investing in Health, the only report on health ever published by the Bank, was the first to make an argument still used by health advocates and ministers across the globe: health is an investment. “The World Bank saying investing in health is no just a cost to society, but an investment that was justified on pure economic grounds … was revolutionary,” Berkley recalled. “Prior to this, people saw it as a cost – if you get richer, you can afford health, but this really changed the thinking.” The Commission’s work has expanded on the World Bank’s initial calculations, incorporating factors such as the impact of out-of-pocket health costs on economies and personal livelihoods. This broader perspective has significantly increased the estimated economic benefits of maintaining healthy societies, from the World Bank’s initial 11% to 24%. “The important thing is that each one of these reports, including this one, says the case is better than ever for investing in health, and we need to keep talking about that, particularly at a time when the headwinds are so strong,” Berkley emphasizes. The latest report continues this tradition, reaffirming that health investment remains one of the most effective strategies for improving both individual and societal outcomes. “Today, the case is better than ever for going for mortality reduction,” said Dr Gavin Yamey, director of Duke University’s Center for Policy Impact in Global Health and lead author of the commission report “It’s a prize within reach. It will have extraordinary health, welfare and economic benefits.” Image Credits: Sarah Johnson. Transformative Potential of Long-Acting Preventive Drugs Takes Centre Stage at HIV Conference 14/10/2024 Edith Magak At a HIVR4P’s press conference: Jeremy Nuttall, Elizabeth Irungu, Mark Marzinke, Alessandro Grattoni, William Hahn and Colleen Kelley. LIMA, Peru – The infection-prevention potential of Lenacapavir, the long-acting anti-HIV injectable administered just twice a year, took centre stage at the fifth HIV Research for Prevention Conference (HIVR4P) held last week. However, several other important studies were also unveiled, including an injectable that combines contraception and HIV protection, results from a three-month vaginal ring, and real-world findings from Zambia’s rollout of long-acting injectable cabotegravir. Lenacapavir in diverse populations Lenacapavir reduced HIV infections by 96% in a gender-diverse population, according to results from the PURPOSE 2 trial, which enrolled over 3,200 participants from Argentina, Brazil, Mexico, Peru, South Africa, Thailand, and the US between June 2021 and December 2023. Participants were randomly assigned to one of two groups: one receiving lenacapavir injections every six months and the other taking daily oral pills for pre-exposure prophylaxis (PrEP) with matched placebos. The average age of participants was 28, with over one-third under the age of 25. Around 70% identified as non-white, and the gender breakdown featured cisgender men, transgender men, transgender women, and non-binary individuals who have sex with partners assigned male at birth. At 39 weeks, only two HIV cases occurred in the lenacapavir group of 2,179 individuals, translating to a 96% reduction in HIV incidence, according to Dr Colleen Kelley from Emory University. In contrast, there were nine new HIV cases among the 1,087 participants taking daily oral TDF pills (comprising tenofovir disoproxil fumarate and emtricitabine and marketed as Truvada). This makes lenacapavir 89% more effective than oral PrEP. The findings echoed earlier results from the PURPOSE 1 trial, which showed 100% efficacy in preventing HIV among cisgender women in Africa. With regulatory filings expected to begin globally by the end of 2024, lenacapavir has the potential to be a transformative HIV prevention tool. Future phases of the study will focus on other groups, including women in the US (PURPOSE 3) and people who inject drugs (PURPOSE 4). The twice-yearly injectable, lenacapavir (marketed as Sunlenca in the US) could make a huge difference to HIV prevention is widely accessible. Injectable contraceptive and HIV prevention in one For millions of young women worldwide, two major health concerns often intersect: HIV acquisition and unintended pregnancy. Many have expressed a preference for a method that protects against both. At the conference, Melissa Peet from CONRAD presented results from a promising solution—a silica-based hydrogel injectable that combines HIV antiretroviral drugs with contraception in a single shot. In designing this dual-purpose method, researchers selected long-acting cabotegravir (CAB-LA) as the HIV prevention drug and levonorgestrel (LNG) as the contraceptive. The hydrogel injectable they developed is a silica-biodegradable material comprising two compartments, one for each medication. The injectable is capable of delivering both drugs with a single injection offering dual protection for three months. Preclinical tests in rats showed sustained drug levels in the bloodstream without significant interactions or safety concerns, and the researchers are now conducting additional studies in non-human primates to fine-tune dosing and asses the duration of protective drug concentration. No interactions between Cabotegravir and contraceptives One concern with combining HIV prevention and contraception has been the potential for drug interactions, particularly between long-acting HIV medications like cabotegravir (CAB-LA) and commonly used contraceptives. To address this, Dr. Mark Marzinke from Johns Hopkins University presented results from a sub-study within the HPTN 084 trial to explore any potential interactions. The study included 170 participants from South Africa with a median age of 23. A total of 80 women were randomised to the CAB-LA arm and 90 in the oral PrEP arm. Participants used three types of hormonal contraceptives: etonogestrel implants, injectable norethindrone, or medroxyprogesterone acetate (MPA), alongside either CAB-LA or oral PrEP. Researchers measured drug concentrations at enrolment and again at weeks 25, 49, and 73 to determine if there were any drug interactions. The results were reassuring: plasma concentrations of the contraceptives remained high enough to prevent pregnancy in both the CAB-LA and oral PrEP groups. CAB-LA concentrations were also consistent across contraceptive types, indicating that CAB-LA does not interfere with contraceptive effectiveness. However, tenofovir concentrations were unquantifiable for most participants, regardless of contraceptive type, due to low adherence to oral PrEP. New data on the three-month vaginal ring For women seeking long-term HIV prevention, the dapivirine vaginal ring, sometimes called the PrEP ring, has been a promising option. This is a flexible silicone ring that is placed in the vagina that releases the anti-HIV drug, dapivirine, over a month. Delegates at the conference heard results from a South African study comparing the bioavailability of the standard one-month dapivirine ring with a new three-month version. The study enrolled 124 women, but only 104 completed the trial. This was a crossover trial with two treatment phases: half the group started with the one-month ring (containing 25 mg of dapivirine) and then switched to the three-month ring, containing 100 mg of dapivirine. The other group followed the reverse order; they began with the three-month ring and later switched to the one-month ring. The three-month ring was identical to the one-month version in silicone, dimensions, and appearance. Plasma and vaginal fluid samples were collected throughout the study to measure drug levels. Based on dapivirine concentrations in plasma, results showed that the three-month ring provided greater overall drug exposure than the one-month version, indicating equal or possibly higher efficacy in preventing HIV. Jeremy Nuttall from the Population Council’s Center for Biomedical Research, who presented the findings, noted that the reduced frequency of ring changes might increase acceptability and adherence, potentially improving overall effectiveness. He also highlighted that the estimated cost of the three-month ring is $16, making it a potentially more affordable option, projecting that the three-month ring could become available on the market by 2026. Roxana Bretoneche protesting about the lack of community participation at HIVR4P. Real-world results from Zambia’s CAB-LA rollout Zambia became the first country in sub-Saharan Africa to roll out long-acting injectable PrEP (CAB-LA) beyond clinical trials, sharing results from their first three months (February to April 2024) in real-world settings. A total of 609 individuals with a median age of 24 were enrolled across six health facilities in two districts. Among the clients, 55% were female, 20% were adolescent boys and young men, 7% identified as key populations, and 40% as other high-risk populations. Adamson Ndhlovu from Zambia’s JSI USAID DISCOVER-Health Project shared that over 90% of participants due for their second injection received it on time. A total of 24 participants (about 4%) discontinued CAB-LA. Most discontinuations were due to hepatitis B (20 cases), with two participants stopping due to pregnancy, one due to a severe rash, and one because of severe pain at the injection site. Those who discontinued were switched to oral PrEP. During a press briefing at the conference, Professor Lloyd Mulenga from Zambia’s Ministry of Health stated that four of those enrolled had acquired HIV, explaining that they likely had undetected HIV at the time they started PrEP. The real-world implementation of CAB-LA is anticipated to expand, as ViiV Healthcare, the manufacturer, announced at the conference its plans to triple the supply of cabotegravir that will be available for low- and middle-income countries in 2025-2026 to at least two million doses. Image Credits: Nicole Bergman / IAS, Gilead, Nicole Bergman / IAS. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Rwanda’s High-Level Critical Care Ensures Low Marburg Fatality Rate 21/10/2024 Kerry Cullinan Rwandan Health Minister Dr Sabin Nsanzimana (left) and WHO Director General Dr Tedros Adhanom Ghebreyesus address a media briefing in Kigali on Sunday. After a full week of no new Marburg cases, Rwanda appears to have contained one of the biggest recorded of the deadly virus outbreaks – and with a low case fatality rate of 24%. World Health Organization (WHO) Director-General Dr Tedros Adhanom Ghebreyesus, who visited the country over the weekend, praised the level of Rwanda’s critical care for patients as well as how the country deployed high-level leadership to address the viral haemorrhagic fever, which often kills over 80% of those infected. “Two of the patients we met had experienced all of the symptoms of Marburg, including multiple organ failure, but they were put on life support, they were successfully intubated and extubated, and are now recovering,” Tedros told a media briefing in Rwanda on Sunday. “We believe this is the first time patients with Marburg virus have been extubated in Africa. These patients would have died in previous outbreaks.” Intubation involves inserting a tube through a patient’s nose or mouth into their windpipe (trachea) to help them breathe. This tube can be connected to a ventilator. Extubation is when the tube is removed. Tedros added that Rwanda had worked for many years to “strengthen its health system, to develop capacities for critical care and life support that can be deployed both in regular hospital care and in emergencies”. However, he warned that Marburg is “one of the world’s most dangerous viruses, and continued vigilance is essential”. The outbreak will only be declared over once no new cases have been recorded for 21 days, potentially on 5 November. Sabin’s vaccine candidate used Although there are no approved vaccines or therapeutics for Marburg, Rwanda fast-tracked the trials of a vaccine candidate from the Sabin Vaccine Institute, and an antiviral drug, remdesivir. On 5 October, Sabin delivered 700 doses of its single-dose candidate vaccine, followed by a further 1,000 on 12 October. These have been used to vaccinate health workers “as part of a Phase 2 rapid response open-label trial, sponsored by the Rwanda Biomedical Centre”, according to Sabin. Patients’ close contacts have also been vaccinated. Rwanda developed its own trial protocol after rejecting the WHO’s protocol which would have involved a control group that got vaccinated three weeks after the trial group, according to the journal, Science. Rwanda opted to vaccinate all trial participants at once. However, the remdesivir trial does involve a control group. “The swift initiation of the open-label trial was set in motion on 26 September, when the Rwandan President’s office contacted Sabin CEO Amy Finan to request assistance with the outbreak response,” Sabin said in a statement. Rwanda officially declared the outbreak the next day. “In an outbreak, every moment counts, and our seamless collaboration with the Rwandan government was key to accelerating the process,” said Finan. Sabin’s manufacturing partner, Italy-based ReiThera, produced the drug substance and filled and finished doses for shipment to Rwanda. “On our side, we moved quickly by leveraging our experience with other outbreaks and having vaccine doses and supporting documents ready, thanks to a strong partnership with ReiThera,” Finan added. Sabin’s team only consists of 15 staff members, but Finan said that “their dedication, along with that of our Rwandan colleagues, BARDA [the US Center for the Biomedical Advanced Research and Development Authority] and other partners, enabled us to mobilise so rapidly. “This remarkable effort highlights the power of partnerships and preparedness in addressing urgent public health needs,” said Finan, who also visited Rwanda over the weekend. Meanwhile, Tedros congratulated Rwanda for the speed with which it initiated trials of both vaccines and therapeutics, adding that the WHO hopes that these trials “will help to generate the data to support approval of these products for future outbreaks”. Belen Calvo Uyarra, the European Union’s Ambassador to Rwanda, also praised the country’s rapid response to containing the virus. “Respect to the government of Rwanda and the Rwanda Ministry of Health for proactive leadership, rapid and robust continued response, and professionalism of health workers,” Uyarra posted on X. She and Tedros also visited the site of the BioNTech vaccine manufacturing facility, announced two years ago to facilitate local production of vaccines. Two years ago I visited #Rwanda for the groundbreaking ceremony of the BioNTech facility in Kigali, which raised great hope for local production of vaccines in Africa. Today, I returned to the site and was proud to witness the fast progress of construction of the facility.… pic.twitter.com/8YGwcTVaYe — Tedros Adhanom Ghebreyesus (@DrTedros) October 20, 2024 “I was very pleased to see the significant progress in construction,” said Tedros. “One of the key lessons of the COVID-19 pandemic was the need to expand local production of vaccines to avoid the inequitable access to vaccines that we saw, and we’re pleased to see the way Rwanda and BioNTech are investing in local production. “You know how Africa was treated when the vaccines arrived, with vaccine inequity and vaccine nationalism, and we hope these strategic investments will fix the inequity problems we faced during COVID.” Cities Face ‘Severe Degradation’ Without Meaningful Climate Action, Warn Experts 21/10/2024 Sophia Samantaroy Experts at the yearly Lancet International Health lecture argued that green urban planning can improve health. Cities that fail to take meaningful climate action face a future of severe degradation with infrastructure collapse and environmental deterioration, warned climate and health experts at the yearly Academy of Medical Sciences & The Lancet International Health Lecture in London. “Madrid’s climate in 2050 will resemble Marrakech’s climate today. I don’t think we want that,” said Professor Mark Nieuwenhuijsen, the keynote speaker. To stave off this scenario, cities must adapt with health priorities at the forefront. “For our cities, we’re looking towards solutions that reduce CO2 emissions and also improve environment, equality and, of course, liveability and health.” By 2050, two-thirds of the global population is expected to live in a city. Yet climate change is increasingly threatening human health in urban areas, where swaths of asphalt and concrete exacerbate rising temperatures. Climate change accounts for 37% of heat-related deaths, leaving cities especially vulnerable to heat waves and extreme heat. Dr Mark Nieuwenhuijsen argues that urban planners must consider health is designing the future of cities. Preventing climate-related mortality in cities requires urban planning with an intentional health focus, commented Nieuwenhuijsen. He argued that smart urban planning reduces greenhouse gas emissions and promotes health, but only if we can break away from an “addiction” to fossil fuels. “We know that these fossil fuels are responsible for more than 5 million deaths each year because of air pollution.” Despite the growing knowledge of the health burden of fossil fuels, cities continue to sprawl “with Europe leading the way.” Fossil fuel use has led to “car-centric asphalt-dominated urban planning and extensive urban sprawl, which have detrimental effects on health,” said Nieuwenhuijsen. Sprawling urban areas increases car dependency, even though public transport systems and active transportation – like walking and cycling – are more cost effective. Compact vs green cities – policies that include the best of both models Four different European city configurations vary in their health and environmental effects–with compact cities being the lowest emittors yet having the highest mortality rates compared to less dense cities. In Europe, where many cities are growing faster than their populations, high population density has potential advantages like shortened commute times, decreased care dependency, higher energy efficiency, and decreased building material consumption. The more compact a city, the more efficient. Yet compact cities have potential drawbacks, including higher mortality rates, traffic density, air and noise pollution, and excess heat. Nieuwenhuijsen presented European cities as falling into one of four groups: compact high-density cities, open low-rise medium-density cities, open lowrise low-density cities, and green low-density cities. Analyzing cities across these categories show a split: cities either fall into higher mortality but lower greenhouse emissions, or lower mortality but higher emissions. A city like Barcelona – compact and high-density -–can expect to have a 10-15% higher mortality rate, poorer air quality, and stronger heat island effect, but lower emission, explained Nieuwenhuijsen. Overall, the researchers estimated that poor urban planning results in 20% of premature mortality. “Barcelona is a wonderful city, but it has too much air pollution, too much noise, not enough green space.” “In contrast, greener and less densely populated cities have lower mortality rates, lower air pollution levels, and a lower urban heat island effect, but higher carbon footprints per person.” This dichotomy – where current urban configurations are either high emitters with better health quality, or lower emitters with worse health – means that cities must implement policies that better health and reduce emissions. Nieuwenhuijsen believes that both are possible. Policies that lower air pollution levels and reliance on cars, and increase green space, cycling lanes, and physical activity would “substantially reduce the mortality rate,” he argued. Super blocks, green space, and 15-minute cities Barcelona is one a several major cities implementing innovative urban planning to improve environmental and human health. Several cities have begun implementing innovative urban models that bridge the goals of lower emissions and healthier environments, especially in how they use public land. “A lot of our public space in our cities is, at the moment, actually used by cars. I mean, in Spain, 69% of public space is used by cars because our roads are also public space. Parking is public space. I mean, this is the kind of space that we could use in a much better way,” commented Nieuwenhuijsen. In Paris, a vision to become a “15-minute city” – where all major destinations can be reached within 15 minutes of the home – has increased investments in bike lanes and car-free zones. Barcelona’s “superblocks,” London’s low traffic neighborhoods, and the Vauban Freiburg car-free neighborhood are all promising solutions to reduce premature deaths and increase green spaces. Nieuwenhuijsen and other experts convened at the event pointed to these examples and others as evidence that urban design changes are possible. Several Chinese cities have also embraced the intersection of urban planning and novel technologies to prevent flooding through their Sponge city designs, commented Dr Maria Neira, the World Health Organization’s director of Public Health, Environment and Social Determinants of Health. “More and more we need to be prepared to work with urban planners, the architects working at the city level. And I have the impression that sometimes they are better prepared, more advanced, more engaged and more passionate, than our public health officers working at the city level,” said Neira. “So we need to sort it out and create these very strong arguments for our public health officers as well, to push at the city level, at the Urban level, for engagement with the Urban healthy urban planning.” Image Credits: Michele Castrezzati, Fons Heijnsbroek, The Lancet, The Lancet. Rwanda’s Marburg Outbreak Wanes But Mpox Continues to Spread 17/10/2024 Kerry Cullinan Dr Jean Kaseya and Dr Sabin Nsanzimana. While Rwanda appears to have its Marburg virus outbreak under control with no new cases reported in the past three days in Rwanda, mpox continues to spread – now affecting 18 countries with 3051 new cases in the past week. Since declaring the Marburg outbreak three weeks ago, Rwanda has confirmed 62 cases, of which 15 have died, 38 have recovered and nine cases are still receiving treatment with the majority improving, said Health Minister Dr Sabin Nsanzimana on Thursday. “The case fatality rate overall is 24% and we’ve vaccinated 856 people,” Nsanzimana told an Africa Centres for Disease Control and Prevention (CDC) briefing, describing the trend as “very encouraging”. As the vaccine is “investigational”, its rollout required more rigorous consent, sampling and documentation, but demand for it has been “very high”, he added. the vaccines you are providing highly accepted, especially among healthcare providers. Around 90% of those infected are health workers and their close contacts from the intensive care units of two hospitals that treated the very first patients. The index patients was co-infected with malaria which slowed the diagnosis of Marburg, which has similar symptoms. Rwanda’s health ministry has also tested over 4,000 people “to make sure we don’t miss any cases”, added Nsanzimana. He attributed “intense activity on the ground”, ring vaccination [vaccinating the close contacts of people with Marburg] and new antivirals for the turnaround in what is the biggest Marburg outbreak ever recorded. The virus, which is from the same family as Ebola and, in some outbreaks, has killed over 80% of those infected. While the zoonotic origin of the outbreak is still unknown, Nsanzimana said Rwanda will be reporting its findings on the the serology and gene sequencing of the virus within a few days. At the same time, it has a team on the ground hunting for the source of the virus. Mpox ‘not under control’ Mpox cases have now been identified in 18 African countries, with new additions being Zambia and Zimbabwe. In the past week, 3051 new cases have been reported – including two male prisoners in Uganda. “Mpox is not under control,” warned Africa CDC Director-General Dr Jean Kaseya. Despite calling a continental meeting in April to warn countries of the risk, cases have risen exponentially: from slightly under 6,000 then to 42,438 suspected mpox cases at present – although only 8,113 have been clinically confirmed. A rapid test to diagnose mpox is in the pipeline and will transform the testing landscape, said Kaseya. Kaseya flagged the threat to internally displaced people (IDP), particularly in the Democratic Republic of Congo (DRC), and prisoners – both groups characterised by close contact. In the eastern DRC, conflict has displaced some 2.5 million people who are now living in camps in close quarters with limited access to water, sanitation and hygiene. The two Ugandan prisoners were initially diagnosed with chicken pox – which has small lesions that are itchy not painful like mpox. DRC vaccination plan includes MSM, transgender people The DRC’s vaccination campaign started two weeks ago in three provinces – North Kivu, South Kivu and Tshopo – and is “moving well”, said Kaseya, who hails from DRC. The country’s plan includes men who have sex with men (MSM) and sex workers, as mpox can be sexually transmitted. In DRC, same-sex sexual contact is not outlawed as it is in many of the other countries currently affected by mpox – Uganda, Burundi, Kenya, Tanzania, Zambia and Zimbabwe. “When are talking about MSM, we are clear as Africa CDC. We are saying all human beings have the same rights, and we are supporting countries to plan vaccination for all of them, including men having sex with other men,” said Kaseya empathically. “We are proud and we are glad to see in DRC that we have MSM included,” he added. Kaseya said that early messaging about mpox Clade 1B only being associated with sexual transmission was wrong – as was the failure to talk about MSM as the main mode of transmission iun the 2022 outbreak. “There was the stigma talking about men having sex with other men as the main transmission mode of mpox. But if we put it in the context in Africa, that one in some countries is still a taboo. “We believe with our effort, what we are doing is sensitizing countries, and we are proud to see that DRC are mentioning that.” He added that risk communication and community engagement involving “people who are openly saying we are these key populations” was also important. Uganda tightened its anti-LGBTQ laws recently and, while it plans to test all 1,087 prisoners who possibly had contact with the two prisoners recently diagnosed with mpox, it is unclear how it will approach MSM as a mode of transmission other than to crack down further on smae-sex activity. Europe’s New Air Quality Law is a Breakthrough for Clean Air Globally 16/10/2024 Jane Burston Dirty smoke billows from chimneys in Poland. Europe is now poised to deliver cleaner, healthier air – thanks to adoption this week of the revised Ambient Air Quality Directive (AAQD) by the European Union. This marks a crucial victory for the health and wellbeing of millions across the EU and serves as a beacon for the clean air movement worldwide. The AAQD underpins Europe’s air quality standards, and its revision is a significant breakthrough in addressing the public health crisis of air pollution. Each year, air pollution cuts short the lives of nearly 300,000 Europeans, contributing to respiratory illnesses, cardiovascular disease, and other serious health conditions, according to the EU’s impact assessment report. Improving air quality is a public health imperative. It’s also crucial for the environment and the economy, making the case for stronger EU-wide legislation even clearer. A healthier future The revised AAQD brings Europe’s air quality standards closer to the World Health Organization’s (WHO) air quality guidelines. It sets tougher, legally binding limits on harmful pollutants like nitrogen dioxide (NO₂) and fine particulate matter (PM2.5), representing a doubling of ambition for these two major pollutants, in line with WHO’s interim targets. These pollutants have long been linked to severe health impacts that are particularly harmful for vulnerable groups, such as babies and young children and people with certain conditions such as Chronic Obstructive Pulmonary Disease. By delivering cleaner air, the AAQD could mean the difference between a lifetime of illness and a healthy future for future generations. The AAQD also strengthens the monitoring and measuring provisions for air quality, introducing air quality roadmaps to support progress ahead of its 2030 deadline. The new rules bring about a fairer regime for people affected by air pollution as the rules for access to justice and compensation for those whose health have been impacted by dirty air have been improved. Some of the most polluted regions within member states can delay meeting the new targets for up to 10 years (until 2040) under certain conditions. Although these derogations (or exceptions) provide more leeway than originally envisaged, the compromise, alongside strict conditions for delays, ensure that none of the 27 Member States are left behind. Significant impact if properly implemented Overall, the Directive remains a significant win with ambitious targets and tightly regulated conditions for any delays. Importantly, the initially proposed ambition on limit values remained intact following the two-year legislative process, despite widespread pushback against legislation falling under the EU Green Deal, indicating the scale of this victory for clean air campaigners. One of the key reasons for the AAQD’s success is that it is both an environmental law and a critical public health intervention. By recognising that air quality is a matter of life and death, policymakers have acknowledged the need to protect the most vulnerable in our society. The impact of the new legislation in Europe will be significant if the AAQD is properly implemented. The new rules can prevent more than 55% of premature deaths linked to air pollution in the EU. That’s not just a number – that’s hundreds of thousands of people, each with families, who will live longer, healthier lives. In addition to delivering significant health and environmental benefits, improving the air we breathe makes economic sense. Investing €6 billion annually in cleaner air will deliver up to €121 billion in benefits (according to the EU’s analysis). That’s equivalent to building hundreds of new hospitals or creating hundreds of thousands of new jobs in green industries. Echoing this analysis, the Brussels-based think tank, Bruegel, estimated that implementing clean air measures could boost economic growth by €50 to €60 billion every year[3] and save approximately €600 billion each year in the European Union, the equivalent to 4% of GDP. Ripple effect The importance of the AAQD extends beyond the EU’s borders. By taking decisive action, the EU has positioned itself among the global leaders in air quality management, setting an example for other regions grappling with similar challenges. Air pollution is a global problem, responsible for eight million premature deaths annually worldwide, as reported in the British Medical Journal, and the EU’s solutions will, I hope, inspire other countries to pursue stronger actions. Ongoing engagement and sustained political will are key to ensuring the success of these measures. The real test will come as member states move to transpose the Directive into law and work to implement these new standards. National and local governments will need to invest in cleaner technologies, green transport and clean heating while improving air quality monitoring and ensuring that enforcement is taken seriously. Let’s celebrate this moment, but also remain focused on the work that still needs to be done. Air pollution is an invisible killer, shortening lives and ravaging our communities. With this new Directive, we are fighting back. Jane Burston founded and leads the Clean Air Fund (CAF), a global philanthropic organisation working with governments, funders, businesses and campaigners to create a future where everyone breathes clean air. Before setting up CAF, Jane worked as head of Climate and Energy Science in the UK government. Prior to that, as head of Energy and Environment at the UK National Physical Laboratory, she managed a team of 150 scientists working in air quality, GHG measurement and renewable energy. Image Credits: Janusz Walczak/ Unsplash. World Can Halve Premature Deaths by 2050, Lancet Commission Reports 15/10/2024 Stefan Anderson BERLIN – Countries worldwide, regardless of income level, can halve premature death rates by 2050, a new Lancet report presented at the closing of the World Health Summit in Berlin suggests. Fifteen key health threats are driving premature deaths worldwide, with tobacco use leading the pack “by far”, the Lancet Commission for Investing in Health found. Targeting interventions in these areas – with over half involving maternal, newborn, child, and infectious diseases – could dramatically reduce global deaths before age 70, the Commission said. “Sharp reductions in mortality and morbidity can be achieved by focusing on 15 priority conditions,” Dr Angela Chang from the University of Southern Denmark and lead author of the report, told a panel at the World Health Summit in Berlin on Tuesday. “Doubling down on past health investments, focusing resources on a narrow set of conditions, scaling up financing and developing new technologies can continue to have an enormous impact despite the headwinds.” The 15 priority conditions, selected from over 17,000 internationally recognized health diagnoses, account for approximately 80% of the life expectancy gap between most regions and the North Atlantic, defined in the report as North America and Europe. These conditions account for 86% of the gap between China and the North Atlantic, and 74% between sub-Saharan Africa and the North Atlantic. “There’s a 22-year gap in life expectancy between Sub-Saharan Africa and the North Atlantic, Chang explained. “Close to 80% of this gap can be explained by these 15 priority conditions, and over half of the difference can be attributed to eight infectious and maternal health conditions.” If the global goal is met, the average premature mortality rate worldwide would fall to about 15%, matching levels currently seen in Europe and North America—today’s global benchmark. Achieving this would mean dramatic improvements for billions, especially in low- and middle-income countries. In Sub-Saharan Africa, the worst-performing region, premature mortality sits at 52%. Setting priorities straight The report’s optimism is rooted in historical data. Globally, the probability of dying before 70 has halved since the 1960s, falling from 62% to 31% for individuals born in 2019. Thirty-seven countries, including populous nations like Bangladesh, China, Japan, and Vietnam, have already halved their premature death rates in similar or shorter periods than the 26 years remaining until the 2050 target date. The Commission recommends public financing for essential medicines targeting the 15 key conditions driving premature mortality. It suggests mobilizing international funding and joint procurement efforts, similar to strategies used by GAVI, PEPFAR, and the Global Fund, to reduce costs for patients and governments alike. “Inadequate access to medicines and high out-of-pocket costs are major threats to cutting premature mortality,” Chang noted. “We learned from the Global Fund’s experience how national government subsidies can steer resources towards priority interventions and reduce out-of-pocket payments.” While the Commission believes halving premature mortality by 2050 is globally achievable, it acknowledges this target may be “perhaps only aspirational for some countries, realistically speaking.” “We have a tendency to focus on the new, shiny things,” Chang added. “Our message is for countries to stay focused on these priority conditions.” ‘Tobacco is the new tobacco’ Six out of ten smokers, or 750 million people globally want to quit tobacco use. High tobacco taxes are “by far” the most crucial policy tool for reducing premature deaths, according to the report. “You often hear about other risk factors, but we argue tobacco is the new tobacco,” Chang explained. Recent research suggests raising excise taxes on tobacco, alcohol, and sugary drinks by 50% could yield $2.1 trillion for low- and middle-income countries over five years. This could boost healthcare spending in these nations by 40% if directed towards health initiatives. The Commission highlights the Middle East and North Africa as an example of untapped potential in tobacco control. With 160 million smokers and rising prevalence among youth and women, the region faces a growing health crisis. Egypt’s smoking rates doubled between 2000 and 2018, while tobacco became more affordable in conflict-affected countries like Iraq and Syria. The region’s tobacco taxes, second-lowest globally, fall far short of the World Health Organization’s recommended 70% excise tax. “Despite wide experience with its successful use, tobacco taxation remains a policy tool that is still greatly underused,” the Commission found. “Raising taxes on tobacco can do more to reduce premature mortality than any other single health policy.” High risk of ‘COVID magnitude’ pandemic in next decade The Lancet Comission estimates there is a 23% change of a COVID-scale pandemic in the next decade. New modeling for the Commission’s report indicates a 23% chance of a pandemic as severe as COVID-19 occurring within a decade. Unprepared health systems could see progress on reducing premature deaths plummet if caught off guard again. “There is a high risk of another pandemic of Covid-like magnitude,” Chang warned. “To put it another way, in most years there will be zero pandemic deaths, and in some years there will be millions of pandemic deaths.” The Commission’s analysis estimates an average of 2.5 million deaths per year due to pandemics when viewed over a long time horizon. This figure is comparable to the current annual death toll from AIDS, malaria, and tuberculosis combined, and significantly exceeds even pessimistic projections for annual climate change-related deaths in coming decades. “People should wake up at that figure,” Helen Clark, former Prime Minister of New Zealand, warned the summit. The warning from the Commission comes as global headwinds from conflict, climate change and debt hammer health budgets. Neglecting pandemic preparedness could have severe consequences, particularly for poorer countries less equipped to handle sudden outbreaks. “We need to learn the lessons not just from COVID, but from Mpox, Ebola … and avoid this panic-neglect cycle,” said Dr Seth Berkley, former CEO of Gavi, the Vaccine Alliance. “Unfortunately, I don’t think we’re doing a very good job.” From 1993 to Berlin A figure from the World Bank’s 1993 report making the case for health as an economic investment. The Lancet Comission report is the latest in a line of studies that traces its lineage back to a pivotal World Bank report that changed the landscape of global health finance. The World Bank’s 1993 report, Investing in Health, the only report on health ever published by the Bank, was the first to make an argument still used by health advocates and ministers across the globe: health is an investment. “The World Bank saying investing in health is no just a cost to society, but an investment that was justified on pure economic grounds … was revolutionary,” Berkley recalled. “Prior to this, people saw it as a cost – if you get richer, you can afford health, but this really changed the thinking.” The Commission’s work has expanded on the World Bank’s initial calculations, incorporating factors such as the impact of out-of-pocket health costs on economies and personal livelihoods. This broader perspective has significantly increased the estimated economic benefits of maintaining healthy societies, from the World Bank’s initial 11% to 24%. “The important thing is that each one of these reports, including this one, says the case is better than ever for investing in health, and we need to keep talking about that, particularly at a time when the headwinds are so strong,” Berkley emphasizes. The latest report continues this tradition, reaffirming that health investment remains one of the most effective strategies for improving both individual and societal outcomes. “Today, the case is better than ever for going for mortality reduction,” said Dr Gavin Yamey, director of Duke University’s Center for Policy Impact in Global Health and lead author of the commission report “It’s a prize within reach. It will have extraordinary health, welfare and economic benefits.” Image Credits: Sarah Johnson. Transformative Potential of Long-Acting Preventive Drugs Takes Centre Stage at HIV Conference 14/10/2024 Edith Magak At a HIVR4P’s press conference: Jeremy Nuttall, Elizabeth Irungu, Mark Marzinke, Alessandro Grattoni, William Hahn and Colleen Kelley. LIMA, Peru – The infection-prevention potential of Lenacapavir, the long-acting anti-HIV injectable administered just twice a year, took centre stage at the fifth HIV Research for Prevention Conference (HIVR4P) held last week. However, several other important studies were also unveiled, including an injectable that combines contraception and HIV protection, results from a three-month vaginal ring, and real-world findings from Zambia’s rollout of long-acting injectable cabotegravir. Lenacapavir in diverse populations Lenacapavir reduced HIV infections by 96% in a gender-diverse population, according to results from the PURPOSE 2 trial, which enrolled over 3,200 participants from Argentina, Brazil, Mexico, Peru, South Africa, Thailand, and the US between June 2021 and December 2023. Participants were randomly assigned to one of two groups: one receiving lenacapavir injections every six months and the other taking daily oral pills for pre-exposure prophylaxis (PrEP) with matched placebos. The average age of participants was 28, with over one-third under the age of 25. Around 70% identified as non-white, and the gender breakdown featured cisgender men, transgender men, transgender women, and non-binary individuals who have sex with partners assigned male at birth. At 39 weeks, only two HIV cases occurred in the lenacapavir group of 2,179 individuals, translating to a 96% reduction in HIV incidence, according to Dr Colleen Kelley from Emory University. In contrast, there were nine new HIV cases among the 1,087 participants taking daily oral TDF pills (comprising tenofovir disoproxil fumarate and emtricitabine and marketed as Truvada). This makes lenacapavir 89% more effective than oral PrEP. The findings echoed earlier results from the PURPOSE 1 trial, which showed 100% efficacy in preventing HIV among cisgender women in Africa. With regulatory filings expected to begin globally by the end of 2024, lenacapavir has the potential to be a transformative HIV prevention tool. Future phases of the study will focus on other groups, including women in the US (PURPOSE 3) and people who inject drugs (PURPOSE 4). The twice-yearly injectable, lenacapavir (marketed as Sunlenca in the US) could make a huge difference to HIV prevention is widely accessible. Injectable contraceptive and HIV prevention in one For millions of young women worldwide, two major health concerns often intersect: HIV acquisition and unintended pregnancy. Many have expressed a preference for a method that protects against both. At the conference, Melissa Peet from CONRAD presented results from a promising solution—a silica-based hydrogel injectable that combines HIV antiretroviral drugs with contraception in a single shot. In designing this dual-purpose method, researchers selected long-acting cabotegravir (CAB-LA) as the HIV prevention drug and levonorgestrel (LNG) as the contraceptive. The hydrogel injectable they developed is a silica-biodegradable material comprising two compartments, one for each medication. The injectable is capable of delivering both drugs with a single injection offering dual protection for three months. Preclinical tests in rats showed sustained drug levels in the bloodstream without significant interactions or safety concerns, and the researchers are now conducting additional studies in non-human primates to fine-tune dosing and asses the duration of protective drug concentration. No interactions between Cabotegravir and contraceptives One concern with combining HIV prevention and contraception has been the potential for drug interactions, particularly between long-acting HIV medications like cabotegravir (CAB-LA) and commonly used contraceptives. To address this, Dr. Mark Marzinke from Johns Hopkins University presented results from a sub-study within the HPTN 084 trial to explore any potential interactions. The study included 170 participants from South Africa with a median age of 23. A total of 80 women were randomised to the CAB-LA arm and 90 in the oral PrEP arm. Participants used three types of hormonal contraceptives: etonogestrel implants, injectable norethindrone, or medroxyprogesterone acetate (MPA), alongside either CAB-LA or oral PrEP. Researchers measured drug concentrations at enrolment and again at weeks 25, 49, and 73 to determine if there were any drug interactions. The results were reassuring: plasma concentrations of the contraceptives remained high enough to prevent pregnancy in both the CAB-LA and oral PrEP groups. CAB-LA concentrations were also consistent across contraceptive types, indicating that CAB-LA does not interfere with contraceptive effectiveness. However, tenofovir concentrations were unquantifiable for most participants, regardless of contraceptive type, due to low adherence to oral PrEP. New data on the three-month vaginal ring For women seeking long-term HIV prevention, the dapivirine vaginal ring, sometimes called the PrEP ring, has been a promising option. This is a flexible silicone ring that is placed in the vagina that releases the anti-HIV drug, dapivirine, over a month. Delegates at the conference heard results from a South African study comparing the bioavailability of the standard one-month dapivirine ring with a new three-month version. The study enrolled 124 women, but only 104 completed the trial. This was a crossover trial with two treatment phases: half the group started with the one-month ring (containing 25 mg of dapivirine) and then switched to the three-month ring, containing 100 mg of dapivirine. The other group followed the reverse order; they began with the three-month ring and later switched to the one-month ring. The three-month ring was identical to the one-month version in silicone, dimensions, and appearance. Plasma and vaginal fluid samples were collected throughout the study to measure drug levels. Based on dapivirine concentrations in plasma, results showed that the three-month ring provided greater overall drug exposure than the one-month version, indicating equal or possibly higher efficacy in preventing HIV. Jeremy Nuttall from the Population Council’s Center for Biomedical Research, who presented the findings, noted that the reduced frequency of ring changes might increase acceptability and adherence, potentially improving overall effectiveness. He also highlighted that the estimated cost of the three-month ring is $16, making it a potentially more affordable option, projecting that the three-month ring could become available on the market by 2026. Roxana Bretoneche protesting about the lack of community participation at HIVR4P. Real-world results from Zambia’s CAB-LA rollout Zambia became the first country in sub-Saharan Africa to roll out long-acting injectable PrEP (CAB-LA) beyond clinical trials, sharing results from their first three months (February to April 2024) in real-world settings. A total of 609 individuals with a median age of 24 were enrolled across six health facilities in two districts. Among the clients, 55% were female, 20% were adolescent boys and young men, 7% identified as key populations, and 40% as other high-risk populations. Adamson Ndhlovu from Zambia’s JSI USAID DISCOVER-Health Project shared that over 90% of participants due for their second injection received it on time. A total of 24 participants (about 4%) discontinued CAB-LA. Most discontinuations were due to hepatitis B (20 cases), with two participants stopping due to pregnancy, one due to a severe rash, and one because of severe pain at the injection site. Those who discontinued were switched to oral PrEP. During a press briefing at the conference, Professor Lloyd Mulenga from Zambia’s Ministry of Health stated that four of those enrolled had acquired HIV, explaining that they likely had undetected HIV at the time they started PrEP. The real-world implementation of CAB-LA is anticipated to expand, as ViiV Healthcare, the manufacturer, announced at the conference its plans to triple the supply of cabotegravir that will be available for low- and middle-income countries in 2025-2026 to at least two million doses. Image Credits: Nicole Bergman / IAS, Gilead, Nicole Bergman / IAS. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Cities Face ‘Severe Degradation’ Without Meaningful Climate Action, Warn Experts 21/10/2024 Sophia Samantaroy Experts at the yearly Lancet International Health lecture argued that green urban planning can improve health. Cities that fail to take meaningful climate action face a future of severe degradation with infrastructure collapse and environmental deterioration, warned climate and health experts at the yearly Academy of Medical Sciences & The Lancet International Health Lecture in London. “Madrid’s climate in 2050 will resemble Marrakech’s climate today. I don’t think we want that,” said Professor Mark Nieuwenhuijsen, the keynote speaker. To stave off this scenario, cities must adapt with health priorities at the forefront. “For our cities, we’re looking towards solutions that reduce CO2 emissions and also improve environment, equality and, of course, liveability and health.” By 2050, two-thirds of the global population is expected to live in a city. Yet climate change is increasingly threatening human health in urban areas, where swaths of asphalt and concrete exacerbate rising temperatures. Climate change accounts for 37% of heat-related deaths, leaving cities especially vulnerable to heat waves and extreme heat. Dr Mark Nieuwenhuijsen argues that urban planners must consider health is designing the future of cities. Preventing climate-related mortality in cities requires urban planning with an intentional health focus, commented Nieuwenhuijsen. He argued that smart urban planning reduces greenhouse gas emissions and promotes health, but only if we can break away from an “addiction” to fossil fuels. “We know that these fossil fuels are responsible for more than 5 million deaths each year because of air pollution.” Despite the growing knowledge of the health burden of fossil fuels, cities continue to sprawl “with Europe leading the way.” Fossil fuel use has led to “car-centric asphalt-dominated urban planning and extensive urban sprawl, which have detrimental effects on health,” said Nieuwenhuijsen. Sprawling urban areas increases car dependency, even though public transport systems and active transportation – like walking and cycling – are more cost effective. Compact vs green cities – policies that include the best of both models Four different European city configurations vary in their health and environmental effects–with compact cities being the lowest emittors yet having the highest mortality rates compared to less dense cities. In Europe, where many cities are growing faster than their populations, high population density has potential advantages like shortened commute times, decreased care dependency, higher energy efficiency, and decreased building material consumption. The more compact a city, the more efficient. Yet compact cities have potential drawbacks, including higher mortality rates, traffic density, air and noise pollution, and excess heat. Nieuwenhuijsen presented European cities as falling into one of four groups: compact high-density cities, open low-rise medium-density cities, open lowrise low-density cities, and green low-density cities. Analyzing cities across these categories show a split: cities either fall into higher mortality but lower greenhouse emissions, or lower mortality but higher emissions. A city like Barcelona – compact and high-density -–can expect to have a 10-15% higher mortality rate, poorer air quality, and stronger heat island effect, but lower emission, explained Nieuwenhuijsen. Overall, the researchers estimated that poor urban planning results in 20% of premature mortality. “Barcelona is a wonderful city, but it has too much air pollution, too much noise, not enough green space.” “In contrast, greener and less densely populated cities have lower mortality rates, lower air pollution levels, and a lower urban heat island effect, but higher carbon footprints per person.” This dichotomy – where current urban configurations are either high emitters with better health quality, or lower emitters with worse health – means that cities must implement policies that better health and reduce emissions. Nieuwenhuijsen believes that both are possible. Policies that lower air pollution levels and reliance on cars, and increase green space, cycling lanes, and physical activity would “substantially reduce the mortality rate,” he argued. Super blocks, green space, and 15-minute cities Barcelona is one a several major cities implementing innovative urban planning to improve environmental and human health. Several cities have begun implementing innovative urban models that bridge the goals of lower emissions and healthier environments, especially in how they use public land. “A lot of our public space in our cities is, at the moment, actually used by cars. I mean, in Spain, 69% of public space is used by cars because our roads are also public space. Parking is public space. I mean, this is the kind of space that we could use in a much better way,” commented Nieuwenhuijsen. In Paris, a vision to become a “15-minute city” – where all major destinations can be reached within 15 minutes of the home – has increased investments in bike lanes and car-free zones. Barcelona’s “superblocks,” London’s low traffic neighborhoods, and the Vauban Freiburg car-free neighborhood are all promising solutions to reduce premature deaths and increase green spaces. Nieuwenhuijsen and other experts convened at the event pointed to these examples and others as evidence that urban design changes are possible. Several Chinese cities have also embraced the intersection of urban planning and novel technologies to prevent flooding through their Sponge city designs, commented Dr Maria Neira, the World Health Organization’s director of Public Health, Environment and Social Determinants of Health. “More and more we need to be prepared to work with urban planners, the architects working at the city level. And I have the impression that sometimes they are better prepared, more advanced, more engaged and more passionate, than our public health officers working at the city level,” said Neira. “So we need to sort it out and create these very strong arguments for our public health officers as well, to push at the city level, at the Urban level, for engagement with the Urban healthy urban planning.” Image Credits: Michele Castrezzati, Fons Heijnsbroek, The Lancet, The Lancet. Rwanda’s Marburg Outbreak Wanes But Mpox Continues to Spread 17/10/2024 Kerry Cullinan Dr Jean Kaseya and Dr Sabin Nsanzimana. While Rwanda appears to have its Marburg virus outbreak under control with no new cases reported in the past three days in Rwanda, mpox continues to spread – now affecting 18 countries with 3051 new cases in the past week. Since declaring the Marburg outbreak three weeks ago, Rwanda has confirmed 62 cases, of which 15 have died, 38 have recovered and nine cases are still receiving treatment with the majority improving, said Health Minister Dr Sabin Nsanzimana on Thursday. “The case fatality rate overall is 24% and we’ve vaccinated 856 people,” Nsanzimana told an Africa Centres for Disease Control and Prevention (CDC) briefing, describing the trend as “very encouraging”. As the vaccine is “investigational”, its rollout required more rigorous consent, sampling and documentation, but demand for it has been “very high”, he added. the vaccines you are providing highly accepted, especially among healthcare providers. Around 90% of those infected are health workers and their close contacts from the intensive care units of two hospitals that treated the very first patients. The index patients was co-infected with malaria which slowed the diagnosis of Marburg, which has similar symptoms. Rwanda’s health ministry has also tested over 4,000 people “to make sure we don’t miss any cases”, added Nsanzimana. He attributed “intense activity on the ground”, ring vaccination [vaccinating the close contacts of people with Marburg] and new antivirals for the turnaround in what is the biggest Marburg outbreak ever recorded. The virus, which is from the same family as Ebola and, in some outbreaks, has killed over 80% of those infected. While the zoonotic origin of the outbreak is still unknown, Nsanzimana said Rwanda will be reporting its findings on the the serology and gene sequencing of the virus within a few days. At the same time, it has a team on the ground hunting for the source of the virus. Mpox ‘not under control’ Mpox cases have now been identified in 18 African countries, with new additions being Zambia and Zimbabwe. In the past week, 3051 new cases have been reported – including two male prisoners in Uganda. “Mpox is not under control,” warned Africa CDC Director-General Dr Jean Kaseya. Despite calling a continental meeting in April to warn countries of the risk, cases have risen exponentially: from slightly under 6,000 then to 42,438 suspected mpox cases at present – although only 8,113 have been clinically confirmed. A rapid test to diagnose mpox is in the pipeline and will transform the testing landscape, said Kaseya. Kaseya flagged the threat to internally displaced people (IDP), particularly in the Democratic Republic of Congo (DRC), and prisoners – both groups characterised by close contact. In the eastern DRC, conflict has displaced some 2.5 million people who are now living in camps in close quarters with limited access to water, sanitation and hygiene. The two Ugandan prisoners were initially diagnosed with chicken pox – which has small lesions that are itchy not painful like mpox. DRC vaccination plan includes MSM, transgender people The DRC’s vaccination campaign started two weeks ago in three provinces – North Kivu, South Kivu and Tshopo – and is “moving well”, said Kaseya, who hails from DRC. The country’s plan includes men who have sex with men (MSM) and sex workers, as mpox can be sexually transmitted. In DRC, same-sex sexual contact is not outlawed as it is in many of the other countries currently affected by mpox – Uganda, Burundi, Kenya, Tanzania, Zambia and Zimbabwe. “When are talking about MSM, we are clear as Africa CDC. We are saying all human beings have the same rights, and we are supporting countries to plan vaccination for all of them, including men having sex with other men,” said Kaseya empathically. “We are proud and we are glad to see in DRC that we have MSM included,” he added. Kaseya said that early messaging about mpox Clade 1B only being associated with sexual transmission was wrong – as was the failure to talk about MSM as the main mode of transmission iun the 2022 outbreak. “There was the stigma talking about men having sex with other men as the main transmission mode of mpox. But if we put it in the context in Africa, that one in some countries is still a taboo. “We believe with our effort, what we are doing is sensitizing countries, and we are proud to see that DRC are mentioning that.” He added that risk communication and community engagement involving “people who are openly saying we are these key populations” was also important. Uganda tightened its anti-LGBTQ laws recently and, while it plans to test all 1,087 prisoners who possibly had contact with the two prisoners recently diagnosed with mpox, it is unclear how it will approach MSM as a mode of transmission other than to crack down further on smae-sex activity. Europe’s New Air Quality Law is a Breakthrough for Clean Air Globally 16/10/2024 Jane Burston Dirty smoke billows from chimneys in Poland. Europe is now poised to deliver cleaner, healthier air – thanks to adoption this week of the revised Ambient Air Quality Directive (AAQD) by the European Union. This marks a crucial victory for the health and wellbeing of millions across the EU and serves as a beacon for the clean air movement worldwide. The AAQD underpins Europe’s air quality standards, and its revision is a significant breakthrough in addressing the public health crisis of air pollution. Each year, air pollution cuts short the lives of nearly 300,000 Europeans, contributing to respiratory illnesses, cardiovascular disease, and other serious health conditions, according to the EU’s impact assessment report. Improving air quality is a public health imperative. It’s also crucial for the environment and the economy, making the case for stronger EU-wide legislation even clearer. A healthier future The revised AAQD brings Europe’s air quality standards closer to the World Health Organization’s (WHO) air quality guidelines. It sets tougher, legally binding limits on harmful pollutants like nitrogen dioxide (NO₂) and fine particulate matter (PM2.5), representing a doubling of ambition for these two major pollutants, in line with WHO’s interim targets. These pollutants have long been linked to severe health impacts that are particularly harmful for vulnerable groups, such as babies and young children and people with certain conditions such as Chronic Obstructive Pulmonary Disease. By delivering cleaner air, the AAQD could mean the difference between a lifetime of illness and a healthy future for future generations. The AAQD also strengthens the monitoring and measuring provisions for air quality, introducing air quality roadmaps to support progress ahead of its 2030 deadline. The new rules bring about a fairer regime for people affected by air pollution as the rules for access to justice and compensation for those whose health have been impacted by dirty air have been improved. Some of the most polluted regions within member states can delay meeting the new targets for up to 10 years (until 2040) under certain conditions. Although these derogations (or exceptions) provide more leeway than originally envisaged, the compromise, alongside strict conditions for delays, ensure that none of the 27 Member States are left behind. Significant impact if properly implemented Overall, the Directive remains a significant win with ambitious targets and tightly regulated conditions for any delays. Importantly, the initially proposed ambition on limit values remained intact following the two-year legislative process, despite widespread pushback against legislation falling under the EU Green Deal, indicating the scale of this victory for clean air campaigners. One of the key reasons for the AAQD’s success is that it is both an environmental law and a critical public health intervention. By recognising that air quality is a matter of life and death, policymakers have acknowledged the need to protect the most vulnerable in our society. The impact of the new legislation in Europe will be significant if the AAQD is properly implemented. The new rules can prevent more than 55% of premature deaths linked to air pollution in the EU. That’s not just a number – that’s hundreds of thousands of people, each with families, who will live longer, healthier lives. In addition to delivering significant health and environmental benefits, improving the air we breathe makes economic sense. Investing €6 billion annually in cleaner air will deliver up to €121 billion in benefits (according to the EU’s analysis). That’s equivalent to building hundreds of new hospitals or creating hundreds of thousands of new jobs in green industries. Echoing this analysis, the Brussels-based think tank, Bruegel, estimated that implementing clean air measures could boost economic growth by €50 to €60 billion every year[3] and save approximately €600 billion each year in the European Union, the equivalent to 4% of GDP. Ripple effect The importance of the AAQD extends beyond the EU’s borders. By taking decisive action, the EU has positioned itself among the global leaders in air quality management, setting an example for other regions grappling with similar challenges. Air pollution is a global problem, responsible for eight million premature deaths annually worldwide, as reported in the British Medical Journal, and the EU’s solutions will, I hope, inspire other countries to pursue stronger actions. Ongoing engagement and sustained political will are key to ensuring the success of these measures. The real test will come as member states move to transpose the Directive into law and work to implement these new standards. National and local governments will need to invest in cleaner technologies, green transport and clean heating while improving air quality monitoring and ensuring that enforcement is taken seriously. Let’s celebrate this moment, but also remain focused on the work that still needs to be done. Air pollution is an invisible killer, shortening lives and ravaging our communities. With this new Directive, we are fighting back. Jane Burston founded and leads the Clean Air Fund (CAF), a global philanthropic organisation working with governments, funders, businesses and campaigners to create a future where everyone breathes clean air. Before setting up CAF, Jane worked as head of Climate and Energy Science in the UK government. Prior to that, as head of Energy and Environment at the UK National Physical Laboratory, she managed a team of 150 scientists working in air quality, GHG measurement and renewable energy. Image Credits: Janusz Walczak/ Unsplash. World Can Halve Premature Deaths by 2050, Lancet Commission Reports 15/10/2024 Stefan Anderson BERLIN – Countries worldwide, regardless of income level, can halve premature death rates by 2050, a new Lancet report presented at the closing of the World Health Summit in Berlin suggests. Fifteen key health threats are driving premature deaths worldwide, with tobacco use leading the pack “by far”, the Lancet Commission for Investing in Health found. Targeting interventions in these areas – with over half involving maternal, newborn, child, and infectious diseases – could dramatically reduce global deaths before age 70, the Commission said. “Sharp reductions in mortality and morbidity can be achieved by focusing on 15 priority conditions,” Dr Angela Chang from the University of Southern Denmark and lead author of the report, told a panel at the World Health Summit in Berlin on Tuesday. “Doubling down on past health investments, focusing resources on a narrow set of conditions, scaling up financing and developing new technologies can continue to have an enormous impact despite the headwinds.” The 15 priority conditions, selected from over 17,000 internationally recognized health diagnoses, account for approximately 80% of the life expectancy gap between most regions and the North Atlantic, defined in the report as North America and Europe. These conditions account for 86% of the gap between China and the North Atlantic, and 74% between sub-Saharan Africa and the North Atlantic. “There’s a 22-year gap in life expectancy between Sub-Saharan Africa and the North Atlantic, Chang explained. “Close to 80% of this gap can be explained by these 15 priority conditions, and over half of the difference can be attributed to eight infectious and maternal health conditions.” If the global goal is met, the average premature mortality rate worldwide would fall to about 15%, matching levels currently seen in Europe and North America—today’s global benchmark. Achieving this would mean dramatic improvements for billions, especially in low- and middle-income countries. In Sub-Saharan Africa, the worst-performing region, premature mortality sits at 52%. Setting priorities straight The report’s optimism is rooted in historical data. Globally, the probability of dying before 70 has halved since the 1960s, falling from 62% to 31% for individuals born in 2019. Thirty-seven countries, including populous nations like Bangladesh, China, Japan, and Vietnam, have already halved their premature death rates in similar or shorter periods than the 26 years remaining until the 2050 target date. The Commission recommends public financing for essential medicines targeting the 15 key conditions driving premature mortality. It suggests mobilizing international funding and joint procurement efforts, similar to strategies used by GAVI, PEPFAR, and the Global Fund, to reduce costs for patients and governments alike. “Inadequate access to medicines and high out-of-pocket costs are major threats to cutting premature mortality,” Chang noted. “We learned from the Global Fund’s experience how national government subsidies can steer resources towards priority interventions and reduce out-of-pocket payments.” While the Commission believes halving premature mortality by 2050 is globally achievable, it acknowledges this target may be “perhaps only aspirational for some countries, realistically speaking.” “We have a tendency to focus on the new, shiny things,” Chang added. “Our message is for countries to stay focused on these priority conditions.” ‘Tobacco is the new tobacco’ Six out of ten smokers, or 750 million people globally want to quit tobacco use. High tobacco taxes are “by far” the most crucial policy tool for reducing premature deaths, according to the report. “You often hear about other risk factors, but we argue tobacco is the new tobacco,” Chang explained. Recent research suggests raising excise taxes on tobacco, alcohol, and sugary drinks by 50% could yield $2.1 trillion for low- and middle-income countries over five years. This could boost healthcare spending in these nations by 40% if directed towards health initiatives. The Commission highlights the Middle East and North Africa as an example of untapped potential in tobacco control. With 160 million smokers and rising prevalence among youth and women, the region faces a growing health crisis. Egypt’s smoking rates doubled between 2000 and 2018, while tobacco became more affordable in conflict-affected countries like Iraq and Syria. The region’s tobacco taxes, second-lowest globally, fall far short of the World Health Organization’s recommended 70% excise tax. “Despite wide experience with its successful use, tobacco taxation remains a policy tool that is still greatly underused,” the Commission found. “Raising taxes on tobacco can do more to reduce premature mortality than any other single health policy.” High risk of ‘COVID magnitude’ pandemic in next decade The Lancet Comission estimates there is a 23% change of a COVID-scale pandemic in the next decade. New modeling for the Commission’s report indicates a 23% chance of a pandemic as severe as COVID-19 occurring within a decade. Unprepared health systems could see progress on reducing premature deaths plummet if caught off guard again. “There is a high risk of another pandemic of Covid-like magnitude,” Chang warned. “To put it another way, in most years there will be zero pandemic deaths, and in some years there will be millions of pandemic deaths.” The Commission’s analysis estimates an average of 2.5 million deaths per year due to pandemics when viewed over a long time horizon. This figure is comparable to the current annual death toll from AIDS, malaria, and tuberculosis combined, and significantly exceeds even pessimistic projections for annual climate change-related deaths in coming decades. “People should wake up at that figure,” Helen Clark, former Prime Minister of New Zealand, warned the summit. The warning from the Commission comes as global headwinds from conflict, climate change and debt hammer health budgets. Neglecting pandemic preparedness could have severe consequences, particularly for poorer countries less equipped to handle sudden outbreaks. “We need to learn the lessons not just from COVID, but from Mpox, Ebola … and avoid this panic-neglect cycle,” said Dr Seth Berkley, former CEO of Gavi, the Vaccine Alliance. “Unfortunately, I don’t think we’re doing a very good job.” From 1993 to Berlin A figure from the World Bank’s 1993 report making the case for health as an economic investment. The Lancet Comission report is the latest in a line of studies that traces its lineage back to a pivotal World Bank report that changed the landscape of global health finance. The World Bank’s 1993 report, Investing in Health, the only report on health ever published by the Bank, was the first to make an argument still used by health advocates and ministers across the globe: health is an investment. “The World Bank saying investing in health is no just a cost to society, but an investment that was justified on pure economic grounds … was revolutionary,” Berkley recalled. “Prior to this, people saw it as a cost – if you get richer, you can afford health, but this really changed the thinking.” The Commission’s work has expanded on the World Bank’s initial calculations, incorporating factors such as the impact of out-of-pocket health costs on economies and personal livelihoods. This broader perspective has significantly increased the estimated economic benefits of maintaining healthy societies, from the World Bank’s initial 11% to 24%. “The important thing is that each one of these reports, including this one, says the case is better than ever for investing in health, and we need to keep talking about that, particularly at a time when the headwinds are so strong,” Berkley emphasizes. The latest report continues this tradition, reaffirming that health investment remains one of the most effective strategies for improving both individual and societal outcomes. “Today, the case is better than ever for going for mortality reduction,” said Dr Gavin Yamey, director of Duke University’s Center for Policy Impact in Global Health and lead author of the commission report “It’s a prize within reach. It will have extraordinary health, welfare and economic benefits.” Image Credits: Sarah Johnson. Transformative Potential of Long-Acting Preventive Drugs Takes Centre Stage at HIV Conference 14/10/2024 Edith Magak At a HIVR4P’s press conference: Jeremy Nuttall, Elizabeth Irungu, Mark Marzinke, Alessandro Grattoni, William Hahn and Colleen Kelley. LIMA, Peru – The infection-prevention potential of Lenacapavir, the long-acting anti-HIV injectable administered just twice a year, took centre stage at the fifth HIV Research for Prevention Conference (HIVR4P) held last week. However, several other important studies were also unveiled, including an injectable that combines contraception and HIV protection, results from a three-month vaginal ring, and real-world findings from Zambia’s rollout of long-acting injectable cabotegravir. Lenacapavir in diverse populations Lenacapavir reduced HIV infections by 96% in a gender-diverse population, according to results from the PURPOSE 2 trial, which enrolled over 3,200 participants from Argentina, Brazil, Mexico, Peru, South Africa, Thailand, and the US between June 2021 and December 2023. Participants were randomly assigned to one of two groups: one receiving lenacapavir injections every six months and the other taking daily oral pills for pre-exposure prophylaxis (PrEP) with matched placebos. The average age of participants was 28, with over one-third under the age of 25. Around 70% identified as non-white, and the gender breakdown featured cisgender men, transgender men, transgender women, and non-binary individuals who have sex with partners assigned male at birth. At 39 weeks, only two HIV cases occurred in the lenacapavir group of 2,179 individuals, translating to a 96% reduction in HIV incidence, according to Dr Colleen Kelley from Emory University. In contrast, there were nine new HIV cases among the 1,087 participants taking daily oral TDF pills (comprising tenofovir disoproxil fumarate and emtricitabine and marketed as Truvada). This makes lenacapavir 89% more effective than oral PrEP. The findings echoed earlier results from the PURPOSE 1 trial, which showed 100% efficacy in preventing HIV among cisgender women in Africa. With regulatory filings expected to begin globally by the end of 2024, lenacapavir has the potential to be a transformative HIV prevention tool. Future phases of the study will focus on other groups, including women in the US (PURPOSE 3) and people who inject drugs (PURPOSE 4). The twice-yearly injectable, lenacapavir (marketed as Sunlenca in the US) could make a huge difference to HIV prevention is widely accessible. Injectable contraceptive and HIV prevention in one For millions of young women worldwide, two major health concerns often intersect: HIV acquisition and unintended pregnancy. Many have expressed a preference for a method that protects against both. At the conference, Melissa Peet from CONRAD presented results from a promising solution—a silica-based hydrogel injectable that combines HIV antiretroviral drugs with contraception in a single shot. In designing this dual-purpose method, researchers selected long-acting cabotegravir (CAB-LA) as the HIV prevention drug and levonorgestrel (LNG) as the contraceptive. The hydrogel injectable they developed is a silica-biodegradable material comprising two compartments, one for each medication. The injectable is capable of delivering both drugs with a single injection offering dual protection for three months. Preclinical tests in rats showed sustained drug levels in the bloodstream without significant interactions or safety concerns, and the researchers are now conducting additional studies in non-human primates to fine-tune dosing and asses the duration of protective drug concentration. No interactions between Cabotegravir and contraceptives One concern with combining HIV prevention and contraception has been the potential for drug interactions, particularly between long-acting HIV medications like cabotegravir (CAB-LA) and commonly used contraceptives. To address this, Dr. Mark Marzinke from Johns Hopkins University presented results from a sub-study within the HPTN 084 trial to explore any potential interactions. The study included 170 participants from South Africa with a median age of 23. A total of 80 women were randomised to the CAB-LA arm and 90 in the oral PrEP arm. Participants used three types of hormonal contraceptives: etonogestrel implants, injectable norethindrone, or medroxyprogesterone acetate (MPA), alongside either CAB-LA or oral PrEP. Researchers measured drug concentrations at enrolment and again at weeks 25, 49, and 73 to determine if there were any drug interactions. The results were reassuring: plasma concentrations of the contraceptives remained high enough to prevent pregnancy in both the CAB-LA and oral PrEP groups. CAB-LA concentrations were also consistent across contraceptive types, indicating that CAB-LA does not interfere with contraceptive effectiveness. However, tenofovir concentrations were unquantifiable for most participants, regardless of contraceptive type, due to low adherence to oral PrEP. New data on the three-month vaginal ring For women seeking long-term HIV prevention, the dapivirine vaginal ring, sometimes called the PrEP ring, has been a promising option. This is a flexible silicone ring that is placed in the vagina that releases the anti-HIV drug, dapivirine, over a month. Delegates at the conference heard results from a South African study comparing the bioavailability of the standard one-month dapivirine ring with a new three-month version. The study enrolled 124 women, but only 104 completed the trial. This was a crossover trial with two treatment phases: half the group started with the one-month ring (containing 25 mg of dapivirine) and then switched to the three-month ring, containing 100 mg of dapivirine. The other group followed the reverse order; they began with the three-month ring and later switched to the one-month ring. The three-month ring was identical to the one-month version in silicone, dimensions, and appearance. Plasma and vaginal fluid samples were collected throughout the study to measure drug levels. Based on dapivirine concentrations in plasma, results showed that the three-month ring provided greater overall drug exposure than the one-month version, indicating equal or possibly higher efficacy in preventing HIV. Jeremy Nuttall from the Population Council’s Center for Biomedical Research, who presented the findings, noted that the reduced frequency of ring changes might increase acceptability and adherence, potentially improving overall effectiveness. He also highlighted that the estimated cost of the three-month ring is $16, making it a potentially more affordable option, projecting that the three-month ring could become available on the market by 2026. Roxana Bretoneche protesting about the lack of community participation at HIVR4P. Real-world results from Zambia’s CAB-LA rollout Zambia became the first country in sub-Saharan Africa to roll out long-acting injectable PrEP (CAB-LA) beyond clinical trials, sharing results from their first three months (February to April 2024) in real-world settings. A total of 609 individuals with a median age of 24 were enrolled across six health facilities in two districts. Among the clients, 55% were female, 20% were adolescent boys and young men, 7% identified as key populations, and 40% as other high-risk populations. Adamson Ndhlovu from Zambia’s JSI USAID DISCOVER-Health Project shared that over 90% of participants due for their second injection received it on time. A total of 24 participants (about 4%) discontinued CAB-LA. Most discontinuations were due to hepatitis B (20 cases), with two participants stopping due to pregnancy, one due to a severe rash, and one because of severe pain at the injection site. Those who discontinued were switched to oral PrEP. During a press briefing at the conference, Professor Lloyd Mulenga from Zambia’s Ministry of Health stated that four of those enrolled had acquired HIV, explaining that they likely had undetected HIV at the time they started PrEP. The real-world implementation of CAB-LA is anticipated to expand, as ViiV Healthcare, the manufacturer, announced at the conference its plans to triple the supply of cabotegravir that will be available for low- and middle-income countries in 2025-2026 to at least two million doses. Image Credits: Nicole Bergman / IAS, Gilead, Nicole Bergman / IAS. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Rwanda’s Marburg Outbreak Wanes But Mpox Continues to Spread 17/10/2024 Kerry Cullinan Dr Jean Kaseya and Dr Sabin Nsanzimana. While Rwanda appears to have its Marburg virus outbreak under control with no new cases reported in the past three days in Rwanda, mpox continues to spread – now affecting 18 countries with 3051 new cases in the past week. Since declaring the Marburg outbreak three weeks ago, Rwanda has confirmed 62 cases, of which 15 have died, 38 have recovered and nine cases are still receiving treatment with the majority improving, said Health Minister Dr Sabin Nsanzimana on Thursday. “The case fatality rate overall is 24% and we’ve vaccinated 856 people,” Nsanzimana told an Africa Centres for Disease Control and Prevention (CDC) briefing, describing the trend as “very encouraging”. As the vaccine is “investigational”, its rollout required more rigorous consent, sampling and documentation, but demand for it has been “very high”, he added. the vaccines you are providing highly accepted, especially among healthcare providers. Around 90% of those infected are health workers and their close contacts from the intensive care units of two hospitals that treated the very first patients. The index patients was co-infected with malaria which slowed the diagnosis of Marburg, which has similar symptoms. Rwanda’s health ministry has also tested over 4,000 people “to make sure we don’t miss any cases”, added Nsanzimana. He attributed “intense activity on the ground”, ring vaccination [vaccinating the close contacts of people with Marburg] and new antivirals for the turnaround in what is the biggest Marburg outbreak ever recorded. The virus, which is from the same family as Ebola and, in some outbreaks, has killed over 80% of those infected. While the zoonotic origin of the outbreak is still unknown, Nsanzimana said Rwanda will be reporting its findings on the the serology and gene sequencing of the virus within a few days. At the same time, it has a team on the ground hunting for the source of the virus. Mpox ‘not under control’ Mpox cases have now been identified in 18 African countries, with new additions being Zambia and Zimbabwe. In the past week, 3051 new cases have been reported – including two male prisoners in Uganda. “Mpox is not under control,” warned Africa CDC Director-General Dr Jean Kaseya. Despite calling a continental meeting in April to warn countries of the risk, cases have risen exponentially: from slightly under 6,000 then to 42,438 suspected mpox cases at present – although only 8,113 have been clinically confirmed. A rapid test to diagnose mpox is in the pipeline and will transform the testing landscape, said Kaseya. Kaseya flagged the threat to internally displaced people (IDP), particularly in the Democratic Republic of Congo (DRC), and prisoners – both groups characterised by close contact. In the eastern DRC, conflict has displaced some 2.5 million people who are now living in camps in close quarters with limited access to water, sanitation and hygiene. The two Ugandan prisoners were initially diagnosed with chicken pox – which has small lesions that are itchy not painful like mpox. DRC vaccination plan includes MSM, transgender people The DRC’s vaccination campaign started two weeks ago in three provinces – North Kivu, South Kivu and Tshopo – and is “moving well”, said Kaseya, who hails from DRC. The country’s plan includes men who have sex with men (MSM) and sex workers, as mpox can be sexually transmitted. In DRC, same-sex sexual contact is not outlawed as it is in many of the other countries currently affected by mpox – Uganda, Burundi, Kenya, Tanzania, Zambia and Zimbabwe. “When are talking about MSM, we are clear as Africa CDC. We are saying all human beings have the same rights, and we are supporting countries to plan vaccination for all of them, including men having sex with other men,” said Kaseya empathically. “We are proud and we are glad to see in DRC that we have MSM included,” he added. Kaseya said that early messaging about mpox Clade 1B only being associated with sexual transmission was wrong – as was the failure to talk about MSM as the main mode of transmission iun the 2022 outbreak. “There was the stigma talking about men having sex with other men as the main transmission mode of mpox. But if we put it in the context in Africa, that one in some countries is still a taboo. “We believe with our effort, what we are doing is sensitizing countries, and we are proud to see that DRC are mentioning that.” He added that risk communication and community engagement involving “people who are openly saying we are these key populations” was also important. Uganda tightened its anti-LGBTQ laws recently and, while it plans to test all 1,087 prisoners who possibly had contact with the two prisoners recently diagnosed with mpox, it is unclear how it will approach MSM as a mode of transmission other than to crack down further on smae-sex activity. Europe’s New Air Quality Law is a Breakthrough for Clean Air Globally 16/10/2024 Jane Burston Dirty smoke billows from chimneys in Poland. Europe is now poised to deliver cleaner, healthier air – thanks to adoption this week of the revised Ambient Air Quality Directive (AAQD) by the European Union. This marks a crucial victory for the health and wellbeing of millions across the EU and serves as a beacon for the clean air movement worldwide. The AAQD underpins Europe’s air quality standards, and its revision is a significant breakthrough in addressing the public health crisis of air pollution. Each year, air pollution cuts short the lives of nearly 300,000 Europeans, contributing to respiratory illnesses, cardiovascular disease, and other serious health conditions, according to the EU’s impact assessment report. Improving air quality is a public health imperative. It’s also crucial for the environment and the economy, making the case for stronger EU-wide legislation even clearer. A healthier future The revised AAQD brings Europe’s air quality standards closer to the World Health Organization’s (WHO) air quality guidelines. It sets tougher, legally binding limits on harmful pollutants like nitrogen dioxide (NO₂) and fine particulate matter (PM2.5), representing a doubling of ambition for these two major pollutants, in line with WHO’s interim targets. These pollutants have long been linked to severe health impacts that are particularly harmful for vulnerable groups, such as babies and young children and people with certain conditions such as Chronic Obstructive Pulmonary Disease. By delivering cleaner air, the AAQD could mean the difference between a lifetime of illness and a healthy future for future generations. The AAQD also strengthens the monitoring and measuring provisions for air quality, introducing air quality roadmaps to support progress ahead of its 2030 deadline. The new rules bring about a fairer regime for people affected by air pollution as the rules for access to justice and compensation for those whose health have been impacted by dirty air have been improved. Some of the most polluted regions within member states can delay meeting the new targets for up to 10 years (until 2040) under certain conditions. Although these derogations (or exceptions) provide more leeway than originally envisaged, the compromise, alongside strict conditions for delays, ensure that none of the 27 Member States are left behind. Significant impact if properly implemented Overall, the Directive remains a significant win with ambitious targets and tightly regulated conditions for any delays. Importantly, the initially proposed ambition on limit values remained intact following the two-year legislative process, despite widespread pushback against legislation falling under the EU Green Deal, indicating the scale of this victory for clean air campaigners. One of the key reasons for the AAQD’s success is that it is both an environmental law and a critical public health intervention. By recognising that air quality is a matter of life and death, policymakers have acknowledged the need to protect the most vulnerable in our society. The impact of the new legislation in Europe will be significant if the AAQD is properly implemented. The new rules can prevent more than 55% of premature deaths linked to air pollution in the EU. That’s not just a number – that’s hundreds of thousands of people, each with families, who will live longer, healthier lives. In addition to delivering significant health and environmental benefits, improving the air we breathe makes economic sense. Investing €6 billion annually in cleaner air will deliver up to €121 billion in benefits (according to the EU’s analysis). That’s equivalent to building hundreds of new hospitals or creating hundreds of thousands of new jobs in green industries. Echoing this analysis, the Brussels-based think tank, Bruegel, estimated that implementing clean air measures could boost economic growth by €50 to €60 billion every year[3] and save approximately €600 billion each year in the European Union, the equivalent to 4% of GDP. Ripple effect The importance of the AAQD extends beyond the EU’s borders. By taking decisive action, the EU has positioned itself among the global leaders in air quality management, setting an example for other regions grappling with similar challenges. Air pollution is a global problem, responsible for eight million premature deaths annually worldwide, as reported in the British Medical Journal, and the EU’s solutions will, I hope, inspire other countries to pursue stronger actions. Ongoing engagement and sustained political will are key to ensuring the success of these measures. The real test will come as member states move to transpose the Directive into law and work to implement these new standards. National and local governments will need to invest in cleaner technologies, green transport and clean heating while improving air quality monitoring and ensuring that enforcement is taken seriously. Let’s celebrate this moment, but also remain focused on the work that still needs to be done. Air pollution is an invisible killer, shortening lives and ravaging our communities. With this new Directive, we are fighting back. Jane Burston founded and leads the Clean Air Fund (CAF), a global philanthropic organisation working with governments, funders, businesses and campaigners to create a future where everyone breathes clean air. Before setting up CAF, Jane worked as head of Climate and Energy Science in the UK government. Prior to that, as head of Energy and Environment at the UK National Physical Laboratory, she managed a team of 150 scientists working in air quality, GHG measurement and renewable energy. Image Credits: Janusz Walczak/ Unsplash. World Can Halve Premature Deaths by 2050, Lancet Commission Reports 15/10/2024 Stefan Anderson BERLIN – Countries worldwide, regardless of income level, can halve premature death rates by 2050, a new Lancet report presented at the closing of the World Health Summit in Berlin suggests. Fifteen key health threats are driving premature deaths worldwide, with tobacco use leading the pack “by far”, the Lancet Commission for Investing in Health found. Targeting interventions in these areas – with over half involving maternal, newborn, child, and infectious diseases – could dramatically reduce global deaths before age 70, the Commission said. “Sharp reductions in mortality and morbidity can be achieved by focusing on 15 priority conditions,” Dr Angela Chang from the University of Southern Denmark and lead author of the report, told a panel at the World Health Summit in Berlin on Tuesday. “Doubling down on past health investments, focusing resources on a narrow set of conditions, scaling up financing and developing new technologies can continue to have an enormous impact despite the headwinds.” The 15 priority conditions, selected from over 17,000 internationally recognized health diagnoses, account for approximately 80% of the life expectancy gap between most regions and the North Atlantic, defined in the report as North America and Europe. These conditions account for 86% of the gap between China and the North Atlantic, and 74% between sub-Saharan Africa and the North Atlantic. “There’s a 22-year gap in life expectancy between Sub-Saharan Africa and the North Atlantic, Chang explained. “Close to 80% of this gap can be explained by these 15 priority conditions, and over half of the difference can be attributed to eight infectious and maternal health conditions.” If the global goal is met, the average premature mortality rate worldwide would fall to about 15%, matching levels currently seen in Europe and North America—today’s global benchmark. Achieving this would mean dramatic improvements for billions, especially in low- and middle-income countries. In Sub-Saharan Africa, the worst-performing region, premature mortality sits at 52%. Setting priorities straight The report’s optimism is rooted in historical data. Globally, the probability of dying before 70 has halved since the 1960s, falling from 62% to 31% for individuals born in 2019. Thirty-seven countries, including populous nations like Bangladesh, China, Japan, and Vietnam, have already halved their premature death rates in similar or shorter periods than the 26 years remaining until the 2050 target date. The Commission recommends public financing for essential medicines targeting the 15 key conditions driving premature mortality. It suggests mobilizing international funding and joint procurement efforts, similar to strategies used by GAVI, PEPFAR, and the Global Fund, to reduce costs for patients and governments alike. “Inadequate access to medicines and high out-of-pocket costs are major threats to cutting premature mortality,” Chang noted. “We learned from the Global Fund’s experience how national government subsidies can steer resources towards priority interventions and reduce out-of-pocket payments.” While the Commission believes halving premature mortality by 2050 is globally achievable, it acknowledges this target may be “perhaps only aspirational for some countries, realistically speaking.” “We have a tendency to focus on the new, shiny things,” Chang added. “Our message is for countries to stay focused on these priority conditions.” ‘Tobacco is the new tobacco’ Six out of ten smokers, or 750 million people globally want to quit tobacco use. High tobacco taxes are “by far” the most crucial policy tool for reducing premature deaths, according to the report. “You often hear about other risk factors, but we argue tobacco is the new tobacco,” Chang explained. Recent research suggests raising excise taxes on tobacco, alcohol, and sugary drinks by 50% could yield $2.1 trillion for low- and middle-income countries over five years. This could boost healthcare spending in these nations by 40% if directed towards health initiatives. The Commission highlights the Middle East and North Africa as an example of untapped potential in tobacco control. With 160 million smokers and rising prevalence among youth and women, the region faces a growing health crisis. Egypt’s smoking rates doubled between 2000 and 2018, while tobacco became more affordable in conflict-affected countries like Iraq and Syria. The region’s tobacco taxes, second-lowest globally, fall far short of the World Health Organization’s recommended 70% excise tax. “Despite wide experience with its successful use, tobacco taxation remains a policy tool that is still greatly underused,” the Commission found. “Raising taxes on tobacco can do more to reduce premature mortality than any other single health policy.” High risk of ‘COVID magnitude’ pandemic in next decade The Lancet Comission estimates there is a 23% change of a COVID-scale pandemic in the next decade. New modeling for the Commission’s report indicates a 23% chance of a pandemic as severe as COVID-19 occurring within a decade. Unprepared health systems could see progress on reducing premature deaths plummet if caught off guard again. “There is a high risk of another pandemic of Covid-like magnitude,” Chang warned. “To put it another way, in most years there will be zero pandemic deaths, and in some years there will be millions of pandemic deaths.” The Commission’s analysis estimates an average of 2.5 million deaths per year due to pandemics when viewed over a long time horizon. This figure is comparable to the current annual death toll from AIDS, malaria, and tuberculosis combined, and significantly exceeds even pessimistic projections for annual climate change-related deaths in coming decades. “People should wake up at that figure,” Helen Clark, former Prime Minister of New Zealand, warned the summit. The warning from the Commission comes as global headwinds from conflict, climate change and debt hammer health budgets. Neglecting pandemic preparedness could have severe consequences, particularly for poorer countries less equipped to handle sudden outbreaks. “We need to learn the lessons not just from COVID, but from Mpox, Ebola … and avoid this panic-neglect cycle,” said Dr Seth Berkley, former CEO of Gavi, the Vaccine Alliance. “Unfortunately, I don’t think we’re doing a very good job.” From 1993 to Berlin A figure from the World Bank’s 1993 report making the case for health as an economic investment. The Lancet Comission report is the latest in a line of studies that traces its lineage back to a pivotal World Bank report that changed the landscape of global health finance. The World Bank’s 1993 report, Investing in Health, the only report on health ever published by the Bank, was the first to make an argument still used by health advocates and ministers across the globe: health is an investment. “The World Bank saying investing in health is no just a cost to society, but an investment that was justified on pure economic grounds … was revolutionary,” Berkley recalled. “Prior to this, people saw it as a cost – if you get richer, you can afford health, but this really changed the thinking.” The Commission’s work has expanded on the World Bank’s initial calculations, incorporating factors such as the impact of out-of-pocket health costs on economies and personal livelihoods. This broader perspective has significantly increased the estimated economic benefits of maintaining healthy societies, from the World Bank’s initial 11% to 24%. “The important thing is that each one of these reports, including this one, says the case is better than ever for investing in health, and we need to keep talking about that, particularly at a time when the headwinds are so strong,” Berkley emphasizes. The latest report continues this tradition, reaffirming that health investment remains one of the most effective strategies for improving both individual and societal outcomes. “Today, the case is better than ever for going for mortality reduction,” said Dr Gavin Yamey, director of Duke University’s Center for Policy Impact in Global Health and lead author of the commission report “It’s a prize within reach. It will have extraordinary health, welfare and economic benefits.” Image Credits: Sarah Johnson. Transformative Potential of Long-Acting Preventive Drugs Takes Centre Stage at HIV Conference 14/10/2024 Edith Magak At a HIVR4P’s press conference: Jeremy Nuttall, Elizabeth Irungu, Mark Marzinke, Alessandro Grattoni, William Hahn and Colleen Kelley. LIMA, Peru – The infection-prevention potential of Lenacapavir, the long-acting anti-HIV injectable administered just twice a year, took centre stage at the fifth HIV Research for Prevention Conference (HIVR4P) held last week. However, several other important studies were also unveiled, including an injectable that combines contraception and HIV protection, results from a three-month vaginal ring, and real-world findings from Zambia’s rollout of long-acting injectable cabotegravir. Lenacapavir in diverse populations Lenacapavir reduced HIV infections by 96% in a gender-diverse population, according to results from the PURPOSE 2 trial, which enrolled over 3,200 participants from Argentina, Brazil, Mexico, Peru, South Africa, Thailand, and the US between June 2021 and December 2023. Participants were randomly assigned to one of two groups: one receiving lenacapavir injections every six months and the other taking daily oral pills for pre-exposure prophylaxis (PrEP) with matched placebos. The average age of participants was 28, with over one-third under the age of 25. Around 70% identified as non-white, and the gender breakdown featured cisgender men, transgender men, transgender women, and non-binary individuals who have sex with partners assigned male at birth. At 39 weeks, only two HIV cases occurred in the lenacapavir group of 2,179 individuals, translating to a 96% reduction in HIV incidence, according to Dr Colleen Kelley from Emory University. In contrast, there were nine new HIV cases among the 1,087 participants taking daily oral TDF pills (comprising tenofovir disoproxil fumarate and emtricitabine and marketed as Truvada). This makes lenacapavir 89% more effective than oral PrEP. The findings echoed earlier results from the PURPOSE 1 trial, which showed 100% efficacy in preventing HIV among cisgender women in Africa. With regulatory filings expected to begin globally by the end of 2024, lenacapavir has the potential to be a transformative HIV prevention tool. Future phases of the study will focus on other groups, including women in the US (PURPOSE 3) and people who inject drugs (PURPOSE 4). The twice-yearly injectable, lenacapavir (marketed as Sunlenca in the US) could make a huge difference to HIV prevention is widely accessible. Injectable contraceptive and HIV prevention in one For millions of young women worldwide, two major health concerns often intersect: HIV acquisition and unintended pregnancy. Many have expressed a preference for a method that protects against both. At the conference, Melissa Peet from CONRAD presented results from a promising solution—a silica-based hydrogel injectable that combines HIV antiretroviral drugs with contraception in a single shot. In designing this dual-purpose method, researchers selected long-acting cabotegravir (CAB-LA) as the HIV prevention drug and levonorgestrel (LNG) as the contraceptive. The hydrogel injectable they developed is a silica-biodegradable material comprising two compartments, one for each medication. The injectable is capable of delivering both drugs with a single injection offering dual protection for three months. Preclinical tests in rats showed sustained drug levels in the bloodstream without significant interactions or safety concerns, and the researchers are now conducting additional studies in non-human primates to fine-tune dosing and asses the duration of protective drug concentration. No interactions between Cabotegravir and contraceptives One concern with combining HIV prevention and contraception has been the potential for drug interactions, particularly between long-acting HIV medications like cabotegravir (CAB-LA) and commonly used contraceptives. To address this, Dr. Mark Marzinke from Johns Hopkins University presented results from a sub-study within the HPTN 084 trial to explore any potential interactions. The study included 170 participants from South Africa with a median age of 23. A total of 80 women were randomised to the CAB-LA arm and 90 in the oral PrEP arm. Participants used three types of hormonal contraceptives: etonogestrel implants, injectable norethindrone, or medroxyprogesterone acetate (MPA), alongside either CAB-LA or oral PrEP. Researchers measured drug concentrations at enrolment and again at weeks 25, 49, and 73 to determine if there were any drug interactions. The results were reassuring: plasma concentrations of the contraceptives remained high enough to prevent pregnancy in both the CAB-LA and oral PrEP groups. CAB-LA concentrations were also consistent across contraceptive types, indicating that CAB-LA does not interfere with contraceptive effectiveness. However, tenofovir concentrations were unquantifiable for most participants, regardless of contraceptive type, due to low adherence to oral PrEP. New data on the three-month vaginal ring For women seeking long-term HIV prevention, the dapivirine vaginal ring, sometimes called the PrEP ring, has been a promising option. This is a flexible silicone ring that is placed in the vagina that releases the anti-HIV drug, dapivirine, over a month. Delegates at the conference heard results from a South African study comparing the bioavailability of the standard one-month dapivirine ring with a new three-month version. The study enrolled 124 women, but only 104 completed the trial. This was a crossover trial with two treatment phases: half the group started with the one-month ring (containing 25 mg of dapivirine) and then switched to the three-month ring, containing 100 mg of dapivirine. The other group followed the reverse order; they began with the three-month ring and later switched to the one-month ring. The three-month ring was identical to the one-month version in silicone, dimensions, and appearance. Plasma and vaginal fluid samples were collected throughout the study to measure drug levels. Based on dapivirine concentrations in plasma, results showed that the three-month ring provided greater overall drug exposure than the one-month version, indicating equal or possibly higher efficacy in preventing HIV. Jeremy Nuttall from the Population Council’s Center for Biomedical Research, who presented the findings, noted that the reduced frequency of ring changes might increase acceptability and adherence, potentially improving overall effectiveness. He also highlighted that the estimated cost of the three-month ring is $16, making it a potentially more affordable option, projecting that the three-month ring could become available on the market by 2026. Roxana Bretoneche protesting about the lack of community participation at HIVR4P. Real-world results from Zambia’s CAB-LA rollout Zambia became the first country in sub-Saharan Africa to roll out long-acting injectable PrEP (CAB-LA) beyond clinical trials, sharing results from their first three months (February to April 2024) in real-world settings. A total of 609 individuals with a median age of 24 were enrolled across six health facilities in two districts. Among the clients, 55% were female, 20% were adolescent boys and young men, 7% identified as key populations, and 40% as other high-risk populations. Adamson Ndhlovu from Zambia’s JSI USAID DISCOVER-Health Project shared that over 90% of participants due for their second injection received it on time. A total of 24 participants (about 4%) discontinued CAB-LA. Most discontinuations were due to hepatitis B (20 cases), with two participants stopping due to pregnancy, one due to a severe rash, and one because of severe pain at the injection site. Those who discontinued were switched to oral PrEP. During a press briefing at the conference, Professor Lloyd Mulenga from Zambia’s Ministry of Health stated that four of those enrolled had acquired HIV, explaining that they likely had undetected HIV at the time they started PrEP. The real-world implementation of CAB-LA is anticipated to expand, as ViiV Healthcare, the manufacturer, announced at the conference its plans to triple the supply of cabotegravir that will be available for low- and middle-income countries in 2025-2026 to at least two million doses. Image Credits: Nicole Bergman / IAS, Gilead, Nicole Bergman / IAS. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Europe’s New Air Quality Law is a Breakthrough for Clean Air Globally 16/10/2024 Jane Burston Dirty smoke billows from chimneys in Poland. Europe is now poised to deliver cleaner, healthier air – thanks to adoption this week of the revised Ambient Air Quality Directive (AAQD) by the European Union. This marks a crucial victory for the health and wellbeing of millions across the EU and serves as a beacon for the clean air movement worldwide. The AAQD underpins Europe’s air quality standards, and its revision is a significant breakthrough in addressing the public health crisis of air pollution. Each year, air pollution cuts short the lives of nearly 300,000 Europeans, contributing to respiratory illnesses, cardiovascular disease, and other serious health conditions, according to the EU’s impact assessment report. Improving air quality is a public health imperative. It’s also crucial for the environment and the economy, making the case for stronger EU-wide legislation even clearer. A healthier future The revised AAQD brings Europe’s air quality standards closer to the World Health Organization’s (WHO) air quality guidelines. It sets tougher, legally binding limits on harmful pollutants like nitrogen dioxide (NO₂) and fine particulate matter (PM2.5), representing a doubling of ambition for these two major pollutants, in line with WHO’s interim targets. These pollutants have long been linked to severe health impacts that are particularly harmful for vulnerable groups, such as babies and young children and people with certain conditions such as Chronic Obstructive Pulmonary Disease. By delivering cleaner air, the AAQD could mean the difference between a lifetime of illness and a healthy future for future generations. The AAQD also strengthens the monitoring and measuring provisions for air quality, introducing air quality roadmaps to support progress ahead of its 2030 deadline. The new rules bring about a fairer regime for people affected by air pollution as the rules for access to justice and compensation for those whose health have been impacted by dirty air have been improved. Some of the most polluted regions within member states can delay meeting the new targets for up to 10 years (until 2040) under certain conditions. Although these derogations (or exceptions) provide more leeway than originally envisaged, the compromise, alongside strict conditions for delays, ensure that none of the 27 Member States are left behind. Significant impact if properly implemented Overall, the Directive remains a significant win with ambitious targets and tightly regulated conditions for any delays. Importantly, the initially proposed ambition on limit values remained intact following the two-year legislative process, despite widespread pushback against legislation falling under the EU Green Deal, indicating the scale of this victory for clean air campaigners. One of the key reasons for the AAQD’s success is that it is both an environmental law and a critical public health intervention. By recognising that air quality is a matter of life and death, policymakers have acknowledged the need to protect the most vulnerable in our society. The impact of the new legislation in Europe will be significant if the AAQD is properly implemented. The new rules can prevent more than 55% of premature deaths linked to air pollution in the EU. That’s not just a number – that’s hundreds of thousands of people, each with families, who will live longer, healthier lives. In addition to delivering significant health and environmental benefits, improving the air we breathe makes economic sense. Investing €6 billion annually in cleaner air will deliver up to €121 billion in benefits (according to the EU’s analysis). That’s equivalent to building hundreds of new hospitals or creating hundreds of thousands of new jobs in green industries. Echoing this analysis, the Brussels-based think tank, Bruegel, estimated that implementing clean air measures could boost economic growth by €50 to €60 billion every year[3] and save approximately €600 billion each year in the European Union, the equivalent to 4% of GDP. Ripple effect The importance of the AAQD extends beyond the EU’s borders. By taking decisive action, the EU has positioned itself among the global leaders in air quality management, setting an example for other regions grappling with similar challenges. Air pollution is a global problem, responsible for eight million premature deaths annually worldwide, as reported in the British Medical Journal, and the EU’s solutions will, I hope, inspire other countries to pursue stronger actions. Ongoing engagement and sustained political will are key to ensuring the success of these measures. The real test will come as member states move to transpose the Directive into law and work to implement these new standards. National and local governments will need to invest in cleaner technologies, green transport and clean heating while improving air quality monitoring and ensuring that enforcement is taken seriously. Let’s celebrate this moment, but also remain focused on the work that still needs to be done. Air pollution is an invisible killer, shortening lives and ravaging our communities. With this new Directive, we are fighting back. Jane Burston founded and leads the Clean Air Fund (CAF), a global philanthropic organisation working with governments, funders, businesses and campaigners to create a future where everyone breathes clean air. Before setting up CAF, Jane worked as head of Climate and Energy Science in the UK government. Prior to that, as head of Energy and Environment at the UK National Physical Laboratory, she managed a team of 150 scientists working in air quality, GHG measurement and renewable energy. Image Credits: Janusz Walczak/ Unsplash. World Can Halve Premature Deaths by 2050, Lancet Commission Reports 15/10/2024 Stefan Anderson BERLIN – Countries worldwide, regardless of income level, can halve premature death rates by 2050, a new Lancet report presented at the closing of the World Health Summit in Berlin suggests. Fifteen key health threats are driving premature deaths worldwide, with tobacco use leading the pack “by far”, the Lancet Commission for Investing in Health found. Targeting interventions in these areas – with over half involving maternal, newborn, child, and infectious diseases – could dramatically reduce global deaths before age 70, the Commission said. “Sharp reductions in mortality and morbidity can be achieved by focusing on 15 priority conditions,” Dr Angela Chang from the University of Southern Denmark and lead author of the report, told a panel at the World Health Summit in Berlin on Tuesday. “Doubling down on past health investments, focusing resources on a narrow set of conditions, scaling up financing and developing new technologies can continue to have an enormous impact despite the headwinds.” The 15 priority conditions, selected from over 17,000 internationally recognized health diagnoses, account for approximately 80% of the life expectancy gap between most regions and the North Atlantic, defined in the report as North America and Europe. These conditions account for 86% of the gap between China and the North Atlantic, and 74% between sub-Saharan Africa and the North Atlantic. “There’s a 22-year gap in life expectancy between Sub-Saharan Africa and the North Atlantic, Chang explained. “Close to 80% of this gap can be explained by these 15 priority conditions, and over half of the difference can be attributed to eight infectious and maternal health conditions.” If the global goal is met, the average premature mortality rate worldwide would fall to about 15%, matching levels currently seen in Europe and North America—today’s global benchmark. Achieving this would mean dramatic improvements for billions, especially in low- and middle-income countries. In Sub-Saharan Africa, the worst-performing region, premature mortality sits at 52%. Setting priorities straight The report’s optimism is rooted in historical data. Globally, the probability of dying before 70 has halved since the 1960s, falling from 62% to 31% for individuals born in 2019. Thirty-seven countries, including populous nations like Bangladesh, China, Japan, and Vietnam, have already halved their premature death rates in similar or shorter periods than the 26 years remaining until the 2050 target date. The Commission recommends public financing for essential medicines targeting the 15 key conditions driving premature mortality. It suggests mobilizing international funding and joint procurement efforts, similar to strategies used by GAVI, PEPFAR, and the Global Fund, to reduce costs for patients and governments alike. “Inadequate access to medicines and high out-of-pocket costs are major threats to cutting premature mortality,” Chang noted. “We learned from the Global Fund’s experience how national government subsidies can steer resources towards priority interventions and reduce out-of-pocket payments.” While the Commission believes halving premature mortality by 2050 is globally achievable, it acknowledges this target may be “perhaps only aspirational for some countries, realistically speaking.” “We have a tendency to focus on the new, shiny things,” Chang added. “Our message is for countries to stay focused on these priority conditions.” ‘Tobacco is the new tobacco’ Six out of ten smokers, or 750 million people globally want to quit tobacco use. High tobacco taxes are “by far” the most crucial policy tool for reducing premature deaths, according to the report. “You often hear about other risk factors, but we argue tobacco is the new tobacco,” Chang explained. Recent research suggests raising excise taxes on tobacco, alcohol, and sugary drinks by 50% could yield $2.1 trillion for low- and middle-income countries over five years. This could boost healthcare spending in these nations by 40% if directed towards health initiatives. The Commission highlights the Middle East and North Africa as an example of untapped potential in tobacco control. With 160 million smokers and rising prevalence among youth and women, the region faces a growing health crisis. Egypt’s smoking rates doubled between 2000 and 2018, while tobacco became more affordable in conflict-affected countries like Iraq and Syria. The region’s tobacco taxes, second-lowest globally, fall far short of the World Health Organization’s recommended 70% excise tax. “Despite wide experience with its successful use, tobacco taxation remains a policy tool that is still greatly underused,” the Commission found. “Raising taxes on tobacco can do more to reduce premature mortality than any other single health policy.” High risk of ‘COVID magnitude’ pandemic in next decade The Lancet Comission estimates there is a 23% change of a COVID-scale pandemic in the next decade. New modeling for the Commission’s report indicates a 23% chance of a pandemic as severe as COVID-19 occurring within a decade. Unprepared health systems could see progress on reducing premature deaths plummet if caught off guard again. “There is a high risk of another pandemic of Covid-like magnitude,” Chang warned. “To put it another way, in most years there will be zero pandemic deaths, and in some years there will be millions of pandemic deaths.” The Commission’s analysis estimates an average of 2.5 million deaths per year due to pandemics when viewed over a long time horizon. This figure is comparable to the current annual death toll from AIDS, malaria, and tuberculosis combined, and significantly exceeds even pessimistic projections for annual climate change-related deaths in coming decades. “People should wake up at that figure,” Helen Clark, former Prime Minister of New Zealand, warned the summit. The warning from the Commission comes as global headwinds from conflict, climate change and debt hammer health budgets. Neglecting pandemic preparedness could have severe consequences, particularly for poorer countries less equipped to handle sudden outbreaks. “We need to learn the lessons not just from COVID, but from Mpox, Ebola … and avoid this panic-neglect cycle,” said Dr Seth Berkley, former CEO of Gavi, the Vaccine Alliance. “Unfortunately, I don’t think we’re doing a very good job.” From 1993 to Berlin A figure from the World Bank’s 1993 report making the case for health as an economic investment. The Lancet Comission report is the latest in a line of studies that traces its lineage back to a pivotal World Bank report that changed the landscape of global health finance. The World Bank’s 1993 report, Investing in Health, the only report on health ever published by the Bank, was the first to make an argument still used by health advocates and ministers across the globe: health is an investment. “The World Bank saying investing in health is no just a cost to society, but an investment that was justified on pure economic grounds … was revolutionary,” Berkley recalled. “Prior to this, people saw it as a cost – if you get richer, you can afford health, but this really changed the thinking.” The Commission’s work has expanded on the World Bank’s initial calculations, incorporating factors such as the impact of out-of-pocket health costs on economies and personal livelihoods. This broader perspective has significantly increased the estimated economic benefits of maintaining healthy societies, from the World Bank’s initial 11% to 24%. “The important thing is that each one of these reports, including this one, says the case is better than ever for investing in health, and we need to keep talking about that, particularly at a time when the headwinds are so strong,” Berkley emphasizes. The latest report continues this tradition, reaffirming that health investment remains one of the most effective strategies for improving both individual and societal outcomes. “Today, the case is better than ever for going for mortality reduction,” said Dr Gavin Yamey, director of Duke University’s Center for Policy Impact in Global Health and lead author of the commission report “It’s a prize within reach. It will have extraordinary health, welfare and economic benefits.” Image Credits: Sarah Johnson. Transformative Potential of Long-Acting Preventive Drugs Takes Centre Stage at HIV Conference 14/10/2024 Edith Magak At a HIVR4P’s press conference: Jeremy Nuttall, Elizabeth Irungu, Mark Marzinke, Alessandro Grattoni, William Hahn and Colleen Kelley. LIMA, Peru – The infection-prevention potential of Lenacapavir, the long-acting anti-HIV injectable administered just twice a year, took centre stage at the fifth HIV Research for Prevention Conference (HIVR4P) held last week. However, several other important studies were also unveiled, including an injectable that combines contraception and HIV protection, results from a three-month vaginal ring, and real-world findings from Zambia’s rollout of long-acting injectable cabotegravir. Lenacapavir in diverse populations Lenacapavir reduced HIV infections by 96% in a gender-diverse population, according to results from the PURPOSE 2 trial, which enrolled over 3,200 participants from Argentina, Brazil, Mexico, Peru, South Africa, Thailand, and the US between June 2021 and December 2023. Participants were randomly assigned to one of two groups: one receiving lenacapavir injections every six months and the other taking daily oral pills for pre-exposure prophylaxis (PrEP) with matched placebos. The average age of participants was 28, with over one-third under the age of 25. Around 70% identified as non-white, and the gender breakdown featured cisgender men, transgender men, transgender women, and non-binary individuals who have sex with partners assigned male at birth. At 39 weeks, only two HIV cases occurred in the lenacapavir group of 2,179 individuals, translating to a 96% reduction in HIV incidence, according to Dr Colleen Kelley from Emory University. In contrast, there were nine new HIV cases among the 1,087 participants taking daily oral TDF pills (comprising tenofovir disoproxil fumarate and emtricitabine and marketed as Truvada). This makes lenacapavir 89% more effective than oral PrEP. The findings echoed earlier results from the PURPOSE 1 trial, which showed 100% efficacy in preventing HIV among cisgender women in Africa. With regulatory filings expected to begin globally by the end of 2024, lenacapavir has the potential to be a transformative HIV prevention tool. Future phases of the study will focus on other groups, including women in the US (PURPOSE 3) and people who inject drugs (PURPOSE 4). The twice-yearly injectable, lenacapavir (marketed as Sunlenca in the US) could make a huge difference to HIV prevention is widely accessible. Injectable contraceptive and HIV prevention in one For millions of young women worldwide, two major health concerns often intersect: HIV acquisition and unintended pregnancy. Many have expressed a preference for a method that protects against both. At the conference, Melissa Peet from CONRAD presented results from a promising solution—a silica-based hydrogel injectable that combines HIV antiretroviral drugs with contraception in a single shot. In designing this dual-purpose method, researchers selected long-acting cabotegravir (CAB-LA) as the HIV prevention drug and levonorgestrel (LNG) as the contraceptive. The hydrogel injectable they developed is a silica-biodegradable material comprising two compartments, one for each medication. The injectable is capable of delivering both drugs with a single injection offering dual protection for three months. Preclinical tests in rats showed sustained drug levels in the bloodstream without significant interactions or safety concerns, and the researchers are now conducting additional studies in non-human primates to fine-tune dosing and asses the duration of protective drug concentration. No interactions between Cabotegravir and contraceptives One concern with combining HIV prevention and contraception has been the potential for drug interactions, particularly between long-acting HIV medications like cabotegravir (CAB-LA) and commonly used contraceptives. To address this, Dr. Mark Marzinke from Johns Hopkins University presented results from a sub-study within the HPTN 084 trial to explore any potential interactions. The study included 170 participants from South Africa with a median age of 23. A total of 80 women were randomised to the CAB-LA arm and 90 in the oral PrEP arm. Participants used three types of hormonal contraceptives: etonogestrel implants, injectable norethindrone, or medroxyprogesterone acetate (MPA), alongside either CAB-LA or oral PrEP. Researchers measured drug concentrations at enrolment and again at weeks 25, 49, and 73 to determine if there were any drug interactions. The results were reassuring: plasma concentrations of the contraceptives remained high enough to prevent pregnancy in both the CAB-LA and oral PrEP groups. CAB-LA concentrations were also consistent across contraceptive types, indicating that CAB-LA does not interfere with contraceptive effectiveness. However, tenofovir concentrations were unquantifiable for most participants, regardless of contraceptive type, due to low adherence to oral PrEP. New data on the three-month vaginal ring For women seeking long-term HIV prevention, the dapivirine vaginal ring, sometimes called the PrEP ring, has been a promising option. This is a flexible silicone ring that is placed in the vagina that releases the anti-HIV drug, dapivirine, over a month. Delegates at the conference heard results from a South African study comparing the bioavailability of the standard one-month dapivirine ring with a new three-month version. The study enrolled 124 women, but only 104 completed the trial. This was a crossover trial with two treatment phases: half the group started with the one-month ring (containing 25 mg of dapivirine) and then switched to the three-month ring, containing 100 mg of dapivirine. The other group followed the reverse order; they began with the three-month ring and later switched to the one-month ring. The three-month ring was identical to the one-month version in silicone, dimensions, and appearance. Plasma and vaginal fluid samples were collected throughout the study to measure drug levels. Based on dapivirine concentrations in plasma, results showed that the three-month ring provided greater overall drug exposure than the one-month version, indicating equal or possibly higher efficacy in preventing HIV. Jeremy Nuttall from the Population Council’s Center for Biomedical Research, who presented the findings, noted that the reduced frequency of ring changes might increase acceptability and adherence, potentially improving overall effectiveness. He also highlighted that the estimated cost of the three-month ring is $16, making it a potentially more affordable option, projecting that the three-month ring could become available on the market by 2026. Roxana Bretoneche protesting about the lack of community participation at HIVR4P. Real-world results from Zambia’s CAB-LA rollout Zambia became the first country in sub-Saharan Africa to roll out long-acting injectable PrEP (CAB-LA) beyond clinical trials, sharing results from their first three months (February to April 2024) in real-world settings. A total of 609 individuals with a median age of 24 were enrolled across six health facilities in two districts. Among the clients, 55% were female, 20% were adolescent boys and young men, 7% identified as key populations, and 40% as other high-risk populations. Adamson Ndhlovu from Zambia’s JSI USAID DISCOVER-Health Project shared that over 90% of participants due for their second injection received it on time. A total of 24 participants (about 4%) discontinued CAB-LA. Most discontinuations were due to hepatitis B (20 cases), with two participants stopping due to pregnancy, one due to a severe rash, and one because of severe pain at the injection site. Those who discontinued were switched to oral PrEP. During a press briefing at the conference, Professor Lloyd Mulenga from Zambia’s Ministry of Health stated that four of those enrolled had acquired HIV, explaining that they likely had undetected HIV at the time they started PrEP. The real-world implementation of CAB-LA is anticipated to expand, as ViiV Healthcare, the manufacturer, announced at the conference its plans to triple the supply of cabotegravir that will be available for low- and middle-income countries in 2025-2026 to at least two million doses. Image Credits: Nicole Bergman / IAS, Gilead, Nicole Bergman / IAS. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
World Can Halve Premature Deaths by 2050, Lancet Commission Reports 15/10/2024 Stefan Anderson BERLIN – Countries worldwide, regardless of income level, can halve premature death rates by 2050, a new Lancet report presented at the closing of the World Health Summit in Berlin suggests. Fifteen key health threats are driving premature deaths worldwide, with tobacco use leading the pack “by far”, the Lancet Commission for Investing in Health found. Targeting interventions in these areas – with over half involving maternal, newborn, child, and infectious diseases – could dramatically reduce global deaths before age 70, the Commission said. “Sharp reductions in mortality and morbidity can be achieved by focusing on 15 priority conditions,” Dr Angela Chang from the University of Southern Denmark and lead author of the report, told a panel at the World Health Summit in Berlin on Tuesday. “Doubling down on past health investments, focusing resources on a narrow set of conditions, scaling up financing and developing new technologies can continue to have an enormous impact despite the headwinds.” The 15 priority conditions, selected from over 17,000 internationally recognized health diagnoses, account for approximately 80% of the life expectancy gap between most regions and the North Atlantic, defined in the report as North America and Europe. These conditions account for 86% of the gap between China and the North Atlantic, and 74% between sub-Saharan Africa and the North Atlantic. “There’s a 22-year gap in life expectancy between Sub-Saharan Africa and the North Atlantic, Chang explained. “Close to 80% of this gap can be explained by these 15 priority conditions, and over half of the difference can be attributed to eight infectious and maternal health conditions.” If the global goal is met, the average premature mortality rate worldwide would fall to about 15%, matching levels currently seen in Europe and North America—today’s global benchmark. Achieving this would mean dramatic improvements for billions, especially in low- and middle-income countries. In Sub-Saharan Africa, the worst-performing region, premature mortality sits at 52%. Setting priorities straight The report’s optimism is rooted in historical data. Globally, the probability of dying before 70 has halved since the 1960s, falling from 62% to 31% for individuals born in 2019. Thirty-seven countries, including populous nations like Bangladesh, China, Japan, and Vietnam, have already halved their premature death rates in similar or shorter periods than the 26 years remaining until the 2050 target date. The Commission recommends public financing for essential medicines targeting the 15 key conditions driving premature mortality. It suggests mobilizing international funding and joint procurement efforts, similar to strategies used by GAVI, PEPFAR, and the Global Fund, to reduce costs for patients and governments alike. “Inadequate access to medicines and high out-of-pocket costs are major threats to cutting premature mortality,” Chang noted. “We learned from the Global Fund’s experience how national government subsidies can steer resources towards priority interventions and reduce out-of-pocket payments.” While the Commission believes halving premature mortality by 2050 is globally achievable, it acknowledges this target may be “perhaps only aspirational for some countries, realistically speaking.” “We have a tendency to focus on the new, shiny things,” Chang added. “Our message is for countries to stay focused on these priority conditions.” ‘Tobacco is the new tobacco’ Six out of ten smokers, or 750 million people globally want to quit tobacco use. High tobacco taxes are “by far” the most crucial policy tool for reducing premature deaths, according to the report. “You often hear about other risk factors, but we argue tobacco is the new tobacco,” Chang explained. Recent research suggests raising excise taxes on tobacco, alcohol, and sugary drinks by 50% could yield $2.1 trillion for low- and middle-income countries over five years. This could boost healthcare spending in these nations by 40% if directed towards health initiatives. The Commission highlights the Middle East and North Africa as an example of untapped potential in tobacco control. With 160 million smokers and rising prevalence among youth and women, the region faces a growing health crisis. Egypt’s smoking rates doubled between 2000 and 2018, while tobacco became more affordable in conflict-affected countries like Iraq and Syria. The region’s tobacco taxes, second-lowest globally, fall far short of the World Health Organization’s recommended 70% excise tax. “Despite wide experience with its successful use, tobacco taxation remains a policy tool that is still greatly underused,” the Commission found. “Raising taxes on tobacco can do more to reduce premature mortality than any other single health policy.” High risk of ‘COVID magnitude’ pandemic in next decade The Lancet Comission estimates there is a 23% change of a COVID-scale pandemic in the next decade. New modeling for the Commission’s report indicates a 23% chance of a pandemic as severe as COVID-19 occurring within a decade. Unprepared health systems could see progress on reducing premature deaths plummet if caught off guard again. “There is a high risk of another pandemic of Covid-like magnitude,” Chang warned. “To put it another way, in most years there will be zero pandemic deaths, and in some years there will be millions of pandemic deaths.” The Commission’s analysis estimates an average of 2.5 million deaths per year due to pandemics when viewed over a long time horizon. This figure is comparable to the current annual death toll from AIDS, malaria, and tuberculosis combined, and significantly exceeds even pessimistic projections for annual climate change-related deaths in coming decades. “People should wake up at that figure,” Helen Clark, former Prime Minister of New Zealand, warned the summit. The warning from the Commission comes as global headwinds from conflict, climate change and debt hammer health budgets. Neglecting pandemic preparedness could have severe consequences, particularly for poorer countries less equipped to handle sudden outbreaks. “We need to learn the lessons not just from COVID, but from Mpox, Ebola … and avoid this panic-neglect cycle,” said Dr Seth Berkley, former CEO of Gavi, the Vaccine Alliance. “Unfortunately, I don’t think we’re doing a very good job.” From 1993 to Berlin A figure from the World Bank’s 1993 report making the case for health as an economic investment. The Lancet Comission report is the latest in a line of studies that traces its lineage back to a pivotal World Bank report that changed the landscape of global health finance. The World Bank’s 1993 report, Investing in Health, the only report on health ever published by the Bank, was the first to make an argument still used by health advocates and ministers across the globe: health is an investment. “The World Bank saying investing in health is no just a cost to society, but an investment that was justified on pure economic grounds … was revolutionary,” Berkley recalled. “Prior to this, people saw it as a cost – if you get richer, you can afford health, but this really changed the thinking.” The Commission’s work has expanded on the World Bank’s initial calculations, incorporating factors such as the impact of out-of-pocket health costs on economies and personal livelihoods. This broader perspective has significantly increased the estimated economic benefits of maintaining healthy societies, from the World Bank’s initial 11% to 24%. “The important thing is that each one of these reports, including this one, says the case is better than ever for investing in health, and we need to keep talking about that, particularly at a time when the headwinds are so strong,” Berkley emphasizes. The latest report continues this tradition, reaffirming that health investment remains one of the most effective strategies for improving both individual and societal outcomes. “Today, the case is better than ever for going for mortality reduction,” said Dr Gavin Yamey, director of Duke University’s Center for Policy Impact in Global Health and lead author of the commission report “It’s a prize within reach. It will have extraordinary health, welfare and economic benefits.” Image Credits: Sarah Johnson. Transformative Potential of Long-Acting Preventive Drugs Takes Centre Stage at HIV Conference 14/10/2024 Edith Magak At a HIVR4P’s press conference: Jeremy Nuttall, Elizabeth Irungu, Mark Marzinke, Alessandro Grattoni, William Hahn and Colleen Kelley. LIMA, Peru – The infection-prevention potential of Lenacapavir, the long-acting anti-HIV injectable administered just twice a year, took centre stage at the fifth HIV Research for Prevention Conference (HIVR4P) held last week. However, several other important studies were also unveiled, including an injectable that combines contraception and HIV protection, results from a three-month vaginal ring, and real-world findings from Zambia’s rollout of long-acting injectable cabotegravir. Lenacapavir in diverse populations Lenacapavir reduced HIV infections by 96% in a gender-diverse population, according to results from the PURPOSE 2 trial, which enrolled over 3,200 participants from Argentina, Brazil, Mexico, Peru, South Africa, Thailand, and the US between June 2021 and December 2023. Participants were randomly assigned to one of two groups: one receiving lenacapavir injections every six months and the other taking daily oral pills for pre-exposure prophylaxis (PrEP) with matched placebos. The average age of participants was 28, with over one-third under the age of 25. Around 70% identified as non-white, and the gender breakdown featured cisgender men, transgender men, transgender women, and non-binary individuals who have sex with partners assigned male at birth. At 39 weeks, only two HIV cases occurred in the lenacapavir group of 2,179 individuals, translating to a 96% reduction in HIV incidence, according to Dr Colleen Kelley from Emory University. In contrast, there were nine new HIV cases among the 1,087 participants taking daily oral TDF pills (comprising tenofovir disoproxil fumarate and emtricitabine and marketed as Truvada). This makes lenacapavir 89% more effective than oral PrEP. The findings echoed earlier results from the PURPOSE 1 trial, which showed 100% efficacy in preventing HIV among cisgender women in Africa. With regulatory filings expected to begin globally by the end of 2024, lenacapavir has the potential to be a transformative HIV prevention tool. Future phases of the study will focus on other groups, including women in the US (PURPOSE 3) and people who inject drugs (PURPOSE 4). The twice-yearly injectable, lenacapavir (marketed as Sunlenca in the US) could make a huge difference to HIV prevention is widely accessible. Injectable contraceptive and HIV prevention in one For millions of young women worldwide, two major health concerns often intersect: HIV acquisition and unintended pregnancy. Many have expressed a preference for a method that protects against both. At the conference, Melissa Peet from CONRAD presented results from a promising solution—a silica-based hydrogel injectable that combines HIV antiretroviral drugs with contraception in a single shot. In designing this dual-purpose method, researchers selected long-acting cabotegravir (CAB-LA) as the HIV prevention drug and levonorgestrel (LNG) as the contraceptive. The hydrogel injectable they developed is a silica-biodegradable material comprising two compartments, one for each medication. The injectable is capable of delivering both drugs with a single injection offering dual protection for three months. Preclinical tests in rats showed sustained drug levels in the bloodstream without significant interactions or safety concerns, and the researchers are now conducting additional studies in non-human primates to fine-tune dosing and asses the duration of protective drug concentration. No interactions between Cabotegravir and contraceptives One concern with combining HIV prevention and contraception has been the potential for drug interactions, particularly between long-acting HIV medications like cabotegravir (CAB-LA) and commonly used contraceptives. To address this, Dr. Mark Marzinke from Johns Hopkins University presented results from a sub-study within the HPTN 084 trial to explore any potential interactions. The study included 170 participants from South Africa with a median age of 23. A total of 80 women were randomised to the CAB-LA arm and 90 in the oral PrEP arm. Participants used three types of hormonal contraceptives: etonogestrel implants, injectable norethindrone, or medroxyprogesterone acetate (MPA), alongside either CAB-LA or oral PrEP. Researchers measured drug concentrations at enrolment and again at weeks 25, 49, and 73 to determine if there were any drug interactions. The results were reassuring: plasma concentrations of the contraceptives remained high enough to prevent pregnancy in both the CAB-LA and oral PrEP groups. CAB-LA concentrations were also consistent across contraceptive types, indicating that CAB-LA does not interfere with contraceptive effectiveness. However, tenofovir concentrations were unquantifiable for most participants, regardless of contraceptive type, due to low adherence to oral PrEP. New data on the three-month vaginal ring For women seeking long-term HIV prevention, the dapivirine vaginal ring, sometimes called the PrEP ring, has been a promising option. This is a flexible silicone ring that is placed in the vagina that releases the anti-HIV drug, dapivirine, over a month. Delegates at the conference heard results from a South African study comparing the bioavailability of the standard one-month dapivirine ring with a new three-month version. The study enrolled 124 women, but only 104 completed the trial. This was a crossover trial with two treatment phases: half the group started with the one-month ring (containing 25 mg of dapivirine) and then switched to the three-month ring, containing 100 mg of dapivirine. The other group followed the reverse order; they began with the three-month ring and later switched to the one-month ring. The three-month ring was identical to the one-month version in silicone, dimensions, and appearance. Plasma and vaginal fluid samples were collected throughout the study to measure drug levels. Based on dapivirine concentrations in plasma, results showed that the three-month ring provided greater overall drug exposure than the one-month version, indicating equal or possibly higher efficacy in preventing HIV. Jeremy Nuttall from the Population Council’s Center for Biomedical Research, who presented the findings, noted that the reduced frequency of ring changes might increase acceptability and adherence, potentially improving overall effectiveness. He also highlighted that the estimated cost of the three-month ring is $16, making it a potentially more affordable option, projecting that the three-month ring could become available on the market by 2026. Roxana Bretoneche protesting about the lack of community participation at HIVR4P. Real-world results from Zambia’s CAB-LA rollout Zambia became the first country in sub-Saharan Africa to roll out long-acting injectable PrEP (CAB-LA) beyond clinical trials, sharing results from their first three months (February to April 2024) in real-world settings. A total of 609 individuals with a median age of 24 were enrolled across six health facilities in two districts. Among the clients, 55% were female, 20% were adolescent boys and young men, 7% identified as key populations, and 40% as other high-risk populations. Adamson Ndhlovu from Zambia’s JSI USAID DISCOVER-Health Project shared that over 90% of participants due for their second injection received it on time. A total of 24 participants (about 4%) discontinued CAB-LA. Most discontinuations were due to hepatitis B (20 cases), with two participants stopping due to pregnancy, one due to a severe rash, and one because of severe pain at the injection site. Those who discontinued were switched to oral PrEP. During a press briefing at the conference, Professor Lloyd Mulenga from Zambia’s Ministry of Health stated that four of those enrolled had acquired HIV, explaining that they likely had undetected HIV at the time they started PrEP. The real-world implementation of CAB-LA is anticipated to expand, as ViiV Healthcare, the manufacturer, announced at the conference its plans to triple the supply of cabotegravir that will be available for low- and middle-income countries in 2025-2026 to at least two million doses. Image Credits: Nicole Bergman / IAS, Gilead, Nicole Bergman / IAS. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Transformative Potential of Long-Acting Preventive Drugs Takes Centre Stage at HIV Conference 14/10/2024 Edith Magak At a HIVR4P’s press conference: Jeremy Nuttall, Elizabeth Irungu, Mark Marzinke, Alessandro Grattoni, William Hahn and Colleen Kelley. LIMA, Peru – The infection-prevention potential of Lenacapavir, the long-acting anti-HIV injectable administered just twice a year, took centre stage at the fifth HIV Research for Prevention Conference (HIVR4P) held last week. However, several other important studies were also unveiled, including an injectable that combines contraception and HIV protection, results from a three-month vaginal ring, and real-world findings from Zambia’s rollout of long-acting injectable cabotegravir. Lenacapavir in diverse populations Lenacapavir reduced HIV infections by 96% in a gender-diverse population, according to results from the PURPOSE 2 trial, which enrolled over 3,200 participants from Argentina, Brazil, Mexico, Peru, South Africa, Thailand, and the US between June 2021 and December 2023. Participants were randomly assigned to one of two groups: one receiving lenacapavir injections every six months and the other taking daily oral pills for pre-exposure prophylaxis (PrEP) with matched placebos. The average age of participants was 28, with over one-third under the age of 25. Around 70% identified as non-white, and the gender breakdown featured cisgender men, transgender men, transgender women, and non-binary individuals who have sex with partners assigned male at birth. At 39 weeks, only two HIV cases occurred in the lenacapavir group of 2,179 individuals, translating to a 96% reduction in HIV incidence, according to Dr Colleen Kelley from Emory University. In contrast, there were nine new HIV cases among the 1,087 participants taking daily oral TDF pills (comprising tenofovir disoproxil fumarate and emtricitabine and marketed as Truvada). This makes lenacapavir 89% more effective than oral PrEP. The findings echoed earlier results from the PURPOSE 1 trial, which showed 100% efficacy in preventing HIV among cisgender women in Africa. With regulatory filings expected to begin globally by the end of 2024, lenacapavir has the potential to be a transformative HIV prevention tool. Future phases of the study will focus on other groups, including women in the US (PURPOSE 3) and people who inject drugs (PURPOSE 4). The twice-yearly injectable, lenacapavir (marketed as Sunlenca in the US) could make a huge difference to HIV prevention is widely accessible. Injectable contraceptive and HIV prevention in one For millions of young women worldwide, two major health concerns often intersect: HIV acquisition and unintended pregnancy. Many have expressed a preference for a method that protects against both. At the conference, Melissa Peet from CONRAD presented results from a promising solution—a silica-based hydrogel injectable that combines HIV antiretroviral drugs with contraception in a single shot. In designing this dual-purpose method, researchers selected long-acting cabotegravir (CAB-LA) as the HIV prevention drug and levonorgestrel (LNG) as the contraceptive. The hydrogel injectable they developed is a silica-biodegradable material comprising two compartments, one for each medication. The injectable is capable of delivering both drugs with a single injection offering dual protection for three months. Preclinical tests in rats showed sustained drug levels in the bloodstream without significant interactions or safety concerns, and the researchers are now conducting additional studies in non-human primates to fine-tune dosing and asses the duration of protective drug concentration. No interactions between Cabotegravir and contraceptives One concern with combining HIV prevention and contraception has been the potential for drug interactions, particularly between long-acting HIV medications like cabotegravir (CAB-LA) and commonly used contraceptives. To address this, Dr. Mark Marzinke from Johns Hopkins University presented results from a sub-study within the HPTN 084 trial to explore any potential interactions. The study included 170 participants from South Africa with a median age of 23. A total of 80 women were randomised to the CAB-LA arm and 90 in the oral PrEP arm. Participants used three types of hormonal contraceptives: etonogestrel implants, injectable norethindrone, or medroxyprogesterone acetate (MPA), alongside either CAB-LA or oral PrEP. Researchers measured drug concentrations at enrolment and again at weeks 25, 49, and 73 to determine if there were any drug interactions. The results were reassuring: plasma concentrations of the contraceptives remained high enough to prevent pregnancy in both the CAB-LA and oral PrEP groups. CAB-LA concentrations were also consistent across contraceptive types, indicating that CAB-LA does not interfere with contraceptive effectiveness. However, tenofovir concentrations were unquantifiable for most participants, regardless of contraceptive type, due to low adherence to oral PrEP. New data on the three-month vaginal ring For women seeking long-term HIV prevention, the dapivirine vaginal ring, sometimes called the PrEP ring, has been a promising option. This is a flexible silicone ring that is placed in the vagina that releases the anti-HIV drug, dapivirine, over a month. Delegates at the conference heard results from a South African study comparing the bioavailability of the standard one-month dapivirine ring with a new three-month version. The study enrolled 124 women, but only 104 completed the trial. This was a crossover trial with two treatment phases: half the group started with the one-month ring (containing 25 mg of dapivirine) and then switched to the three-month ring, containing 100 mg of dapivirine. The other group followed the reverse order; they began with the three-month ring and later switched to the one-month ring. The three-month ring was identical to the one-month version in silicone, dimensions, and appearance. Plasma and vaginal fluid samples were collected throughout the study to measure drug levels. Based on dapivirine concentrations in plasma, results showed that the three-month ring provided greater overall drug exposure than the one-month version, indicating equal or possibly higher efficacy in preventing HIV. Jeremy Nuttall from the Population Council’s Center for Biomedical Research, who presented the findings, noted that the reduced frequency of ring changes might increase acceptability and adherence, potentially improving overall effectiveness. He also highlighted that the estimated cost of the three-month ring is $16, making it a potentially more affordable option, projecting that the three-month ring could become available on the market by 2026. Roxana Bretoneche protesting about the lack of community participation at HIVR4P. Real-world results from Zambia’s CAB-LA rollout Zambia became the first country in sub-Saharan Africa to roll out long-acting injectable PrEP (CAB-LA) beyond clinical trials, sharing results from their first three months (February to April 2024) in real-world settings. A total of 609 individuals with a median age of 24 were enrolled across six health facilities in two districts. Among the clients, 55% were female, 20% were adolescent boys and young men, 7% identified as key populations, and 40% as other high-risk populations. Adamson Ndhlovu from Zambia’s JSI USAID DISCOVER-Health Project shared that over 90% of participants due for their second injection received it on time. A total of 24 participants (about 4%) discontinued CAB-LA. Most discontinuations were due to hepatitis B (20 cases), with two participants stopping due to pregnancy, one due to a severe rash, and one because of severe pain at the injection site. Those who discontinued were switched to oral PrEP. During a press briefing at the conference, Professor Lloyd Mulenga from Zambia’s Ministry of Health stated that four of those enrolled had acquired HIV, explaining that they likely had undetected HIV at the time they started PrEP. The real-world implementation of CAB-LA is anticipated to expand, as ViiV Healthcare, the manufacturer, announced at the conference its plans to triple the supply of cabotegravir that will be available for low- and middle-income countries in 2025-2026 to at least two million doses. Image Credits: Nicole Bergman / IAS, Gilead, Nicole Bergman / IAS. Posts navigation Older postsNewer posts